{
  "generated_at": "2026-02-27T23:29:47.268421Z",
  "summary": {
    "tool_calls": 24,
    "status_counts": {
      "success": 23,
      "error": 1
    },
    "strict_mode": true,
    "strict_science_tools_checked": 24,
    "strict_science_tools_failed": 1,
    "strict_passed": false,
    "strict_failure_tools": [
      "semanticscholar_search"
    ]
  },
  "results": [
    {
      "tool": "normalize_drug",
      "payload": {
        "query": "rapamycin",
        "mode": "precision"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "id_list",
          "summary": "Resolved 1 RxNorm candidate(s) for 'rapamycin'.",
          "data": {
            "query": "rapamycin",
            "mode": "precision",
            "candidates": [
              {
                "rxcui": "35302",
                "name": "sirolimus",
                "tty": "IN"
              }
            ],
            "best": {
              "rxcui": "35302",
              "name": "sirolimus",
              "tty": "IN"
            },
            "ingredient_rxcui": "35302"
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "normalize_drug_rapamycin.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/normalize_drug/manual-001/raw/normalize_drug_rapamycin.json",
              "sha256": "8d64b47c09b1677554176ed7b8eae2dd4877dbd5b476c7568b8f565e83d1194d",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "rxnorm",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:29.534318Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-001"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_drug_related",
              "normalize_merge_candidates"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 1790.49,
      "endpoint": "https://rxnav.nlm.nih.gov/REST/rxcui.json",
      "enabled": true
    },
    {
      "tool": "normalize_drug_related",
      "payload": {
        "ids": [
          "35302"
        ],
        "mode": "precision"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 15 related RxNorm concept(s).",
          "data": {
            "mode": "precision",
            "records": [
              {
                "input_rxcui": "35302",
                "rxcui": "258355",
                "name": "Rapamune",
                "tty": "BN"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "2586864",
                "name": "Fyarro",
                "tty": "BN"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "2596865",
                "name": "Hyftor",
                "tty": "BN"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "2717268",
                "name": "Felycin",
                "tty": "BN"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "10312",
                "name": "Delayed Release Oral Tablet",
                "tty": "DF"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "1649574",
                "name": "Injection",
                "tty": "DF"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "316968",
                "name": "Oral Solution",
                "tty": "DF"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "317541",
                "name": "Oral Tablet",
                "tty": "DF"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "346286",
                "name": "Topical Gel",
                "tty": "DF"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "1151122",
                "name": "Topical Product",
                "tty": "DFG"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "1151126",
                "name": "Injectable Product",
                "tty": "DFG"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "1151131",
                "name": "Oral Product",
                "tty": "DFG"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "1151133",
                "name": "Pill",
                "tty": "DFG"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "1151137",
                "name": "Oral Liquid Product",
                "tty": "DFG"
              },
              {
                "input_rxcui": "35302",
                "rxcui": "35302",
                "name": "sirolimus",
                "tty": "IN"
              }
            ]
          },
          "ids": [
            "258355",
            "2586864",
            "2596865",
            "2717268",
            "10312",
            "1649574",
            "316968",
            "317541",
            "346286",
            "1151122",
            "1151126",
            "1151131",
            "1151133",
            "1151137",
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "normalize_drug_related_35302.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/normalize_drug_related/manual-002/raw/normalize_drug_related_35302.json",
              "sha256": "a4ba9a47415762c1ba5e01c0fcced7e94e39c287715e28b2fd4de317572c4396",
              "size_bytes": 19795
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "rxnorm",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:30.312539Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-002"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_merge_candidates",
              "retrieval_build_query_terms"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 779.24,
      "endpoint": "https://rxnav.nlm.nih.gov/REST/rxcui/{id}/allrelated.json",
      "enabled": true
    },
    {
      "tool": "normalize_compound",
      "payload": {
        "query": "nicotinamide mononucleotide",
        "mode": "balanced"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Resolved 1 PubChem compound candidate(s) for 'nicotinamide mononucleotide'.",
          "data": {
            "query": "nicotinamide mononucleotide",
            "mode": "balanced",
            "records": [
              {
                "cid": "14180",
                "preferred_name": "Nicotinamide Mononucleotide",
                "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
                "canonical_smiles": null,
                "synonyms": [
                  {
                    "text": "1094-61-7",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamide ribotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "2KG6QX4W0V",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXSID50911152",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Alpha9",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "ELITEHEALTH",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "REUS NR",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "RefChem:854107",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Mononucleotide, Nicotinamide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "CHEBI:50383",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXCID001511294",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "214-136-5",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN zwitterion",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide nucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "BETANMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  }
                ]
              }
            ],
            "best": {
              "cid": "14180",
              "preferred_name": "Nicotinamide Mononucleotide",
              "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
              "canonical_smiles": null,
              "synonyms": [
                {
                  "text": "1094-61-7",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXSID50911152",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Alpha9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ELITEHEALTH",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "REUS NR",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "RefChem:854107",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Mononucleotide, Nicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEBI:50383",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXCID001511294",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN zwitterion",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide nucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETANMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                }
              ]
            }
          },
          "ids": [
            "14180",
            "DAYLJWODMCOQEW-TURQNECASA-N"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "normalize_compound_nicotinamide_mononucleotide.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/normalize_compound/manual-003/raw/normalize_compound_nicotinamide_mononucleotide.json",
              "sha256": "281a74573b3c7e085121f014cb67a406863bb644cf24d02f46f9973220bd08d9",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubchem",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:32.100909Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-003"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_compound_fetch",
              "normalize_merge_candidates"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 1789.27,
      "endpoint": "https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/{query}/cids/JSON",
      "enabled": true
    },
    {
      "tool": "normalize_compound_fetch",
      "payload": {
        "ids": [
          "14180"
        ],
        "mode": "balanced"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 1 PubChem compound record(s).",
          "data": {
            "mode": "balanced",
            "records": [
              {
                "cid": "14180",
                "preferred_name": "Nicotinamide Mononucleotide",
                "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
                "canonical_smiles": null,
                "synonyms": [
                  {
                    "text": "1094-61-7",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamide ribotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "2KG6QX4W0V",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXSID50911152",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Alpha9",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "ELITEHEALTH",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "REUS NR",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "RefChem:854107",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Mononucleotide, Nicotinamide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "CHEBI:50383",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXCID001511294",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "214-136-5",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN zwitterion",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide nucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "BETANMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "MFCD00038748",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "B-NICOTINAMIDE MONONUCLEOTIDE",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamide ribonucleoside 5'-phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-nicotinamide ribose monophosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "b-D-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "C11H15N2O8P",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "BETA-D-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "UNII-2KG6QX4W0V",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "reinvigorator",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Fosribnicotinamide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "EINECS 214-136-5",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "ss-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotine Impurity 9",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamidmononucleotid",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "fosribnicotinamide [INN]",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "-NM;NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "bmse000260",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "-Nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "?-Nicotinamidemononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  }
                ]
              }
            ]
          },
          "ids": [
            "14180"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubchem",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:33.401516Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-004"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_merge_candidates",
              "retrieval_build_query_terms"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 1299.38,
      "endpoint": "https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/{cid}/property/JSON",
      "enabled": true
    },
    {
      "tool": "normalize_ontology",
      "payload": {
        "query": "hyperbaric oxygen therapy",
        "mode": "precision",
        "ontologies": [
          "efo",
          "mondo",
          "hp"
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 5 ontology candidate(s) for 'hyperbaric oxygen therapy'.",
          "data": {
            "query": "hyperbaric oxygen therapy",
            "mode": "precision",
            "page": 1,
            "hits": [
              {
                "obo_id": "EFO:0009796",
                "label": "response to supplemental oxygen",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:0004887",
                "label": "maximal oxygen uptake measurement",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0004887",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "MONDO:0006450",
                "label": "therapy-related myeloid neoplasm",
                "iri": "http://purl.obolibrary.org/obo/MONDO_0006450",
                "ontology": "mondo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:1000575",
                "label": "Therapy-Related Myeloid Neoplasm",
                "iri": "http://www.ebi.ac.uk/efo/EFO_1000575",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "HP:0500259",
                "label": "Abnormal oxygen level in cord blood",
                "iri": "http://purl.obolibrary.org/obo/HP_0500259",
                "ontology": "hp",
                "synonyms": [],
                "xrefs": []
              }
            ],
            "best": {
              "obo_id": "EFO:0009796",
              "label": "response to supplemental oxygen",
              "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
              "ontology": "efo",
              "synonyms": [],
              "xrefs": []
            }
          },
          "ids": [
            "EFO:0009796",
            "EFO:0004887",
            "MONDO:0006450",
            "EFO:1000575",
            "HP:0500259"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": "2",
            "has_more": true
          },
          "source_meta": {
            "source": "ols",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:33.769481Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-005"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_ontology_fetch",
              "normalize_merge_candidates"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 368.68,
      "endpoint": "https://www.ebi.ac.uk/ols4/api/search",
      "enabled": true
    },
    {
      "tool": "normalize_ontology_fetch",
      "payload": {
        "ids": [
          "EFO:0009796"
        ],
        "mode": "precision"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 1 ontology term record(s).",
          "data": {
            "mode": "precision",
            "records": [
              {
                "obo_id": "EFO:0009796",
                "label": "response to supplemental oxygen",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              }
            ]
          },
          "ids": [
            "EFO:0009796"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "ols",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:34.144160Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-006"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_merge_candidates",
              "retrieval_build_query_terms"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 373.36,
      "endpoint": "https://www.ebi.ac.uk/ols4/api/terms",
      "enabled": true
    },
    {
      "tool": "normalize_merge_candidates",
      "payload": {
        "user_text": "rapamycin",
        "drug_candidates": {
          "contract_version": "2.0",
          "result_kind": "id_list",
          "summary": "Resolved 1 RxNorm candidate(s) for 'rapamycin'.",
          "data": {
            "query": "rapamycin",
            "mode": "precision",
            "candidates": [
              {
                "rxcui": "35302",
                "name": "sirolimus",
                "tty": "IN"
              }
            ],
            "best": {
              "rxcui": "35302",
              "name": "sirolimus",
              "tty": "IN"
            },
            "ingredient_rxcui": "35302"
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "normalize_drug_rapamycin.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/normalize_drug/manual-001/raw/normalize_drug_rapamycin.json",
              "sha256": "8d64b47c09b1677554176ed7b8eae2dd4877dbd5b476c7568b8f565e83d1194d",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "rxnorm",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:29.534318Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-001"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_drug_related",
              "normalize_merge_candidates"
            ]
          }
        },
        "compound_candidates": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Resolved 1 PubChem compound candidate(s) for 'nicotinamide mononucleotide'.",
          "data": {
            "query": "nicotinamide mononucleotide",
            "mode": "balanced",
            "records": [
              {
                "cid": "14180",
                "preferred_name": "Nicotinamide Mononucleotide",
                "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
                "canonical_smiles": null,
                "synonyms": [
                  {
                    "text": "1094-61-7",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Nicotinamide ribotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "2KG6QX4W0V",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXSID50911152",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Alpha9",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "ELITEHEALTH",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "REUS NR",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "RefChem:854107",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "Mononucleotide, Nicotinamide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "CHEBI:50383",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "DTXCID001511294",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "214-136-5",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide mononucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN zwitterion",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "NMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide nucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "nicotinamide D-ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "BETANMN",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "beta-Nicotinamide ribonucleotide",
                    "source": "pubchem",
                    "weight": 0.7
                  },
                  {
                    "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                    "source": "pubchem",
                    "weight": 0.7
                  }
                ]
              }
            ],
            "best": {
              "cid": "14180",
              "preferred_name": "Nicotinamide Mononucleotide",
              "inchikey": "DAYLJWODMCOQEW-TURQNECASA-N",
              "canonical_smiles": null,
              "synonyms": [
                {
                  "text": "1094-61-7",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXSID50911152",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Alpha9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ELITEHEALTH",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "REUS NR",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "RefChem:854107",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Mononucleotide, Nicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEBI:50383",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXCID001511294",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN zwitterion",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide nucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETANMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                }
              ]
            }
          },
          "ids": [
            "14180",
            "DAYLJWODMCOQEW-TURQNECASA-N"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "normalize_compound_nicotinamide_mononucleotide.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/normalize_compound/manual-003/raw/normalize_compound_nicotinamide_mononucleotide.json",
              "sha256": "281a74573b3c7e085121f014cb67a406863bb644cf24d02f46f9973220bd08d9",
              "size_bytes": 60
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubchem",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:32.100909Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-003"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_compound_fetch",
              "normalize_merge_candidates"
            ]
          }
        },
        "ontology_candidates": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 5 ontology candidate(s) for 'hyperbaric oxygen therapy'.",
          "data": {
            "query": "hyperbaric oxygen therapy",
            "mode": "precision",
            "page": 1,
            "hits": [
              {
                "obo_id": "EFO:0009796",
                "label": "response to supplemental oxygen",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:0004887",
                "label": "maximal oxygen uptake measurement",
                "iri": "http://www.ebi.ac.uk/efo/EFO_0004887",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "MONDO:0006450",
                "label": "therapy-related myeloid neoplasm",
                "iri": "http://purl.obolibrary.org/obo/MONDO_0006450",
                "ontology": "mondo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "EFO:1000575",
                "label": "Therapy-Related Myeloid Neoplasm",
                "iri": "http://www.ebi.ac.uk/efo/EFO_1000575",
                "ontology": "efo",
                "synonyms": [],
                "xrefs": []
              },
              {
                "obo_id": "HP:0500259",
                "label": "Abnormal oxygen level in cord blood",
                "iri": "http://purl.obolibrary.org/obo/HP_0500259",
                "ontology": "hp",
                "synonyms": [],
                "xrefs": []
              }
            ],
            "best": {
              "obo_id": "EFO:0009796",
              "label": "response to supplemental oxygen",
              "iri": "http://www.ebi.ac.uk/efo/EFO_0009796",
              "ontology": "efo",
              "synonyms": [],
              "xrefs": []
            }
          },
          "ids": [
            "EFO:0009796",
            "EFO:0004887",
            "MONDO:0006450",
            "EFO:1000575",
            "HP:0500259"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": "2",
            "has_more": true
          },
          "source_meta": {
            "source": "ols",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:33.769481Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-005"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "normalize_ontology_fetch",
              "normalize_merge_candidates"
            ]
          }
        }
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "document",
          "summary": "Merged candidates into concept type 'drug'.",
          "data": {
            "concept": {
              "label": "sirolimus",
              "type": "drug",
              "pivot": {
                "source": "rxnorm",
                "id": "35302"
              },
              "synonyms": [
                {
                  "text": "1094-61-7",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXSID50911152",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Alpha9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ELITEHEALTH",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "REUS NR",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "RefChem:854107",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Mononucleotide, Nicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEBI:50383",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXCID001511294",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN zwitterion",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide nucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETANMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                }
              ],
              "xrefs": [
                {
                  "source": "rxnorm",
                  "id": "RxCUI:35302"
                }
              ],
              "warnings": [],
              "recommended_initial_tools": [
                "normalize_drug",
                "pubmed_search",
                "clinicaltrials_search"
              ]
            }
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:34.147685Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-007"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "retrieval_build_query_terms",
              "retrieval_build_pubmed_templates"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 3.2,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "retrieval_build_query_terms",
      "payload": {
        "concept": {
          "contract_version": "2.0",
          "result_kind": "document",
          "summary": "Merged candidates into concept type 'drug'.",
          "data": {
            "concept": {
              "label": "sirolimus",
              "type": "drug",
              "pivot": {
                "source": "rxnorm",
                "id": "35302"
              },
              "synonyms": [
                {
                  "text": "1094-61-7",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Nicotinamide ribotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "2KG6QX4W0V",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXSID50911152",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Alpha9",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-((2R,3R,4S,5R)-5-((hydrogen phosphonatooxy)methyl)-3,4-dihydroxyoxolan-2-yl)-1$l^(5)-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "ELITEHEALTH",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "REUS NR",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "RefChem:854107",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "Mononucleotide, Nicotinamide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "CHEBI:50383",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "DTXCID001511294",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "214-136-5",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "3-carboxy-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-((phosphonooxy)methyl)oxolan-2-yl)-1lambda5-pyridin-1-ylium",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide mononucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN zwitterion",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "NMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide nucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "nicotinamide D-ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "BETANMN",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "beta-Nicotinamide ribonucleotide",
                  "source": "pubchem",
                  "weight": 0.7
                },
                {
                  "text": "((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate",
                  "source": "pubchem",
                  "weight": 0.7
                }
              ],
              "xrefs": [
                {
                  "source": "rxnorm",
                  "id": "RxCUI:35302"
                }
              ],
              "warnings": [],
              "recommended_initial_tools": [
                "normalize_drug",
                "pubmed_search",
                "clinicaltrials_search"
              ]
            }
          },
          "ids": [
            "35302"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:34.147685Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-007"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "retrieval_build_query_terms",
              "retrieval_build_pubmed_templates"
            ]
          }
        },
        "mode": "precision"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "document",
          "summary": "Built source-specific retrieval terms.",
          "data": {
            "label": "sirolimus",
            "mode": "precision",
            "terms": {
              "pubmed": [
                "sirolimus",
                "1094-61-7",
                "nicotinamide mononucleotide",
                "Nicotinamide ribotide",
                "2KG6QX4W0V",
                "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt"
              ],
              "clinicaltrials": [
                "sirolimus",
                "1094-61-7",
                "nicotinamide mononucleotide",
                "Nicotinamide ribotide",
                "2KG6QX4W0V",
                "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt"
              ],
              "safety": [
                "sirolimus"
              ],
              "expansion": [
                "1094-61-7",
                "nicotinamide mononucleotide",
                "Nicotinamide ribotide",
                "2KG6QX4W0V",
                "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt"
              ]
            }
          },
          "ids": [
            "sirolimus",
            "1094-61-7",
            "nicotinamide mononucleotide",
            "Nicotinamide ribotide",
            "2KG6QX4W0V",
            "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:34.150357Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-008"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "retrieval_build_pubmed_templates",
              "pubmed_search",
              "clinicaltrials_search"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 2.96,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "retrieval_build_pubmed_templates",
      "payload": {
        "intervention_terms": [
          "sirolimus",
          "1094-61-7",
          "nicotinamide mononucleotide",
          "Nicotinamide ribotide",
          "2KG6QX4W0V",
          "Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt"
        ],
        "outcome_terms": [
          "aging",
          "healthspan"
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "document",
          "summary": "Built high-evidence-first PubMed query templates.",
          "data": {
            "queries": {
              "systematic_reviews": "(\"sirolimus\"[Title/Abstract] OR \"1094-61-7\"[Title/Abstract] OR \"nicotinamide mononucleotide\"[Title/Abstract] OR \"Nicotinamide ribotide\"[Title/Abstract] OR \"2KG6QX4W0V\"[Title/Abstract] OR \"Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt\"[Title/Abstract]) AND (\"aging\"[Title/Abstract] OR \"healthspan\"[Title/Abstract]) AND (meta-analysis[pt] OR systematic review[pt])",
              "rcts": "(\"sirolimus\"[Title/Abstract] OR \"1094-61-7\"[Title/Abstract] OR \"nicotinamide mononucleotide\"[Title/Abstract] OR \"Nicotinamide ribotide\"[Title/Abstract] OR \"2KG6QX4W0V\"[Title/Abstract] OR \"Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt\"[Title/Abstract]) AND (\"aging\"[Title/Abstract] OR \"healthspan\"[Title/Abstract]) AND (randomized controlled trial[pt] OR clinical trial[pt])",
              "observational": "(\"sirolimus\"[Title/Abstract] OR \"1094-61-7\"[Title/Abstract] OR \"nicotinamide mononucleotide\"[Title/Abstract] OR \"Nicotinamide ribotide\"[Title/Abstract] OR \"2KG6QX4W0V\"[Title/Abstract] OR \"Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt\"[Title/Abstract]) AND (\"aging\"[Title/Abstract] OR \"healthspan\"[Title/Abstract]) AND (cohort[Title/Abstract] OR observational[Title/Abstract])",
              "broad": "(\"sirolimus\"[Title/Abstract] OR \"1094-61-7\"[Title/Abstract] OR \"nicotinamide mononucleotide\"[Title/Abstract] OR \"Nicotinamide ribotide\"[Title/Abstract] OR \"2KG6QX4W0V\"[Title/Abstract] OR \"Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt\"[Title/Abstract]) AND (\"aging\"[Title/Abstract] OR \"healthspan\"[Title/Abstract])"
            }
          },
          "ids": [
            "systematic_reviews",
            "rcts",
            "observational",
            "broad"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:34.153072Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-009"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "pubmed_search"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 1.62,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "pubmed_search",
      "payload": {
        "query": "\"rapamycin\"[Title/Abstract] AND aging[Title/Abstract]",
        "mode": "precision",
        "limit": 10
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "id_list",
          "summary": "Retrieved 10 PMID(s) from PubMed search.",
          "data": {
            "query": "\"rapamycin\"[Title/Abstract] AND aging[Title/Abstract]",
            "mode": "precision",
            "count": 1804,
            "retstart": 0,
            "webenv": "MCID_69a228dec6d59124820dc338",
            "query_key": "1",
            "query_translation": "\"rapamycin\"[Title/Abstract] AND \"aging\"[Title/Abstract]"
          },
          "ids": [
            "33037985",
            "31761958",
            "33599151",
            "39951177",
            "37142830",
            "35316619",
            "23454757",
            "29190625",
            "38126098",
            "25015322"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubmed_search_0.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/pubmed_search/manual-010/raw/pubmed_search_0.json",
              "sha256": "569ae5a3759bcf8b29fb263a02f121e2091c5b3dfca914ef704f9bd65c0ead2a",
              "size_bytes": 535
            }
          ],
          "pagination": {
            "next_page_token": "10",
            "has_more": true
          },
          "source_meta": {
            "source": "pubmed",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:34.848585Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-010"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "pubmed_fetch"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 696.46,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi",
      "enabled": true
    },
    {
      "tool": "pubmed_fetch",
      "payload": {
        "ids": [
          "33037985",
          "31761958",
          "33599151",
          "39951177",
          "37142830"
        ],
        "mode": "balanced"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 5 PubMed record(s).",
          "data": {
            "mode": "balanced",
            "records": [
              {
                "pmid": "33037985",
                "title": "Effect of rapamycin on aging and age-related diseases-past and future.",
                "pubdate": "2021 Jun",
                "source": "Geroscience",
                "pub_types": [
                  "Journal Article",
                  "Research Support, N.I.H., Extramural",
                  "Research Support, Non-U.S. Gov't",
                  "Research Support, U.S. Gov't, Non-P.H.S.",
                  "Review"
                ],
                "article_ids": [
                  {
                    "idtype": "pubmed",
                    "idtypen": 1,
                    "value": "33037985"
                  },
                  {
                    "idtype": "pmc",
                    "idtypen": 8,
                    "value": "PMC8190242"
                  },
                  {
                    "idtype": "pmcid",
                    "idtypen": 5,
                    "value": "pmc-id: PMC8190242;"
                  },
                  {
                    "idtype": "doi",
                    "idtypen": 3,
                    "value": "10.1007/s11357-020-00274-1"
                  },
                  {
                    "idtype": "pii",
                    "idtypen": 4,
                    "value": "10.1007/s11357-020-00274-1"
                  }
                ],
                "doi": "10.1007/s11357-020-00274-1",
                "is_meta_or_systematic": false,
                "is_rct_like": false
              },
              {
                "pmid": "31761958",
                "title": "Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.",
                "pubdate": "2019 Dec",
                "source": "Geroscience",
                "pub_types": [
                  "Journal Article",
                  "Randomized Controlled Trial"
                ],
                "article_ids": [
                  {
                    "idtype": "pubmed",
                    "idtypen": 1,
                    "value": "31761958"
                  },
                  {
                    "idtype": "pmc",
                    "idtypen": 8,
                    "value": "PMC6925069"
                  },
                  {
                    "idtype": "pmcid",
                    "idtypen": 5,
                    "value": "pmc-id: PMC6925069;"
                  },
                  {
                    "idtype": "doi",
                    "idtypen": 3,
                    "value": "10.1007/s11357-019-00113-y"
                  },
                  {
                    "idtype": "pii",
                    "idtypen": 4,
                    "value": "10.1007/s11357-019-00113-y"
                  }
                ],
                "doi": "10.1007/s11357-019-00113-y",
                "is_meta_or_systematic": false,
                "is_rct_like": true
              },
              {
                "pmid": "33599151",
                "title": "Regulation and metabolic functions of mTORC1 and mTORC2.",
                "pubdate": "2021 Jul 1",
                "source": "Physiol Rev",
                "pub_types": [
                  "Journal Article",
                  "Research Support, N.I.H., Extramural",
                  "Research Support, Non-U.S. Gov't",
                  "Review"
                ],
                "article_ids": [
                  {
                    "idtype": "pubmed",
                    "idtypen": 1,
                    "value": "33599151"
                  },
                  {
                    "idtype": "pmc",
                    "idtypen": 8,
                    "value": "PMC8424549"
                  },
                  {
                    "idtype": "pmcid",
                    "idtypen": 5,
                    "value": "pmc-id: PMC8424549;"
                  },
                  {
                    "idtype": "doi",
                    "idtypen": 3,
                    "value": "10.1152/physrev.00026.2020"
                  }
                ],
                "doi": "10.1152/physrev.00026.2020",
                "is_meta_or_systematic": false,
                "is_rct_like": false
              },
              {
                "pmid": "39951177",
                "title": "Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.",
                "pubdate": "2025 Jun",
                "source": "Geroscience",
                "pub_types": [
                  "Clinical Trial Protocol",
                  "Journal Article"
                ],
                "article_ids": [
                  {
                    "idtype": "pubmed",
                    "idtypen": 1,
                    "value": "39951177"
                  },
                  {
                    "idtype": "pmc",
                    "idtypen": 8,
                    "value": "PMC12181551"
                  },
                  {
                    "idtype": "pmcid",
                    "idtypen": 5,
                    "value": "pmc-id: PMC12181551;"
                  },
                  {
                    "idtype": "doi",
                    "idtypen": 3,
                    "value": "10.1007/s11357-024-01484-7"
                  },
                  {
                    "idtype": "pii",
                    "idtypen": 4,
                    "value": "10.1007/s11357-024-01484-7"
                  }
                ],
                "doi": "10.1007/s11357-024-01484-7",
                "is_meta_or_systematic": false,
                "is_rct_like": true
              },
              {
                "pmid": "37142830",
                "title": "Targeting the biology of aging with mTOR inhibitors.",
                "pubdate": "2023 Jun",
                "source": "Nat Aging",
                "pub_types": [
                  "Journal Article",
                  "Review",
                  "Research Support, N.I.H., Extramural",
                  "Research Support, Non-U.S. Gov't"
                ],
                "article_ids": [
                  {
                    "idtype": "pubmed",
                    "idtypen": 1,
                    "value": "37142830"
                  },
                  {
                    "idtype": "mid",
                    "idtypen": 8,
                    "value": "NIHMS1898240"
                  },
                  {
                    "idtype": "pmc",
                    "idtypen": 8,
                    "value": "PMC10330278"
                  },
                  {
                    "idtype": "pmcid",
                    "idtypen": 5,
                    "value": "pmc-id: PMC10330278;manuscript-id: NIHMS1898240;"
                  },
                  {
                    "idtype": "doi",
                    "idtypen": 3,
                    "value": "10.1038/s43587-023-00416-y"
                  },
                  {
                    "idtype": "pii",
                    "idtypen": 4,
                    "value": "10.1038/s43587-023-00416-y"
                  }
                ],
                "doi": "10.1038/s43587-023-00416-y",
                "is_meta_or_systematic": false,
                "is_rct_like": false
              }
            ]
          },
          "ids": [
            "33037985",
            "31761958",
            "33599151",
            "39951177",
            "37142830"
          ],
          "citations": [
            {
              "pmid": "33037985",
              "doi": "10.1007/s11357-020-00274-1",
              "title": "Effect of rapamycin on aging and age-related diseases-past and future.",
              "year": "2021 Jun"
            },
            {
              "pmid": "31761958",
              "doi": "10.1007/s11357-019-00113-y",
              "title": "Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.",
              "year": "2019 Dec"
            },
            {
              "pmid": "33599151",
              "doi": "10.1152/physrev.00026.2020",
              "title": "Regulation and metabolic functions of mTORC1 and mTORC2.",
              "year": "2021 Jul 1"
            },
            {
              "pmid": "39951177",
              "doi": "10.1007/s11357-024-01484-7",
              "title": "Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.",
              "year": "2025 Jun"
            },
            {
              "pmid": "37142830",
              "doi": "10.1038/s43587-023-00416-y",
              "title": "Targeting the biology of aging with mTOR inhibitors.",
              "year": "2023 Jun"
            }
          ],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "pubmed_fetch_esummary.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/pubmed_fetch/manual-011/raw/pubmed_fetch_esummary.json",
              "sha256": "01bf55436f8b5169af12bd1e46e9958873f8856f00bdabad73a1c07b36953e00",
              "size_bytes": 21779
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "pubmed",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:35.717600Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-011"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "clinicaltrials_search",
              "trial_publication_linker"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 870.07,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi",
      "enabled": true
    },
    {
      "tool": "clinicaltrials_search",
      "payload": {
        "query": "rapamycin aging",
        "mode": "precision",
        "limit": 10
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Retrieved 10 ClinicalTrials.gov study record(s).",
          "data": {
            "query": "rapamycin aging",
            "mode": "precision",
            "studies": [
              {
                "nct_id": "NCT03308747",
                "brief_title": "Inflammaging and Muscle Protein Metabolism",
                "official_title": "Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle.",
                "overall_status": "COMPLETED",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "NA"
                ],
                "enrollment": 44,
                "primary_outcomes": [
                  {
                    "measure": "Systemic inflammation",
                    "description": "Levels of systemic inflammation will be assessed by measuring serum levels of hs-CRP, IL-6 and TNF-.",
                    "timeFrame": "At baseline."
                  },
                  {
                    "measure": "Change in muscle protein synthesis (MPS)",
                    "description": "Using deuterium oxide (D2O) 70% atom administration. Individuals will consume a single bolus of 150ml D20 the day before the clinical trial and muscle biopsy samples, collected before and after the exercise bout and protein ingestion, will be analyzed for isotopic measurement using GC-P-IRMS.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  },
                  {
                    "measure": "Change in intracellular signaling proteins in muscle",
                    "description": "Phosphorylation levels of Akt, mammalian target of rapamycin (mTOR), p70S6K and ribosomal protein S6 (rpS6) will be measure using western blotting.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  },
                  {
                    "measure": "Change in proteasome activities in muscle",
                    "description": "Chymotrypsin-like (CT-L), caspase-like (C-L) and trypsin-like (T-L) proteasome activities will be assayed with hydrolysis of the fluorogenic peptide LLVY-AMC, LLE-AMC and LSTR-AMC, respectively.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  },
                  {
                    "measure": "Change in protein expression level of proteasome subunits",
                    "description": "Immunoblot analysis will be used to detect protein expression levels of proteasome (5, 2 and 1) and immunoproteasome (5i, 2i and 1i) subunits.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT03649698",
                "brief_title": "Exercise and Nutrition for Healthy AgeiNg",
                "official_title": "Exercise and Nutrition for Healthy AgeiNg: Anabolic Interventions for Older People With (Pre)Sarcopenia to Improve Physical Functioning, Muscle Mass and Muscle Strength and to Understand the Underlying Mechanisms of Action.",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "NA"
                ],
                "enrollment": 180,
                "primary_outcomes": [
                  {
                    "measure": "Change in physical functioning",
                    "description": "Change in SPPB score",
                    "timeFrame": "Measured at baseline, week 12 and week 24."
                  },
                  {
                    "measure": "Percentage of participants with change in physical functioning",
                    "description": "the percentage of participants with more than 1 or 1 point increase in SPPB score.",
                    "timeFrame": "Measured at baseline, week 12 and week 24."
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT06658093",
                "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "EARLY_PHASE1"
                ],
                "enrollment": 194,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT05836025",
                "brief_title": "Effect of Rapamycin in Ovarian Aging",
                "official_title": "Effect of Rapamycin in Ovarian Aging",
                "overall_status": "ACTIVE_NOT_RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 50,
                "primary_outcomes": [
                  {
                    "measure": "Measure of Ovarian Reserve",
                    "description": "Ovarian reserve will be determined using AMH",
                    "timeFrame": "Up to 1 year"
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT07092618",
                "brief_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation",
                "official_title": "Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2",
                  "PHASE3"
                ],
                "enrollment": 150,
                "primary_outcomes": [
                  {
                    "measure": "Evaluate the effectiveness of metformin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic or Wegovy (or compounded semaglutide equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.\n\n1. Individuals that maintain the relative weight over the course of six months post-GLP-1 receptor agonist cessation\n2. Individuals that have less weight gain over the course of six months post-GLP-1 receptor agonist cessation using the combinatorial therapies than those who do not",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + rapamycin in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  },
                  {
                    "measure": "Evaluate the effectiveness of metformin + LDN in maintaining GLP1-induced weight loss in participants weaning off of Ozempic (or equivalent) or Wegovy (or equivalent)",
                    "description": "Participant weight will be self-reported every 4 weeks and will be compared against baseline weight as percent departure from baseline.",
                    "timeFrame": "6 months"
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT01847261",
                "brief_title": "Effects of Protein Blends on Muscle Protein Synthesis in Healthy Older Adults",
                "official_title": "A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown in Healthy Older Adults",
                "overall_status": "COMPLETED",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "NA"
                ],
                "enrollment": 20,
                "primary_outcomes": [
                  {
                    "measure": "Fractional Synthetic Rate (Muscle Protein Synthesis)",
                    "description": "The fractional synthesis rate (FSR) of mixed muscle proteins will be calculated from the incorporation rate of L-\\[ring-13C6\\]Phenylalanine into the mixed muscle proteins, and the free-tissue phenylalanine enrichment.",
                    "timeFrame": "baseline, 3 hrs, 5 hrs"
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT05237687",
                "brief_title": "The Role of Sirolimus in Preventing Functional Decline in Older Adults",
                "official_title": "Sirolimus in Older Adults- Randomized Trial Assessing the Improvement in Phenotypic/Functional Biomarkers of Aging",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 10,
                "primary_outcomes": [
                  {
                    "measure": "Phenotypic/functional biomarkers of aging",
                    "description": "Phenotypic biomarkers of aging will be measured by SASP (senescence-associated secretory phenotype) index score at 1 year follow-up when compared to elderly patients not receiving sirolimus.",
                    "timeFrame": "1 year"
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT06789900",
                "brief_title": "Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women",
                "official_title": "Targeting mTOR With Everolimus and/or Physical Training for Preventing Postmenopausal Bone Loss and Accelerated Skeletal Aging: The RapaLoad Study",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE2"
                ],
                "enrollment": 136,
                "primary_outcomes": [
                  {
                    "measure": "Procollagen type 1 N-terminal propeptide (P1NP)",
                    "description": "Percentage change in circulating levels of bone formation marker N-terminal fragment of procollagen type 1 (P1NP) at 24 weeks as compared with baseline",
                    "timeFrame": "Baseline and 24 weeks"
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT07058974",
                "brief_title": "A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation",
                "official_title": "A Phase 1b, Multi-cohort Clinical Trial Assessing Safety and Feasibility of Exercise and Spermidine Administered in Conjunction With Lamivudine (RTi) or Rapamycin (mTORi) to Assess Impact on Dynamic Changes of Inflammation and Aging",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "PHASE1"
                ],
                "enrollment": 22,
                "primary_outcomes": [
                  {
                    "measure": "Number and Type of Grade 3/4 Adverse Events per CTCAE Version 5.0",
                    "description": "Number and Type of Grade 3/4 Adverse Events per CTCAE Version 5.0. Toxicity will be assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0. Any patient experiencing a Grade 3 or 4 adverse event must hold drug until toxicity returns to grade 0-1. The treating investigator may hold study drug for any duration if the patient is deemed to be experiencing a Grade 1-2 adverse event related to study drug.",
                    "timeFrame": "at 180 days"
                  },
                  {
                    "measure": "Number of participants with ability to complete >80% of specified pharmacological intervention",
                    "description": "Feasibility of the trial is determined by participant documentation of taking at least 80% of the provided study drug on a regular basis, ability to complete \\>80% of specified pharmacological intervention.",
                    "timeFrame": "at 180 days"
                  }
                ],
                "has_results": false
              },
              {
                "nct_id": "NCT01922167",
                "brief_title": "Resistance Exercise Training and Amino Acid Leucine Supplementation in Frail Elderly Women",
                "official_title": "The Impact of Exercise Training and Leucine Supplementation in Frail Elderly Women With an Exploration Into Mechanistic Explanations",
                "overall_status": "COMPLETED",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "NA"
                ],
                "enrollment": 19,
                "primary_outcomes": [
                  {
                    "measure": "Change from Baseline in Fractional Synthesis Rate (FSR) at 12 weeks",
                    "timeFrame": "Baseline and at 12 weeks"
                  }
                ],
                "has_results": false
              }
            ]
          },
          "ids": [
            "NCT03308747",
            "NCT03649698",
            "NCT06658093",
            "NCT05836025",
            "NCT07092618",
            "NCT01847261",
            "NCT05237687",
            "NCT06789900",
            "NCT07058974",
            "NCT01922167"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "clinicaltrials_search.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/clinicaltrials_search/manual-012/raw/clinicaltrials_search.json",
              "sha256": "5cfa2ea61d841fabcd4c87eaa84e5d72d6c5da4ccdb243b4c02ced067db01afa",
              "size_bytes": 190029
            }
          ],
          "pagination": {
            "next_page_token": "ZVNj7o2Elu8o3lpoCMr95LrumpOQJJxuZ_Sh2PYckA",
            "has_more": true
          },
          "source_meta": {
            "source": "clinicaltrials",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:36.049640Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-012"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "clinicaltrials_fetch",
              "retrieval_should_run_trial_audit"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 331.29,
      "endpoint": "https://clinicaltrials.gov/api/v2/studies",
      "enabled": true
    },
    {
      "tool": "clinicaltrials_fetch",
      "payload": {
        "ids": [
          "NCT03308747",
          "NCT03649698",
          "NCT06658093"
        ],
        "mode": "balanced"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 3 ClinicalTrials.gov study detail record(s).",
          "data": {
            "mode": "balanced",
            "studies": [
              {
                "nct_id": "NCT03308747",
                "brief_title": "Inflammaging and Muscle Protein Metabolism",
                "official_title": "Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle.",
                "overall_status": "COMPLETED",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "NA"
                ],
                "enrollment": 44,
                "primary_outcomes": [
                  {
                    "measure": "Systemic inflammation",
                    "description": "Levels of systemic inflammation will be assessed by measuring serum levels of hs-CRP, IL-6 and TNF-.",
                    "timeFrame": "At baseline."
                  },
                  {
                    "measure": "Change in muscle protein synthesis (MPS)",
                    "description": "Using deuterium oxide (D2O) 70% atom administration. Individuals will consume a single bolus of 150ml D20 the day before the clinical trial and muscle biopsy samples, collected before and after the exercise bout and protein ingestion, will be analyzed for isotopic measurement using GC-P-IRMS.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  },
                  {
                    "measure": "Change in intracellular signaling proteins in muscle",
                    "description": "Phosphorylation levels of Akt, mammalian target of rapamycin (mTOR), p70S6K and ribosomal protein S6 (rpS6) will be measure using western blotting.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  },
                  {
                    "measure": "Change in proteasome activities in muscle",
                    "description": "Chymotrypsin-like (CT-L), caspase-like (C-L) and trypsin-like (T-L) proteasome activities will be assayed with hydrolysis of the fluorogenic peptide LLVY-AMC, LLE-AMC and LSTR-AMC, respectively.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  },
                  {
                    "measure": "Change in protein expression level of proteasome subunits",
                    "description": "Immunoblot analysis will be used to detect protein expression levels of proteasome (5, 2 and 1) and immunoproteasome (5i, 2i and 1i) subunits.",
                    "timeFrame": "At baseline and 180 min following protein ingestion."
                  }
                ],
                "has_results": false,
                "raw_study": {
                  "protocolSection": {
                    "identificationModule": {
                      "nctId": "NCT03308747",
                      "orgStudyIdInfo": {
                        "id": "INFLAMMAGING-UTH"
                      },
                      "organization": {
                        "fullName": "University of Thessaly",
                        "class": "OTHER"
                      },
                      "briefTitle": "Inflammaging and Muscle Protein Metabolism",
                      "officialTitle": "Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle."
                    },
                    "statusModule": {
                      "statusVerifiedDate": "2017-10",
                      "overallStatus": "COMPLETED",
                      "expandedAccessInfo": {
                        "hasExpandedAccess": false
                      },
                      "startDateStruct": {
                        "date": "2017-09-01",
                        "type": "ACTUAL"
                      },
                      "primaryCompletionDateStruct": {
                        "date": "2018-02-15",
                        "type": "ACTUAL"
                      },
                      "completionDateStruct": {
                        "date": "2018-05-30",
                        "type": "ACTUAL"
                      },
                      "studyFirstSubmitDate": "2017-10-02",
                      "studyFirstSubmitQcDate": "2017-10-08",
                      "studyFirstPostDateStruct": {
                        "date": "2017-10-13",
                        "type": "ACTUAL"
                      },
                      "lastUpdateSubmitDate": "2018-07-18",
                      "lastUpdatePostDateStruct": {
                        "date": "2018-07-19",
                        "type": "ACTUAL"
                      }
                    },
                    "sponsorCollaboratorsModule": {
                      "responsibleParty": {
                        "type": "PRINCIPAL_INVESTIGATOR",
                        "investigatorFullName": "Ioannis G. Fatouros",
                        "investigatorTitle": "Associate Professor",
                        "investigatorAffiliation": "University of Thessaly"
                      },
                      "leadSponsor": {
                        "name": "University of Thessaly",
                        "class": "OTHER"
                      }
                    },
                    "oversightModule": {
                      "oversightHasDmc": false,
                      "isFdaRegulatedDrug": false,
                      "isFdaRegulatedDevice": false
                    },
                    "descriptionModule": {
                      "briefSummary": "The development of a low-grade, chronic, systemic inflammation observed in the elderly (inflammaing) has been associated with increased risk for skeletal muscle wasting, strength loss and functional impairments. According to studies performed in animals and cell cultures increased concentrations of pro-inflammatory cytokines such as IL-6 and TNF- as well as increased levels of hs-CRP lead to elevated protein degradation through proteasome activation and reduced muscle protein synthesis (MPS) via downregulation of the Akt-mTOR signaling pathway. However, evidence regarding the effects of inflammaging on skeletal muscle mass in humans is lacking. Thus, the present study will compare proteasome activation and the protein synthetic response in the fasted and postprandial period between older adults with increased systemic inflammation and their healthy control counterparts.",
                      "detailedDescription": "A total number of \\> 60 male, older adults aged 63-73 years will be initially screened for systemic levels of hs-CRP and IL-6. Of these, 24 individuals that will comply with the study criteria will be allocated to either a High (IL6:  1.7 pg/ml; hs-CRP: \\> 1.0 mg/L) (n=12) or a Low (IL6: \\< 1.7 pg/ml; hs-CRP: \\< 1.0 mg/L) (n=12) systemic inflammation group. Approximately 2 weeks before the experimental trial, anthropometry, resting metabolic rate (RMR), body composition (with DXA), sarcopenia status, functional capacity and the knee-extension one repetition maximum (1RM) will be assessed in individuals from both groups. In addition, levels of habitual physical activity will be assessed using accelerometry (over a 7-day period) and daily dietary intake will be monitored through 7-day diet recalls in all participants. 1 week before the experimental day an oral glucose tolerance test (OGTT) will be also performed over a 2-hour period, with blood sampling every 15min during the first hour and every 30min during the second hour. The day before the experimental trial, participants will consume 150ml of D2O 70% atom as a bolus. In the experimental day, participants will arrive at the laboratory after an overnight fast and a baseline blood sample and a muscle biopsy from vastus lateralis muscle will be collected. Immediately after, participants will perform 8 sets with 10 repetitions at 80% of 1RM and 2 min rest between each set, on a knee-extension machine. After exercise, they will ingest 0.4 g whey protein isolate/kg body weight as single bolus and then they will remain in a sitting position over a 3-hour period. Blood samples will be collected every 30min during the 3-hour postprandial period while a second muscle biopsy will be obtained at 3h."
                    },
                    "conditionsModule": {
                      "conditions": [
                        "Inflammaging",
                        "Sarcopenia"
                      ],
                      "keywords": [
                        "Low-grade systemic inflammation",
                        "Muscle protein synthesis",
                        "Proteasome activation",
                        "Anabolic signaling",
                        "Aging",
                        "Sarcopenia"
                      ]
                    },
                    "designModule": {
                      "studyType": "INTERVENTIONAL",
                      "phases": [
                        "NA"
                      ],
                      "designInfo": {
                        "allocation": "NON_RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "BASIC_SCIENCE",
                        "maskingInfo": {
                          "masking": "DOUBLE",
                          "whoMasked": [
                            "PARTICIPANT",
                            "INVESTIGATOR"
                          ]
                        }
                      },
                      "enrollmentInfo": {
                        "count": 44,
                        "type": "ACTUAL"
                      }
                    },
                    "armsInterventionsModule": {
                      "armGroups": [
                        {
                          "label": "High systemic inflammation",
                          "type": "EXPERIMENTAL",
                          "description": "Individuals assigned in the high systemic inflammation group will be characterized by IL6:  1.7 pg/ml and hs-CRP: \\> 2.0 mg/L.",
                          "interventionNames": [
                            "Dietary Supplement: Instantized Whey Protein Isolate"
                          ]
                        },
                        {
                          "label": "Low systemic inflammation",
                          "type": "ACTIVE_COMPARATOR",
                          "description": "Individuals assigned in the high systemic inflammation group will be characterized by IL6: \\< 1.7 pg/ml and hs-CRP: \\< 1.0 mg/L.",
                          "interventionNames": [
                            "Dietary Supplement: Instantized Whey Protein Isolate"
                          ]
                        }
                      ],
                      "interventions": [
                        {
                          "type": "DIETARY_SUPPLEMENT",
                          "name": "Instantized Whey Protein Isolate",
                          "description": "0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.",
                          "armGroupLabels": [
                            "High systemic inflammation",
                            "Low systemic inflammation"
                          ]
                        }
                      ]
                    },
                    "outcomesModule": {
                      "primaryOutcomes": [
                        {
                          "measure": "Systemic inflammation",
                          "description": "Levels of systemic inflammation will be assessed by measuring serum levels of hs-CRP, IL-6 and TNF-.",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Change in muscle protein synthesis (MPS)",
                          "description": "Using deuterium oxide (D2O) 70% atom administration. Individuals will consume a single bolus of 150ml D20 the day before the clinical trial and muscle biopsy samples, collected before and after the exercise bout and protein ingestion, will be analyzed for isotopic measurement using GC-P-IRMS.",
                          "timeFrame": "At baseline and 180 min following protein ingestion."
                        },
                        {
                          "measure": "Change in intracellular signaling proteins in muscle",
                          "description": "Phosphorylation levels of Akt, mammalian target of rapamycin (mTOR), p70S6K and ribosomal protein S6 (rpS6) will be measure using western blotting.",
                          "timeFrame": "At baseline and 180 min following protein ingestion."
                        },
                        {
                          "measure": "Change in proteasome activities in muscle",
                          "description": "Chymotrypsin-like (CT-L), caspase-like (C-L) and trypsin-like (T-L) proteasome activities will be assayed with hydrolysis of the fluorogenic peptide LLVY-AMC, LLE-AMC and LSTR-AMC, respectively.",
                          "timeFrame": "At baseline and 180 min following protein ingestion."
                        },
                        {
                          "measure": "Change in protein expression level of proteasome subunits",
                          "description": "Immunoblot analysis will be used to detect protein expression levels of proteasome (5, 2 and 1) and immunoproteasome (5i, 2i and 1i) subunits.",
                          "timeFrame": "At baseline and 180 min following protein ingestion."
                        }
                      ],
                      "secondaryOutcomes": [
                        {
                          "measure": "Resting metabolic rate (RMR)",
                          "description": "RMR will be assessed after an overnight fast with participants in a supine position following a 15-min stabilization period by taking 30 consecutive 1-min VO2/CO2 measurements using a portable open-circuit indirect calorimeter with a ventilated hood system following a standard calibration protocol.",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Physical activity",
                          "description": "Level of habitual physical activity will be assessed using accelerometry (ActiGraph GT3X-BT accelerometer).",
                          "timeFrame": "Over a 7-day period at baseline."
                        },
                        {
                          "measure": "Dietary intake",
                          "description": "Daily dietary intake will be assessed using 7-day diet recalls.",
                          "timeFrame": "Over a 7-day period at baseline."
                        },
                        {
                          "measure": "Reduced glutathione in blood",
                          "description": "Concentration of reduced glutathione will be measured in red blood cells",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Oxidized glutathione in blood",
                          "description": "Concentration of oxidized glutathione will be measured in red blood cells",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Protein carbonyls in serum",
                          "description": "Concentration of protein carbonyls will be measured in serum.",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Total antioxidant capacity",
                          "description": "Total antioxidant capacity will be measured in serum",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Malondialdehyde in serum",
                          "description": "Concentration of malondialdehyde will be measured in serum.",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "White blood cell count in blood",
                          "description": "White blood cell count will be measured in blood.",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Insulin sensitivity",
                          "description": "Insulin sensitivity will be assessed through an oral glucose tolerance test (OGTT) which involve ingesting glucose solution (75 g) with 5ml arterialized venous blood samples drawn at baseline and every 15 min during the first hour and every 30 min during the second hour over a 2-hour period.",
                          "timeFrame": "At baseline."
                        },
                        {
                          "measure": "Glucose concentration in blood",
                          "description": "Glucose concentration will be measured in plasma during the clinical trial.",
                          "timeFrame": "At baseline and at 30 min, 60 min, 90 min, 120 min, 150 min and 180 min following protein ingestion."
                        },
                        {
                          "measure": "Insulin concentration in blood",
                          "description": "Insulin concentration will be measured in plasma during the clinical trial.",
                          "timeFrame": "At baseline and at 30 min, 60 min, 90 min, 120 min, 150 min and 180 min following protein ingestion."
                        },
                        {
                          "measure": "Body composition",
                          "description": "Body composition will be measured using a dual-energy x-ray absorptiometry scanner (DEXA).",
                          "timeFrame": "At baseline"
                        },
                        {
                          "measure": "Body Mass Index (BMI)",
                          "description": "Calculated as body mass (kg) divided by the height (m) squared.",
                          "timeFrame": "At baseline"
                        },
                        {
                          "measure": "Skeletal muscle index",
                          "description": "Calculated as an appendicular lean mass (kg) divided by height (m) squared.",
                          "timeFrame": "At baseline"
                        },
                        {
                          "measure": "Grip strength",
                          "description": "Using handgrip dynamometry (left and right arm) in a sitting position.",
                          "timeFrame": "At baseline"
                        },
                        {
                          "measure": "Functional performance",
                          "description": "Functional performance will be assessed using the Short Physical Performance Battery (SPPB).",
                          "timeFrame": "At baseline"
                        },
                        {
                          "measure": "Lower limb muscle strength",
                          "description": "Will be assessed by defining the 1 repetition maximum (1RM) on a knee-extension machine.",
                          "timeFrame": "At baseline"
                        }
                      ]
                    },
                    "eligibilityModule": {
                      "eligibilityCriteria": "Inclusion Criteria:\n\n* Non-smokers.\n* BMI 18.5 \\& BMI  35 kg/m2.\n* Moderately active but with no regular participation in heavy resistance exercise within the last 6 months.\n* Absence of chronic disease (i.e. cancer, metabolic, cardiac, or neurological diseases).\n* Free and independently living.\n\nExclusion Criteria:\n\n* Organ failure (unstable, renal, respiratory, liver).\n* Chronic use of corticosteroid medication.\n* Recent use of antibiotics.\n* Presence of frailty.\n* Body weight variation over the past 6mo \\> 10% or weight loss of more than 3kg in the last 3 months.\n* Use of anti-inflammatory or lipid-lowering medication (i.e., statins).\n* Use of medication interacting with muscle metabolism.",
                      "healthyVolunteers": true,
                      "sex": "MALE",
                      "minimumAge": "63 Years",
                      "maximumAge": "75 Years",
                      "stdAges": [
                        "ADULT",
                        "OLDER_ADULT"
                      ]
                    },
                    "contactsLocationsModule": {
                      "overallOfficials": [
                        {
                          "name": "DIMITRIOS DRAGANIDIS, PhDc",
                          "affiliation": "UNIVERSITY OF THESSALY, SCHOOL OF PHYSICAL EDUCATION & SPORTS SCIENCES",
                          "role": "PRINCIPAL_INVESTIGATOR"
                        }
                      ],
                      "locations": [
                        {
                          "facility": "Exercise Biochemistry Laboratory, School of Physical Education & Sports Sciences, University of Thessaly",
                          "city": "Trikala",
                          "zip": "42100",
                          "country": "Greece",
                          "geoPoint": {
                            "lat": 39.55493,
                            "lon": 21.76837
                          }
                        }
                      ]
                    }
                  },
                  "derivedSection": {
                    "miscInfoModule": {
                      "versionHolder": "2026-02-27"
                    },
                    "conditionBrowseModule": {
                      "meshes": [
                        {
                          "id": "D055948",
                          "term": "Sarcopenia"
                        }
                      ],
                      "ancestors": [
                        {
                          "id": "D009133",
                          "term": "Muscular Atrophy"
                        },
                        {
                          "id": "D020879",
                          "term": "Neuromuscular Manifestations"
                        },
                        {
                          "id": "D009461",
                          "term": "Neurologic Manifestations"
                        },
                        {
                          "id": "D009422",
                          "term": "Nervous System Diseases"
                        },
                        {
                          "id": "D001284",
                          "term": "Atrophy"
                        },
                        {
                          "id": "D020763",
                          "term": "Pathological Conditions, Anatomical"
                        },
                        {
                          "id": "D013568",
                          "term": "Pathological Conditions, Signs and Symptoms"
                        },
                        {
                          "id": "D012816",
                          "term": "Signs and Symptoms"
                        }
                      ]
                    }
                  },
                  "hasResults": false
                }
              },
              {
                "nct_id": "NCT03649698",
                "brief_title": "Exercise and Nutrition for Healthy AgeiNg",
                "official_title": "Exercise and Nutrition for Healthy AgeiNg: Anabolic Interventions for Older People With (Pre)Sarcopenia to Improve Physical Functioning, Muscle Mass and Muscle Strength and to Understand the Underlying Mechanisms of Action.",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "NA"
                ],
                "enrollment": 180,
                "primary_outcomes": [
                  {
                    "measure": "Change in physical functioning",
                    "description": "Change in SPPB score",
                    "timeFrame": "Measured at baseline, week 12 and week 24."
                  },
                  {
                    "measure": "Percentage of participants with change in physical functioning",
                    "description": "the percentage of participants with more than 1 or 1 point increase in SPPB score.",
                    "timeFrame": "Measured at baseline, week 12 and week 24."
                  }
                ],
                "has_results": false,
                "raw_study": {
                  "protocolSection": {
                    "identificationModule": {
                      "nctId": "NCT03649698",
                      "orgStudyIdInfo": {
                        "id": "S60763"
                      },
                      "organization": {
                        "fullName": "Universitaire Ziekenhuizen KU Leuven",
                        "class": "OTHER"
                      },
                      "briefTitle": "Exercise and Nutrition for Healthy AgeiNg",
                      "officialTitle": "Exercise and Nutrition for Healthy AgeiNg: Anabolic Interventions for Older People With (Pre)Sarcopenia to Improve Physical Functioning, Muscle Mass and Muscle Strength and to Understand the Underlying Mechanisms of Action.",
                      "acronym": "ENHANce"
                    },
                    "statusModule": {
                      "statusVerifiedDate": "2024-06",
                      "overallStatus": "RECRUITING",
                      "expandedAccessInfo": {
                        "hasExpandedAccess": false
                      },
                      "startDateStruct": {
                        "date": "2018-02-12",
                        "type": "ACTUAL"
                      },
                      "primaryCompletionDateStruct": {
                        "date": "2024-12",
                        "type": "ESTIMATED"
                      },
                      "completionDateStruct": {
                        "date": "2025-06",
                        "type": "ESTIMATED"
                      },
                      "studyFirstSubmitDate": "2018-08-07",
                      "studyFirstSubmitQcDate": "2018-08-24",
                      "studyFirstPostDateStruct": {
                        "date": "2018-08-28",
                        "type": "ACTUAL"
                      },
                      "lastUpdateSubmitDate": "2024-06-27",
                      "lastUpdatePostDateStruct": {
                        "date": "2024-06-28",
                        "type": "ACTUAL"
                      }
                    },
                    "sponsorCollaboratorsModule": {
                      "responsibleParty": {
                        "type": "SPONSOR"
                      },
                      "leadSponsor": {
                        "name": "Universitaire Ziekenhuizen KU Leuven",
                        "class": "OTHER"
                      },
                      "collaborators": [
                        {
                          "name": "KU Leuven",
                          "class": "OTHER"
                        },
                        {
                          "name": "VISTA-Life",
                          "class": "UNKNOWN"
                        },
                        {
                          "name": "Nestle Health Science",
                          "class": "INDUSTRY"
                        }
                      ]
                    },
                    "oversightModule": {
                      "oversightHasDmc": false,
                      "isFdaRegulatedDrug": false,
                      "isFdaRegulatedDevice": false
                    },
                    "descriptionModule": {
                      "briefSummary": "The aim of this randomized placebo-controlled 5-arm clinical trial is to evaluate the effect of combined anabolic interventions compared to single or placebo interventions on physical performance in community-dwelling (pre)sarcopenic elderly ( 65 years) and to determine the underlying mechanisms of action. Important secondary outcome measures are muscle mass, muscle strength, compliance to the interventions (exercise program, protein and omega-3 supplementation) and functional, cognitive and nutritional status.",
                      "detailedDescription": "The aim of this randomized 5-arm clinical trial is to evaluate the effect of combined anabolic interventions compared to single or placebo interventions on physical performance in community-dwelling (pre)sarcopenic elderly ( 65 years) living in Belgium. Physical performance will be evaluated using the Short Physical Performance Battery (SPPB). Muscle mass will be measured using a dual energy x-ray absorptiometry (DXA) and/or bioelectrical impedance analysis (BIA). Muscle strength will be measured by the Biodex (knee-extensor and knee-flexor) and a 1 hand-held dynamometer. The trial will also determine the underlying mechanisms of action using blood measures (such as markers of inflammation and sarcopenia) and muscle biomarkers. Important secondary outcome measures are compliance to the exercise program and to the protein and omega-3 supplementation, as well as functional, cognitive and nutritional status and the patients report on benefits and adverse events.\n\nThe study consists of four parts. Part I is the screening phase, which starts from the moment the participant has signed the informed consent until the start of the preparations of the study. During the screening, participants will be assessed for study eligibility by the study coordinator and contributors. If the participant is eligible, he or she will be randomly assigned into 1 of 5 intervention groups: Group 1: Exercise intervention; Group 2: Protein supplement; Group 3: Exercise intervention + protein supplement; Group 4: Exercise + Protein supplement + omega-3 supplement; Group 5: No intervention.\n\nPart II is the preparation phase, in which the participants starts some of the interventions before the start of the study to familiarize patients with e.g. the intake of a protein supplement. All the participants will take an oral vitamin D supplement (800 IU cholecalciferol) from 4 weeks before the start of the intervention if their vitamin D level is above 20 nmol/L. Patients with a vitamin D level \\< 20 nmol/L will receive repletion therapy. A trial diary will be completed by all participants to record PA, falls and intake of protein/omega3/placebo and vitamin D products. Participants in the exercise intervention (group 1, 3 and 4) will be invited to an information session where the Otago Exercise Program (OEP) will be explained and practiced. With respect to the protein supplementation, participants will receive an individually adapted protein supplement to achieve the recommended total daily intake of 1.5 g protein/kg. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between, before or after meals, based on the subjects' food intake assessed by a food diary. The protein powder is commercially available and consists of 4.5g protein/ 5g powder. The participants in group 2, 3 and 4 will start taking the protein supplement or matched placebo 5 days before the start of the intervention. Four weeks before the start of the intervention, the participants of group 4 will start with the intake of omega-3 (1 capsule providing in total 500 mg eicosapentanoic acid (EPA) and 450 mg docosahexaenoic acid (DHA)) or matched placebo. Placebo will be provided for the participants who are not given a protein and/or omega-3 supplement. Participants are blinded to the nutritional interventions.\n\nThe third part of the study, the intervention period, takes 12 weeks. During this period, there are 8 contact moments (at baseline, week 1, week 2, week 4, week 6, week 8, week 10 and week 12). All the participants continue with the vitamin D supplementation. Participants in the exercise intervention (group 1, 3 and 4) will perform the optimized and personally adapted OEP and will also follow a walking plan. The strength exercises of the OEP are personalised based on the individual's 1 repetition maximum. Balance exercises of the OEP are personalised based on improvements on MiniBESTest scores during the intervention period. The nutritional intervention groups (protein supplementation: group 2, 3 and 4 and omega-3 supplementation: group 4) continue with the protein and/or omega-3 supplements until the last visit of the intervention period.\n\nPart IV is the follow-up period, after the intervention. This phase takes 12 weeks and exists of 2 telephone contacts and 2 contact moments. All the participants continue the vitamin D supplementation until the last visit of the follow-up. The exercise intervention group (group 1, 3 and 4) may continue the OEP, but no personal encouragement will be given during this period. No protein and/ or omega-3 supplements will be given during the follow-up.\n\nSeveral outcomes will be measured during the contact moments of the intervention period and follow-up period (part III and part IV). This will be done by questionnaires about nutritional status, fall history and use of health care (from baseline until end of follow-up), and evaluation of functional and cognitive status. Blood, urine and muscle samples will be taken. The physical activity will be measured by wearing a movement tracker. All participants will wear a movement tracker 5 days before the intervention period and during the first two weeks of the intervention period and last two weeks of the intervention period, and during the last 2 weeks of the follow-up period. Participants who receive an exercise intervention (group 1, 3 and 4) will be encouraged to wear the movement tracker during the complete intervention period. The participants will complete a four-day food diary throughout the trial at week 1, week 6, week 12 and week 24. The participants will be asked for compliance during the preparation period and intervention period and their fall history which can be monitored by using diaries during the intervention period and the follow-up period.\n\nAddendum 27-07-2021: starting from 01-2021 a substudy was initiated in which participants of ENHANce, who agreed for participation in this substudy, collect stool samples at baseline, week 4, week 8 and week 12 of the intervention. This will allow to observe possible changes in gut microbiota composition and intestinal inflammation."
                    },
                    "conditionsModule": {
                      "conditions": [
                        "Sarcopenia"
                      ],
                      "keywords": [
                        "Sarcopenia",
                        "Nutrition",
                        "Protein",
                        "Vitamin D",
                        "Exercise",
                        "Older people",
                        "Frailty"
                      ]
                    },
                    "designModule": {
                      "studyType": "INTERVENTIONAL",
                      "phases": [
                        "NA"
                      ],
                      "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "PARALLEL",
                        "primaryPurpose": "TREATMENT",
                        "maskingInfo": {
                          "masking": "TRIPLE",
                          "maskingDescription": "* Participant: Yes blinded for protein and omega-3\n* Investigator: Yes blinded for protein and omega-3\n* Outcomes Assessor: Yes blinded for protein and omega-3\n* No blinding for exercise intervention.\n* Statistician is blinded for protein, omega-3 and exercise intervention.",
                          "whoMasked": [
                            "PARTICIPANT",
                            "INVESTIGATOR",
                            "OUTCOMES_ASSESSOR"
                          ]
                        }
                      },
                      "enrollmentInfo": {
                        "count": 180,
                        "type": "ESTIMATED"
                      }
                    },
                    "armsInterventionsModule": {
                      "armGroups": [
                        {
                          "label": "Home-based training program",
                          "type": "EXPERIMENTAL",
                          "description": "Home-based training program + protein placebo + omega-3 placebo",
                          "interventionNames": [
                            "Behavioral: Home-based training program",
                            "Drug: Placebo protein powder",
                            "Drug: Placebo omega-3"
                          ]
                        },
                        {
                          "label": "High-quality protein supplement",
                          "type": "EXPERIMENTAL",
                          "description": "High-quality protein supplement + omega-3 placebo",
                          "interventionNames": [
                            "Dietary Supplement: High-quality protein supplement",
                            "Drug: Placebo omega-3"
                          ]
                        },
                        {
                          "label": "2 Anabolic interventions",
                          "type": "EXPERIMENTAL",
                          "description": "Home-based training program and high quality protein supplement",
                          "interventionNames": [
                            "Behavioral: Home-based training program",
                            "Dietary Supplement: High-quality protein supplement",
                            "Drug: Placebo omega-3"
                          ]
                        },
                        {
                          "label": "3 Anabolic interventions",
                          "type": "EXPERIMENTAL",
                          "description": "Home-based training program, high-quality protein supplement and omega-3 fatty acids",
                          "interventionNames": [
                            "Behavioral: Home-based training program",
                            "Dietary Supplement: High-quality protein supplement",
                            "Dietary Supplement: Omega-3 fatty acid"
                          ]
                        },
                        {
                          "label": "Placebo protein powder and omega-3",
                          "type": "PLACEBO_COMPARATOR",
                          "description": "Control group: protein placebo + omega-3 placebo",
                          "interventionNames": [
                            "Drug: Placebo protein powder",
                            "Drug: Placebo omega-3"
                          ]
                        }
                      ],
                      "interventions": [
                        {
                          "type": "BEHAVIORAL",
                          "name": "Home-based training program",
                          "description": "Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.",
                          "armGroupLabels": [
                            "2 Anabolic interventions",
                            "3 Anabolic interventions",
                            "Home-based training program"
                          ]
                        },
                        {
                          "type": "DIETARY_SUPPLEMENT",
                          "name": "High-quality protein supplement",
                          "description": "The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.",
                          "armGroupLabels": [
                            "2 Anabolic interventions",
                            "3 Anabolic interventions",
                            "High-quality protein supplement"
                          ]
                        },
                        {
                          "type": "DIETARY_SUPPLEMENT",
                          "name": "Omega-3 fatty acid",
                          "description": "Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.",
                          "armGroupLabels": [
                            "3 Anabolic interventions"
                          ]
                        },
                        {
                          "type": "DRUG",
                          "name": "Placebo protein powder",
                          "description": "Isocaloric maltodextrin powder. Amount based on food diary.",
                          "armGroupLabels": [
                            "Home-based training program",
                            "Placebo protein powder and omega-3"
                          ]
                        },
                        {
                          "type": "DRUG",
                          "name": "Placebo omega-3",
                          "description": "Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day",
                          "armGroupLabels": [
                            "2 Anabolic interventions",
                            "High-quality protein supplement",
                            "Home-based training program",
                            "Placebo protein powder and omega-3"
                          ]
                        }
                      ]
                    },
                    "outcomesModule": {
                      "primaryOutcomes": [
                        {
                          "measure": "Change in physical functioning",
                          "description": "Change in SPPB score",
                          "timeFrame": "Measured at baseline, week 12 and week 24."
                        },
                        {
                          "measure": "Percentage of participants with change in physical functioning",
                          "description": "the percentage of participants with more than 1 or 1 point increase in SPPB score.",
                          "timeFrame": "Measured at baseline, week 12 and week 24."
                        }
                      ],
                      "secondaryOutcomes": [
                        {
                          "measure": "Change in muscle mass (after intervention-baseline)",
                          "description": "Appendicular lean mass will be measured with a whole-body DXA scan and by BIA.",
                          "timeFrame": "Measured at screening, week 12 and week 24 with DXA or when screening is 6 weeks prior to baseline, DXA will also be performed at baseline. At screening, baseline, week 12 and week 24 with BIA."
                        },
                        {
                          "measure": "Change in muscle strength (after intervention-baseline)",
                          "description": "Muscle strength of the knee-extensor, knee-flexor and hip abductors will be measured by Biodex and hand grip strength with dynamometer.",
                          "timeFrame": "Hand grip measured at screening, baseline, week 12 and week 24. Biodex measured at baseline, week 12 and week 24."
                        },
                        {
                          "measure": "Compliance to the exercise intervention, subjective",
                          "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- The number of Otago sessions the participant performed divided by the number of Otago sessions the participants needed to perform. Likewise, this will be calculated for the walking program and for the integral exercise intervention.",
                          "timeFrame": "baseline until week 12"
                        },
                        {
                          "measure": "Compliance to the exercise intervention, objective",
                          "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- Monitor and diary: Length of exercise session (time). Pattern recognition of exercise groups by algorithm development",
                          "timeFrame": "baseline until week 12"
                        },
                        {
                          "measure": "Compliance to the exercise intervention, subjective, detailed",
                          "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- Diary: the reported intensity of the strength exercises",
                          "timeFrame": "baseline until week 12"
                        },
                        {
                          "measure": "Compliance to the protein supplementation, objective",
                          "description": "Compliance to protein supplementation:\n\n\\- The number of nutritional intakes the participant did divided by the number of intakes of nutritional supplement the participant was prescribed.",
                          "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                        },
                        {
                          "measure": "Compliance to the protein supplementation, subjective",
                          "description": "Compliance to protein supplementation:\n\n\\- Count and weight returned powder boxes",
                          "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                        },
                        {
                          "measure": "Compliance to the protein supplementation objective",
                          "description": "Compliance to protein supplementation:\n\n\\- N content in 8 24h urine samples by the Dumas method (28) to estimate rise in protein intake and Creatinine index to estimate the completion of the urine samples (29, 30)",
                          "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                        },
                        {
                          "measure": "Compliance to the omega-3 supplementation, subjective",
                          "description": "Compliance to omega-3 supplement\n\n\\- Count returned capsules and placebo tablets",
                          "timeFrame": "baseline, week 12 and week 24."
                        },
                        {
                          "measure": "Compliance to the omega-3 supplementation, objective",
                          "description": "Compliance to omega-3 supplement\n\n\\- Compliance to the omega- 3 supplement is assessed by counting the number of capsules during each study visit and by analysis of red blood cell (RBC) membrane fatty acid profile",
                          "timeFrame": "baseline, week 12 and week 24."
                        },
                        {
                          "measure": "Functional status: frailty",
                          "description": "\\- Change in physical frailty stage defined by Fried et al (frail (3-5/5), prefrail (1-2/5), robust (0/5))",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Functional status: activities of daily living",
                          "description": "Change in activity of daily living (ADL) :Barthel-index",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Functional status: balance",
                          "description": "Change in balance (Mini-BESTest)",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Functional status: change in physical activity",
                          "description": "Change in PA by the MoveMonitor+ (MM+) (method under development in our research group)",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Functional status: health-related quality of life",
                          "description": "\\- Change in health-related quality of life, according to Short Form Health Survey (SF-36) questionnaire",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Functional status: falls",
                          "description": "\\- Number of falls and the circumstances, identified using weekly fall calendars + Falls Efficacy Scale International (FES-I)",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Cognitive status: immediate and delayed memory, attention, language and visuospatial skills",
                          "description": "\\- The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): immediate and delayed memory, attention, language and visuospatial skills;",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Cognitive status: inhibition",
                          "description": "Stroop test (inhibition)",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Cognitive status",
                          "description": "\\- Maze test",
                          "timeFrame": "baseline, week 12 and 24"
                        },
                        {
                          "measure": "Nutritional status: malnutrition",
                          "description": "\\- Changes in numbers of participants with malnutrition, according to Mini Nutritional Assessment (MNA).",
                          "timeFrame": "at baseline (preparation for food diary), week 6, week 12 and week 24"
                        },
                        {
                          "measure": "Nutritional status: nutrient intake",
                          "description": "\\- Changes in nutrient intake, according to the four day food diary.",
                          "timeFrame": "at baseline (preparation for food diary), week 6, week 12 and week 24"
                        },
                        {
                          "measure": "Patient reported benefits and adverse effects",
                          "description": "Benefits and adverse effects are asked. Participants will describe their thoughts about the study, what they like and don't like.",
                          "timeFrame": "week 1, 4, 8, 12, 16, 20, 22, 24."
                        },
                        {
                          "measure": "Change in C reactive protein (CRP)",
                          "description": "change in hs-CRP",
                          "timeFrame": "baseline, week 1, 4, 12 and 24"
                        },
                        {
                          "measure": "Change in hemoglobin",
                          "description": "Change in hemoglobin",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in creatinine",
                          "description": "Change in creatinine",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in urea",
                          "description": "Change in urea",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in serum albumin",
                          "description": "Change in serum albumin",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in glucose",
                          "description": "Change in glucose",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in cholesterol (HDL, LDL, total, Triglycerides)",
                          "description": "Change in cholesterol (HDL, LDL, total, Triglycerides)",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in insulin",
                          "description": "Change in insulin",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in insulin like growth factor 1 (IGF-1)",
                          "description": "Change in IGF-1",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in 25-hydroxy-vitamin D",
                          "description": "Change in 25-hydroxy-vitamin D",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in creatinine kinase",
                          "description": "Change in creatinine kinase",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in indoxyl sulfate",
                          "description": "Change in indoxyl sulfate",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in interleukin 6 (IL-6)",
                          "description": "Change in IL-6",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in IL-1b",
                          "description": "Change in IL-1b",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in tumor necrosis factor alpha (TNF-alpha)",
                          "description": "Change in TNF-alpha",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in myostatin",
                          "description": "Change in myostatin",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in activin A",
                          "description": "Change in activin A",
                          "timeFrame": "baseline, week 12 and week 24"
                        },
                        {
                          "measure": "Change in markers of muscle wasting",
                          "description": "Change in markers of muscle wasting (MURF1, Atrogin1, FOXO3)",
                          "timeFrame": "baseline, week 12"
                        },
                        {
                          "measure": "Change in markers of muscle regeneration",
                          "description": "Change in markers of muscle regeneration (PAX7, Myogenic factor 5 (MYF5), myoblast determination protein (MyoD), Ki67, mammalian target of rapamycin (mTOR), AMPK)",
                          "timeFrame": "baseline, week 12"
                        },
                        {
                          "measure": "Change in muscle histology",
                          "description": "Change in muscle histology",
                          "timeFrame": "baseline, week 12"
                        },
                        {
                          "measure": "Change in composition of gut microbiota",
                          "description": "Change in composition of gut microbiota",
                          "timeFrame": "baseline, week 4, week 8, week 12"
                        },
                        {
                          "measure": "Change in markers of intestinal inflammation",
                          "description": "Change in markers of intestinal inflammation (fecal calprotectin, lactoferrin, S100A12)",
                          "timeFrame": "baseline, week 4, week 8, week 12"
                        }
                      ]
                    },
                    "eligibilityModule": {
                      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female persons with (pre)sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP): reduced muscle mass without (presarcopenia) or with (sarcopenia) reduced walking speed ( 0.8m/s) or muscle strength OR probable, confirmed or severe sarcopenia according to EWGSOP 2.\n2. 65 years or older;\n3. Community-dwelling elderly or assisted living;\n4. In case of one or more positive answer(s) on the health screen for exercise, subjects need approval of their general practitioner to participate in this randomized controlled trial (RCT).\n\n   * Uncontrolled or unstable health problems\n   * Uncontrolled pain or feeling unwell the day of the exercise\n   * Recently diagnosed cardiovascular events\n   * systolic blood pressure (SBP)  180 mmHg and/or diastolic blood pressure (DBP)  100 mmHg\n   * Resting tachycardia \\> 100 bpm\n   * Uncontrolled atrial or ventricular arrhythmias\n   * Unstable or acute heart failure\n   * Lasting, increased pain following a previous session\n   * Suspected acute injury\n   * Recent injurious fall without medical assessment\n   * Severe breathlessness or dizziness\n   * Uncontrolled pulmonary problems\n   * Rheumatoid arthritis flare up or acute systemic illness/infection\n   * Unexplained lethargy\n\nExclusion Criteria:\n\n1. Impairments/diseases that impose problems to participation in the study;\n2. Allergy to milk or soy or peanut;\n3. Mini-Mental State Examination (MMSE) \\< 21;\n4. Terminal illness (prognosis \\< 6 months);\n5. Persons who followed a physical training program in the last 6 months (twice or more/week);\n6. Persons with a daily intake of \\> 1.5 g protein/kg body weight (BW)/day;\n7. Diagnosis of severe kidney disease (GFR \\< 30 ml/min) or diabetes mellitus;\n8. Unable to communicate in Dutch, English or French.",
                      "healthyVolunteers": false,
                      "sex": "ALL",
                      "minimumAge": "65 Years",
                      "stdAges": [
                        "OLDER_ADULT"
                      ]
                    },
                    "contactsLocationsModule": {
                      "centralContacts": [
                        {
                          "name": "Laur Vercauteren, MSc",
                          "role": "CONTACT",
                          "phone": "+32 16 34 38 67",
                          "email": "laura.vercauteren@kuleuven.be"
                        },
                        {
                          "name": "Jolan Dupont, MD",
                          "role": "CONTACT",
                          "phone": "+32 16 34 32 01",
                          "email": "jolan.dupont@uzleuven.be"
                        }
                      ],
                      "overallOfficials": [
                        {
                          "name": "Evelien Gielen, Prof MD PhD",
                          "affiliation": "Gerontology and Geriatrics, Department of Public Health and primary care KU Leuven",
                          "role": "PRINCIPAL_INVESTIGATOR"
                        }
                      ],
                      "locations": [
                        {
                          "facility": "Gerontology and Geriatrics, Department of Public Health and Primary Care, KU Leuven",
                          "status": "RECRUITING",
                          "city": "Leuven",
                          "state": "Vlaams-Brabant",
                          "zip": "3000",
                          "country": "Belgium",
                          "contacts": [
                            {
                              "name": "Laura Vercauteren",
                              "role": "CONTACT",
                              "phone": "+32 16 34 38 67",
                              "email": "laura.vercauteren@kuleuven.be"
                            },
                            {
                              "name": "Jolan Dupont, PhD",
                              "role": "CONTACT",
                              "phone": "+32 16 34 32 01",
                              "email": "jolan.dupont@uzleuven.be"
                            },
                            {
                              "name": "Evelien Gielen, Prof MD PhD",
                              "role": "PRINCIPAL_INVESTIGATOR"
                            }
                          ],
                          "geoPoint": {
                            "lat": 50.87959,
                            "lon": 4.70093
                          }
                        }
                      ]
                    },
                    "referencesModule": {
                      "references": [
                        {
                          "pmid": "41632571",
                          "type": "DERIVED",
                          "citation": "Amini N, Dupont J, Lapauw L, Vercauteren L, Peeters L, Dedeyne L, Verschueren S, Tournoy J, Gielen E. A multicomponent intervention consisting of exercise, proteins and omega-3 supplementation to improve sarcopenia in community-dwelling older adults: Lessons learned from a 5-armed randomized controlled feasibility trial. J Frailty Aging. 2026 Feb 2;15(1):100129. doi: 10.1016/j.tjfa.2025.100129. Online ahead of print."
                        },
                        {
                          "pmid": "39787986",
                          "type": "DERIVED",
                          "citation": "Amini N, Devriendt A, Lapauw L, Dupont J, Vercauteren L, Verbeke K, Verschueren S, Tournoy J, Gielen E. Estimating protein intake in sarcopenic older adults: combining food diaries and weighed powders versus 24-hour urine collections. J Nutr Health Aging. 2025 Mar;29(3):100474. doi: 10.1016/j.jnha.2024.100474. Epub 2025 Jan 8."
                        },
                        {
                          "pmid": "37752426",
                          "type": "DERIVED",
                          "citation": "Lapauw L, Dupont J, Amini N, Vercauteren L, Verschueren S, Tournoy J, Raes J, Gielen E. Trial in Elderly with Musculoskeletal Problems due to Underlying Sarcopenia-Faeces to Unravel the Gut and Inflammation Translationally (TEMPUS-FUGIT): protocol of a cross-sequential study to explore the gut-muscle axis in the development and treatment of sarcopenia in community-dwelling older adults. BMC Geriatr. 2023 Sep 26;23(1):599. doi: 10.1186/s12877-023-04291-5."
                        },
                        {
                          "pmid": "33302879",
                          "type": "DERIVED",
                          "citation": "Dedeyne L, Dupont J, Koppo K, Verschueren S, Tournoy J, Gielen E. Exercise and Nutrition for Healthy AgeiNg (ENHANce) project - effects and mechanisms of action of combined anabolic interventions to improve physical functioning in sarcopenic older adults: study protocol of a triple blinded, randomized controlled trial. BMC Geriatr. 2020 Dec 10;20(1):532. doi: 10.1186/s12877-020-01900-5."
                        }
                      ]
                    },
                    "ipdSharingStatementModule": {
                      "ipdSharing": "UNDECIDED"
                    }
                  },
                  "derivedSection": {
                    "miscInfoModule": {
                      "versionHolder": "2026-02-27"
                    },
                    "conditionBrowseModule": {
                      "meshes": [
                        {
                          "id": "D055948",
                          "term": "Sarcopenia"
                        },
                        {
                          "id": "D009043",
                          "term": "Motor Activity"
                        },
                        {
                          "id": "D000073496",
                          "term": "Frailty"
                        }
                      ],
                      "ancestors": [
                        {
                          "id": "D009133",
                          "term": "Muscular Atrophy"
                        },
                        {
                          "id": "D020879",
                          "term": "Neuromuscular Manifestations"
                        },
                        {
                          "id": "D009461",
                          "term": "Neurologic Manifestations"
                        },
                        {
                          "id": "D009422",
                          "term": "Nervous System Diseases"
                        },
                        {
                          "id": "D001284",
                          "term": "Atrophy"
                        },
                        {
                          "id": "D020763",
                          "term": "Pathological Conditions, Anatomical"
                        },
                        {
                          "id": "D013568",
                          "term": "Pathological Conditions, Signs and Symptoms"
                        },
                        {
                          "id": "D012816",
                          "term": "Signs and Symptoms"
                        },
                        {
                          "id": "D001519",
                          "term": "Behavior"
                        },
                        {
                          "id": "D010335",
                          "term": "Pathologic Processes"
                        }
                      ]
                    },
                    "interventionBrowseModule": {
                      "meshes": [
                        {
                          "id": "D015525",
                          "term": "Fatty Acids, Omega-3"
                        }
                      ],
                      "ancestors": [
                        {
                          "id": "D004042",
                          "term": "Dietary Fats, Unsaturated"
                        },
                        {
                          "id": "D004041",
                          "term": "Dietary Fats"
                        },
                        {
                          "id": "D005223",
                          "term": "Fats"
                        },
                        {
                          "id": "D008055",
                          "term": "Lipids"
                        },
                        {
                          "id": "D005231",
                          "term": "Fatty Acids, Unsaturated"
                        },
                        {
                          "id": "D005227",
                          "term": "Fatty Acids"
                        },
                        {
                          "id": "D005395",
                          "term": "Fish Oils"
                        },
                        {
                          "id": "D009821",
                          "term": "Oils"
                        }
                      ]
                    }
                  },
                  "hasResults": false
                }
              },
              {
                "nct_id": "NCT06658093",
                "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                "overall_status": "RECRUITING",
                "study_type": "INTERVENTIONAL",
                "phases": [
                  "EARLY_PHASE1"
                ],
                "enrollment": 194,
                "primary_outcomes": [
                  {
                    "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                    "description": "The levels of the study drug will be measured in whole blood",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                    "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                    "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                  },
                  {
                    "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                    "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                    "timeFrame": "Baseline to study end (approximately 12 months)"
                  }
                ],
                "has_results": false,
                "raw_study": {
                  "protocolSection": {
                    "identificationModule": {
                      "nctId": "NCT06658093",
                      "orgStudyIdInfo": {
                        "id": "STUDY00000471"
                      },
                      "secondaryIdInfos": [
                        {
                          "id": "U01AG089242",
                          "type": "NIH",
                          "link": "https://reporter.nih.gov/quickSearch/U01AG089242"
                        }
                      ],
                      "organization": {
                        "fullName": "The University of Texas Health Science Center at San Antonio",
                        "class": "OTHER"
                      },
                      "briefTitle": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                      "officialTitle": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                      "acronym": "RESTOR"
                    },
                    "statusModule": {
                      "statusVerifiedDate": "2025-08",
                      "overallStatus": "RECRUITING",
                      "expandedAccessInfo": {
                        "hasExpandedAccess": false
                      },
                      "startDateStruct": {
                        "date": "2025-08-13",
                        "type": "ACTUAL"
                      },
                      "primaryCompletionDateStruct": {
                        "date": "2028-07",
                        "type": "ESTIMATED"
                      },
                      "completionDateStruct": {
                        "date": "2028-07",
                        "type": "ESTIMATED"
                      },
                      "studyFirstSubmitDate": "2024-10-22",
                      "studyFirstSubmitQcDate": "2024-10-22",
                      "studyFirstPostDateStruct": {
                        "date": "2024-10-26",
                        "type": "ACTUAL"
                      },
                      "lastUpdateSubmitDate": "2025-08-27",
                      "lastUpdatePostDateStruct": {
                        "date": "2025-09-04",
                        "type": "ACTUAL"
                      }
                    },
                    "sponsorCollaboratorsModule": {
                      "responsibleParty": {
                        "type": "PRINCIPAL_INVESTIGATOR",
                        "investigatorFullName": "Ellen Kraig",
                        "investigatorTitle": "Professor",
                        "investigatorAffiliation": "The University of Texas Health Science Center at San Antonio"
                      },
                      "leadSponsor": {
                        "name": "The University of Texas Health Science Center at San Antonio",
                        "class": "OTHER"
                      },
                      "collaborators": [
                        {
                          "name": "National Institute on Aging (NIA)",
                          "class": "NIH"
                        }
                      ]
                    },
                    "oversightModule": {
                      "oversightHasDmc": true,
                      "isFdaRegulatedDrug": true,
                      "isFdaRegulatedDevice": false
                    },
                    "descriptionModule": {
                      "briefSummary": "As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease. Studies in animal models have been able to identify drugs that slow the aging process, leading to a longer, healthier life. This study is focused on one such family of drugs, called mTOR inhibitors, and the investigators' goal is to test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults to find a dose and dose timing that can be used to safely inhibit mTOR to the levels seen in young healthy persons. The investigators expect that the dose that works well in women may differ from the one that is best in men, so it is important to include both sexes in this research.",
                      "detailedDescription": "The study will be done in three parts, each with different human subject groups. Participants may only enroll in one of the sub-studies.\n\nSub-study 1: Determining target mTOR activity values in YOUNG untreated subjects (ages 20-30 years): NOTE: This aim of the study is not a clinical trial, so this population will not be included in participant flow or included as an arm in the study.\n\nThis study defines \"best dose\" as the choice of drug, dose, and frequency that will come closest to restoring the \"youthful\" levels of mTOR activity in an older individual. The investigators first need to measure mTOR activity in young untreated subjects to define these target \"youthful\" mTOR activity levels.\n\nSub-study 2. Finding the most effective drug, dose, and timing for dosing for oral dosing of the mTOR inhibitor drugs in older adults (65-90 years):\n\nHealthy older persons will be recruited for a short-term (6 week treatment plus 4 week follow-up) dose-finding study. The most effective, but safe dose will then be tested in a larger number of subjects in Sub-study 3. Importantly, the best drug and dose regimen for females may differ from the one determined for males so the cohort will include both sexes.\n\nSub-study 3. Placebo controlled trial testing of DAILY (sustained) vs. INTERMITTENT mTOR inhibition in older human males and females:\n\nSub-study 3 will enroll healthy older persons (65-90 yrs) for a long-term clinical trial (6 months of treatment plus 6 months of follow-up) with 3 test groups:\n\ni) best DAILY dose/drug; ii) best INTERMITTENT dose/drug/interval, and iii) PLACEBO (a pill that looks identical to the medicine, but has no drug in it).\n\nThis study will help find out what effects, good and/or bad, Rapamycin or Everolimus have on older people who take the drug for a longer period of time. The safety of Rapamycin and Everolimus in humans has been tested in prior research studies; however, some side effects may not yet be known in healthy older persons. By completing the entire study, the Research Team hopes to learn more about how older human subjects can best be treated using these drugs (mTOR inhibitors) to help them live longer, healthier lives."
                    },
                    "conditionsModule": {
                      "conditions": [
                        "Aging"
                      ],
                      "keywords": [
                        "mTOR inhibitors"
                      ]
                    },
                    "designModule": {
                      "studyType": "INTERVENTIONAL",
                      "phases": [
                        "EARLY_PHASE1"
                      ],
                      "designInfo": {
                        "allocation": "RANDOMIZED",
                        "interventionModel": "SEQUENTIAL",
                        "interventionModelDescription": "A single site open label adaptive clinical trial (Aim 1:Sub-study 2) followed by a placebo-controlled blinded clinical trial (Aim 2) to optimize the use of mTOR inhibitors in older persons a functions of drug, dose, dosing schedule and sex. It will be carried out in 2 sub-studies:\n\nAim 1:\n\n-Sub-study 2: Comparison of 2 mTOR inhibitors in an adaptive open-label dose finding pharmacokinetic/pharmacodynamic study\n\nAim 2:\n\nSub-study 3: Assess the safety/tolerability/adverse events of optimized dose of mTOR inhibitors in daily vs intermittent dosing",
                        "primaryPurpose": "BASIC_SCIENCE",
                        "maskingInfo": {
                          "masking": "DOUBLE",
                          "maskingDescription": "Blinding will only occur in Aim 2 (Sub-study 3). Randomization will be done by the research pharmacy providing the investigational drug.",
                          "whoMasked": [
                            "PARTICIPANT",
                            "CARE_PROVIDER"
                          ]
                        }
                      },
                      "enrollmentInfo": {
                        "count": 194,
                        "type": "ESTIMATED"
                      }
                    },
                    "armsInterventionsModule": {
                      "armGroups": [
                        {
                          "label": "Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin",
                          "type": "EXPERIMENTAL",
                          "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                          "interventionNames": [
                            "Drug: Rapamycin"
                          ]
                        },
                        {
                          "label": "Aim 1: Sub-study 2 Daily dosing Cohort Everolimus",
                          "type": "EXPERIMENTAL",
                          "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) of everolimus (EVERO) in milligrams based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                          "interventionNames": [
                            "Drug: Everolimus"
                          ]
                        },
                        {
                          "label": "Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin",
                          "type": "EXPERIMENTAL",
                          "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                          "interventionNames": [
                            "Drug: Rapamycin"
                          ]
                        },
                        {
                          "label": "Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus",
                          "type": "EXPERIMENTAL",
                          "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of everolimus (EVERO) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                          "interventionNames": [
                            "Drug: Everolimus"
                          ]
                        },
                        {
                          "label": "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                          "type": "EXPERIMENTAL",
                          "description": "Based on the findings from Aim 1, the optimal drug (RAPA or EVERO) and dose for DAILY delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed.",
                          "interventionNames": [
                            "Drug: Rapamycin",
                            "Drug: Everolimus"
                          ]
                        },
                        {
                          "label": "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor",
                          "type": "EXPERIMENTAL",
                          "description": "Based on the findings from Aim 1, the optimal drug (RAPA or EVERO), interval between doses, and dose for INTERMITTENT delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose/interval used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed. Although drug is delivered on an intermittent schedule, subjects will be given a pill each day (either drug or placebo, as scheduled) to maintain blinding.",
                          "interventionNames": [
                            "Drug: Rapamycin",
                            "Drug: Everolimus"
                          ]
                        },
                        {
                          "label": "Aim 2: Sub-study 3 Placebo control",
                          "type": "PLACEBO_COMPARATOR",
                          "description": "Daily administration of a placebo will be given to a cohort of older human subjects. Both males and females will be enrolled as controls.",
                          "interventionNames": [
                            "Other: Placebo"
                          ]
                        }
                      ],
                      "interventions": [
                        {
                          "type": "DRUG",
                          "name": "Rapamycin",
                          "description": "mTOR inhibitor",
                          "armGroupLabels": [
                            "Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin",
                            "Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin",
                            "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                            "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor"
                          ],
                          "otherNames": [
                            "RAPA"
                          ]
                        },
                        {
                          "type": "DRUG",
                          "name": "Everolimus",
                          "description": "mTOR inhibitor",
                          "armGroupLabels": [
                            "Aim 1: Sub-study 2 Daily dosing Cohort Everolimus",
                            "Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus",
                            "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                            "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor"
                          ],
                          "otherNames": [
                            "EVERO"
                          ]
                        },
                        {
                          "type": "OTHER",
                          "name": "Placebo",
                          "description": "Inert placebo for rapamycin or everolimus",
                          "armGroupLabels": [
                            "Aim 2: Sub-study 3 Placebo control"
                          ],
                          "otherNames": [
                            "Placebo capsule"
                          ]
                        }
                      ]
                    },
                    "outcomesModule": {
                      "primaryOutcomes": [
                        {
                          "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                          "description": "The levels of the study drug will be measured in whole blood",
                          "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                          "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                          "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                        },
                        {
                          "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                          "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        }
                      ],
                      "secondaryOutcomes": [
                        {
                          "measure": "PK of mTOR inhibitor in fat (Aim 2 only)",
                          "description": "The levels of the study drug will be measure in fat tissue obtained by adipose biopsy",
                          "timeFrame": "Baseline and study end (approximately 12 months)"
                        },
                        {
                          "measure": "PK of mTOR inhibitor in muscle (Aim 2 only)",
                          "description": "The levels of the study drug will be measured in skeletal muscle obtained by biopsy.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in fat cells (Aim 2 only) - pS6K",
                          "description": "Proteins prepared from adipose tissue will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in muscle (Aim 2 only) - pS6K",
                          "description": "Proteins prepared from skeletal muscle tissue biopsy will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in PBMCs, S6-kinase",
                          "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in adipose cells, rpS6 (Aim 2 only)",
                          "description": "Proteins prepared from adipose biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in muscle rpS6 (Aim 2 only)",
                          "description": "Proteins prepared from muscle biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in adipose (fat) cells Akt (Aim 2 only)",
                          "description": "Proteins prepared from adipose biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in muscle Akt (Aim 2 only)",
                          "description": "Proteins prepared from muscle biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        },
                        {
                          "measure": "PD measure of inhibition of mTOR activity in PBMCs Akt",
                          "description": "Proteins prepared from PBMCs will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                          "timeFrame": "Baseline to study end (approximately 12 months)"
                        }
                      ]
                    },
                    "eligibilityModule": {
                      "eligibilityCriteria": "Inclusion Criteria:\n\nOlder Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):\n\n1. Age 65 to 90 years\n2. Men and women\n3. In good health with all medical problems stable.\n4. Community-dwelling\n5. Agreement to adhere to Lifestyle Considerations throughout study duration.\n6. Ability of participant to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nOlder Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):\n\n1. Resident of nursing home or long-term care facility\n2. Subjects with diabetes or currently taking glucose lowering medications\n3. History of moderate-severe heart disease (New York Heart Classication greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one ight of stairs or less; abnormal breath sounds on auscultation); Moderate to severe valvular heart disease\n4. Active cancer or history of cancer treatment within the last 5 years\n5. Chronic inammatory condition, autoimmune disease, or infectious processes (e.g., active tuberculosis, HIV, rheumatoid arthritis, systemic lupus erythematosus, acute or chronic hepatitis B or C)\n6. History of a coagulopathy or any medical condition requiring anticoagulation (except low dose ASA)\n7. Renal insuciency with an estimated glomerular ltration rate of \\<30ml/min\n8. Uncontrolled hypercholesterolemia \\>350mg/dl or uncontrolled hypertriglyceridemia \\>500mg/dl\n9. Anemia or abnormal blood cell counts: hemoglobin level \\<9.0g.dl; white blood count \\<3500/mm3; neutrophil count \\<2000/ mm3; platelet count \\<125,000/mm3\n10. History of skin ulcers or poor wound healing\n11. Active tobacco use (within 6 months)\n12. Diagnosis of any disabling neurologic disease such as Parkinson's Disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, cerebrovascular accident with residual decits (muscle weakness or gait disorder), severe neuropathy, diagnosis of dementia or Clox1 score less than 10 at the time of screening visit, cognitive impairment due to any reason such that the patient is unable to provide informed consent\n13. Liver disease\n14. Systemic treatment with an immunosuppressant (prednisone, etc.) within the year prior to enrollment\n15. Treatment with drugs known to affect cytochrome P450 (CYP3A4), i.e., diltiazem, erythromycin.\n16. Patients with history of recent (within 6 months) myocardial infarction or active coronary disease\n17. Patients with history of recent (within 6 months) intestinal disorders\n18. History of severe head trauma, brain injury, brain surgery, inammation of the brain, or history of seizure disorder\n19. History of Long-Covid (PASC) within one year\n20. Acute Covid19 or Covid19 infection within the last 6 months\n21. Unwilling to forgo grapefruit juice consumption.\n22. Participation in mTORi study within the prior year. (Note: participants in AIM 1 will be excluded from participating in AIM 2 of the proposed trial.)\n23. Allergic to RAPA or EVERO\n24. Allergic to lidocaine\n25. Recreational drug use\n26. Donated blood over a two-month period prior to study initiation.\n27. Currently using cannabidiol (CBD) or tetrahydrocannabinol (THC) or any preparation contained these, or related, substances.\n28. Currently using hormone replacement or modulating therapies.",
                      "healthyVolunteers": true,
                      "sex": "ALL",
                      "minimumAge": "65 Years",
                      "maximumAge": "90 Years",
                      "stdAges": [
                        "OLDER_ADULT"
                      ]
                    },
                    "contactsLocationsModule": {
                      "centralContacts": [
                        {
                          "name": "Dean L Kellogg, Jr, MD PhD",
                          "role": "CONTACT",
                          "phone": "(210) 617 5197",
                          "email": "kelloggd@uthscsa.edu"
                        },
                        {
                          "name": "Ellen Kraig, PhD",
                          "role": "CONTACT",
                          "phone": "(210) 367-3171",
                          "email": "kraig@uthscsa.edu"
                        }
                      ],
                      "overallOfficials": [
                        {
                          "name": "Ellen Kraig, PhD",
                          "affiliation": "The University of Texas Health Science Center at San Antonio",
                          "role": "PRINCIPAL_INVESTIGATOR"
                        }
                      ],
                      "locations": [
                        {
                          "facility": "The University of Texas Health Science Center at San Antonio",
                          "status": "RECRUITING",
                          "city": "San Antonio",
                          "state": "Texas",
                          "zip": "78229",
                          "country": "United States",
                          "contacts": [
                            {
                              "name": "Dean L Kellogg Jr.,, MD PhD",
                              "role": "CONTACT",
                              "phone": "210-617-5197",
                              "email": "kelloggd@uthscsa.edu"
                            },
                            {
                              "name": "Dean L Kellogg Jr., MD PhD",
                              "role": "PRINCIPAL_INVESTIGATOR"
                            }
                          ],
                          "geoPoint": {
                            "lat": 29.42412,
                            "lon": -98.49363
                          }
                        }
                      ]
                    },
                    "referencesModule": {
                      "references": [
                        {
                          "pmid": "29408453",
                          "type": "BACKGROUND",
                          "citation": "Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, Benavides AD, Curiel TJ, Javors MA, Musi N, Chiodo L, Koek W, Gelfond JAL, Kellogg DL Jr. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp Gerontol. 2018 May;105:53-69. doi: 10.1016/j.exger.2017.12.026. Epub 2018 Feb 3."
                        }
                      ]
                    },
                    "ipdSharingStatementModule": {
                      "ipdSharing": "YES",
                      "description": "De-identified Individual participant data (IPD) that underlie results in a publication.",
                      "infoTypes": [
                        "STUDY_PROTOCOL",
                        "SAP"
                      ],
                      "timeFrame": "At the time of publication in a peer review journal"
                    }
                  },
                  "derivedSection": {
                    "miscInfoModule": {
                      "versionHolder": "2026-02-27"
                    },
                    "interventionBrowseModule": {
                      "meshes": [
                        {
                          "id": "D020123",
                          "term": "Sirolimus"
                        },
                        {
                          "id": "D000068338",
                          "term": "Everolimus"
                        }
                      ],
                      "ancestors": [
                        {
                          "id": "D018942",
                          "term": "Macrolides"
                        },
                        {
                          "id": "D007783",
                          "term": "Lactones"
                        },
                        {
                          "id": "D009930",
                          "term": "Organic Chemicals"
                        }
                      ]
                    }
                  },
                  "hasResults": false
                }
              }
            ]
          },
          "ids": [
            "NCT03308747",
            "NCT03649698",
            "NCT06658093"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT03308747.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/clinicaltrials_fetch/manual-013/raw/clinicaltrials_NCT03308747.json",
              "sha256": "928d90cc74455d70d59d848af0fffbfd17c7238c18a99d6dc43da1e0f4cdc9be",
              "size_bytes": 15620
            },
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT03649698.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/clinicaltrials_fetch/manual-013/raw/clinicaltrials_NCT03649698.json",
              "sha256": "375f745171f12f9bd7185fffc9fb1a7b2ed606aaafadf034d0672a6b9735bf3e",
              "size_bytes": 34831
            },
            {
              "kind": "raw_json",
              "name": "clinicaltrials_NCT06658093.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/clinicaltrials_fetch/manual-013/raw/clinicaltrials_NCT06658093.json",
              "sha256": "4482a1a06dd9fca7a81621f6c813247b3bb6469af4c723696e13547897c0b016",
              "size_bytes": 23444
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "clinicaltrials",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:36.781288Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-013"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "trial_publication_linker"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 734.57,
      "endpoint": "https://clinicaltrials.gov/api/v2/studies/{nct}",
      "enabled": true
    },
    {
      "tool": "retrieval_should_run_trial_audit",
      "payload": {
        "trials": [
          {
            "nct_id": "NCT03308747",
            "brief_title": "Inflammaging and Muscle Protein Metabolism",
            "official_title": "Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle.",
            "overall_status": "COMPLETED",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "NA"
            ],
            "enrollment": 44,
            "primary_outcomes": [
              {
                "measure": "Systemic inflammation",
                "description": "Levels of systemic inflammation will be assessed by measuring serum levels of hs-CRP, IL-6 and TNF-.",
                "timeFrame": "At baseline."
              },
              {
                "measure": "Change in muscle protein synthesis (MPS)",
                "description": "Using deuterium oxide (D2O) 70% atom administration. Individuals will consume a single bolus of 150ml D20 the day before the clinical trial and muscle biopsy samples, collected before and after the exercise bout and protein ingestion, will be analyzed for isotopic measurement using GC-P-IRMS.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              },
              {
                "measure": "Change in intracellular signaling proteins in muscle",
                "description": "Phosphorylation levels of Akt, mammalian target of rapamycin (mTOR), p70S6K and ribosomal protein S6 (rpS6) will be measure using western blotting.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              },
              {
                "measure": "Change in proteasome activities in muscle",
                "description": "Chymotrypsin-like (CT-L), caspase-like (C-L) and trypsin-like (T-L) proteasome activities will be assayed with hydrolysis of the fluorogenic peptide LLVY-AMC, LLE-AMC and LSTR-AMC, respectively.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              },
              {
                "measure": "Change in protein expression level of proteasome subunits",
                "description": "Immunoblot analysis will be used to detect protein expression levels of proteasome (5, 2 and 1) and immunoproteasome (5i, 2i and 1i) subunits.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              }
            ],
            "has_results": false,
            "raw_study": {
              "protocolSection": {
                "identificationModule": {
                  "nctId": "NCT03308747",
                  "orgStudyIdInfo": {
                    "id": "INFLAMMAGING-UTH"
                  },
                  "organization": {
                    "fullName": "University of Thessaly",
                    "class": "OTHER"
                  },
                  "briefTitle": "Inflammaging and Muscle Protein Metabolism",
                  "officialTitle": "Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle."
                },
                "statusModule": {
                  "statusVerifiedDate": "2017-10",
                  "overallStatus": "COMPLETED",
                  "expandedAccessInfo": {
                    "hasExpandedAccess": false
                  },
                  "startDateStruct": {
                    "date": "2017-09-01",
                    "type": "ACTUAL"
                  },
                  "primaryCompletionDateStruct": {
                    "date": "2018-02-15",
                    "type": "ACTUAL"
                  },
                  "completionDateStruct": {
                    "date": "2018-05-30",
                    "type": "ACTUAL"
                  },
                  "studyFirstSubmitDate": "2017-10-02",
                  "studyFirstSubmitQcDate": "2017-10-08",
                  "studyFirstPostDateStruct": {
                    "date": "2017-10-13",
                    "type": "ACTUAL"
                  },
                  "lastUpdateSubmitDate": "2018-07-18",
                  "lastUpdatePostDateStruct": {
                    "date": "2018-07-19",
                    "type": "ACTUAL"
                  }
                },
                "sponsorCollaboratorsModule": {
                  "responsibleParty": {
                    "type": "PRINCIPAL_INVESTIGATOR",
                    "investigatorFullName": "Ioannis G. Fatouros",
                    "investigatorTitle": "Associate Professor",
                    "investigatorAffiliation": "University of Thessaly"
                  },
                  "leadSponsor": {
                    "name": "University of Thessaly",
                    "class": "OTHER"
                  }
                },
                "oversightModule": {
                  "oversightHasDmc": false,
                  "isFdaRegulatedDrug": false,
                  "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                  "briefSummary": "The development of a low-grade, chronic, systemic inflammation observed in the elderly (inflammaing) has been associated with increased risk for skeletal muscle wasting, strength loss and functional impairments. According to studies performed in animals and cell cultures increased concentrations of pro-inflammatory cytokines such as IL-6 and TNF- as well as increased levels of hs-CRP lead to elevated protein degradation through proteasome activation and reduced muscle protein synthesis (MPS) via downregulation of the Akt-mTOR signaling pathway. However, evidence regarding the effects of inflammaging on skeletal muscle mass in humans is lacking. Thus, the present study will compare proteasome activation and the protein synthetic response in the fasted and postprandial period between older adults with increased systemic inflammation and their healthy control counterparts.",
                  "detailedDescription": "A total number of \\> 60 male, older adults aged 63-73 years will be initially screened for systemic levels of hs-CRP and IL-6. Of these, 24 individuals that will comply with the study criteria will be allocated to either a High (IL6:  1.7 pg/ml; hs-CRP: \\> 1.0 mg/L) (n=12) or a Low (IL6: \\< 1.7 pg/ml; hs-CRP: \\< 1.0 mg/L) (n=12) systemic inflammation group. Approximately 2 weeks before the experimental trial, anthropometry, resting metabolic rate (RMR), body composition (with DXA), sarcopenia status, functional capacity and the knee-extension one repetition maximum (1RM) will be assessed in individuals from both groups. In addition, levels of habitual physical activity will be assessed using accelerometry (over a 7-day period) and daily dietary intake will be monitored through 7-day diet recalls in all participants. 1 week before the experimental day an oral glucose tolerance test (OGTT) will be also performed over a 2-hour period, with blood sampling every 15min during the first hour and every 30min during the second hour. The day before the experimental trial, participants will consume 150ml of D2O 70% atom as a bolus. In the experimental day, participants will arrive at the laboratory after an overnight fast and a baseline blood sample and a muscle biopsy from vastus lateralis muscle will be collected. Immediately after, participants will perform 8 sets with 10 repetitions at 80% of 1RM and 2 min rest between each set, on a knee-extension machine. After exercise, they will ingest 0.4 g whey protein isolate/kg body weight as single bolus and then they will remain in a sitting position over a 3-hour period. Blood samples will be collected every 30min during the 3-hour postprandial period while a second muscle biopsy will be obtained at 3h."
                },
                "conditionsModule": {
                  "conditions": [
                    "Inflammaging",
                    "Sarcopenia"
                  ],
                  "keywords": [
                    "Low-grade systemic inflammation",
                    "Muscle protein synthesis",
                    "Proteasome activation",
                    "Anabolic signaling",
                    "Aging",
                    "Sarcopenia"
                  ]
                },
                "designModule": {
                  "studyType": "INTERVENTIONAL",
                  "phases": [
                    "NA"
                  ],
                  "designInfo": {
                    "allocation": "NON_RANDOMIZED",
                    "interventionModel": "PARALLEL",
                    "primaryPurpose": "BASIC_SCIENCE",
                    "maskingInfo": {
                      "masking": "DOUBLE",
                      "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                      ]
                    }
                  },
                  "enrollmentInfo": {
                    "count": 44,
                    "type": "ACTUAL"
                  }
                },
                "armsInterventionsModule": {
                  "armGroups": [
                    {
                      "label": "High systemic inflammation",
                      "type": "EXPERIMENTAL",
                      "description": "Individuals assigned in the high systemic inflammation group will be characterized by IL6:  1.7 pg/ml and hs-CRP: \\> 2.0 mg/L.",
                      "interventionNames": [
                        "Dietary Supplement: Instantized Whey Protein Isolate"
                      ]
                    },
                    {
                      "label": "Low systemic inflammation",
                      "type": "ACTIVE_COMPARATOR",
                      "description": "Individuals assigned in the high systemic inflammation group will be characterized by IL6: \\< 1.7 pg/ml and hs-CRP: \\< 1.0 mg/L.",
                      "interventionNames": [
                        "Dietary Supplement: Instantized Whey Protein Isolate"
                      ]
                    }
                  ],
                  "interventions": [
                    {
                      "type": "DIETARY_SUPPLEMENT",
                      "name": "Instantized Whey Protein Isolate",
                      "description": "0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.",
                      "armGroupLabels": [
                        "High systemic inflammation",
                        "Low systemic inflammation"
                      ]
                    }
                  ]
                },
                "outcomesModule": {
                  "primaryOutcomes": [
                    {
                      "measure": "Systemic inflammation",
                      "description": "Levels of systemic inflammation will be assessed by measuring serum levels of hs-CRP, IL-6 and TNF-.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Change in muscle protein synthesis (MPS)",
                      "description": "Using deuterium oxide (D2O) 70% atom administration. Individuals will consume a single bolus of 150ml D20 the day before the clinical trial and muscle biopsy samples, collected before and after the exercise bout and protein ingestion, will be analyzed for isotopic measurement using GC-P-IRMS.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Change in intracellular signaling proteins in muscle",
                      "description": "Phosphorylation levels of Akt, mammalian target of rapamycin (mTOR), p70S6K and ribosomal protein S6 (rpS6) will be measure using western blotting.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Change in proteasome activities in muscle",
                      "description": "Chymotrypsin-like (CT-L), caspase-like (C-L) and trypsin-like (T-L) proteasome activities will be assayed with hydrolysis of the fluorogenic peptide LLVY-AMC, LLE-AMC and LSTR-AMC, respectively.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Change in protein expression level of proteasome subunits",
                      "description": "Immunoblot analysis will be used to detect protein expression levels of proteasome (5, 2 and 1) and immunoproteasome (5i, 2i and 1i) subunits.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    }
                  ],
                  "secondaryOutcomes": [
                    {
                      "measure": "Resting metabolic rate (RMR)",
                      "description": "RMR will be assessed after an overnight fast with participants in a supine position following a 15-min stabilization period by taking 30 consecutive 1-min VO2/CO2 measurements using a portable open-circuit indirect calorimeter with a ventilated hood system following a standard calibration protocol.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Physical activity",
                      "description": "Level of habitual physical activity will be assessed using accelerometry (ActiGraph GT3X-BT accelerometer).",
                      "timeFrame": "Over a 7-day period at baseline."
                    },
                    {
                      "measure": "Dietary intake",
                      "description": "Daily dietary intake will be assessed using 7-day diet recalls.",
                      "timeFrame": "Over a 7-day period at baseline."
                    },
                    {
                      "measure": "Reduced glutathione in blood",
                      "description": "Concentration of reduced glutathione will be measured in red blood cells",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Oxidized glutathione in blood",
                      "description": "Concentration of oxidized glutathione will be measured in red blood cells",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Protein carbonyls in serum",
                      "description": "Concentration of protein carbonyls will be measured in serum.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Total antioxidant capacity",
                      "description": "Total antioxidant capacity will be measured in serum",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Malondialdehyde in serum",
                      "description": "Concentration of malondialdehyde will be measured in serum.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "White blood cell count in blood",
                      "description": "White blood cell count will be measured in blood.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Insulin sensitivity",
                      "description": "Insulin sensitivity will be assessed through an oral glucose tolerance test (OGTT) which involve ingesting glucose solution (75 g) with 5ml arterialized venous blood samples drawn at baseline and every 15 min during the first hour and every 30 min during the second hour over a 2-hour period.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Glucose concentration in blood",
                      "description": "Glucose concentration will be measured in plasma during the clinical trial.",
                      "timeFrame": "At baseline and at 30 min, 60 min, 90 min, 120 min, 150 min and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Insulin concentration in blood",
                      "description": "Insulin concentration will be measured in plasma during the clinical trial.",
                      "timeFrame": "At baseline and at 30 min, 60 min, 90 min, 120 min, 150 min and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Body composition",
                      "description": "Body composition will be measured using a dual-energy x-ray absorptiometry scanner (DEXA).",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Body Mass Index (BMI)",
                      "description": "Calculated as body mass (kg) divided by the height (m) squared.",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Skeletal muscle index",
                      "description": "Calculated as an appendicular lean mass (kg) divided by height (m) squared.",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Grip strength",
                      "description": "Using handgrip dynamometry (left and right arm) in a sitting position.",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Functional performance",
                      "description": "Functional performance will be assessed using the Short Physical Performance Battery (SPPB).",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Lower limb muscle strength",
                      "description": "Will be assessed by defining the 1 repetition maximum (1RM) on a knee-extension machine.",
                      "timeFrame": "At baseline"
                    }
                  ]
                },
                "eligibilityModule": {
                  "eligibilityCriteria": "Inclusion Criteria:\n\n* Non-smokers.\n* BMI 18.5 \\& BMI  35 kg/m2.\n* Moderately active but with no regular participation in heavy resistance exercise within the last 6 months.\n* Absence of chronic disease (i.e. cancer, metabolic, cardiac, or neurological diseases).\n* Free and independently living.\n\nExclusion Criteria:\n\n* Organ failure (unstable, renal, respiratory, liver).\n* Chronic use of corticosteroid medication.\n* Recent use of antibiotics.\n* Presence of frailty.\n* Body weight variation over the past 6mo \\> 10% or weight loss of more than 3kg in the last 3 months.\n* Use of anti-inflammatory or lipid-lowering medication (i.e., statins).\n* Use of medication interacting with muscle metabolism.",
                  "healthyVolunteers": true,
                  "sex": "MALE",
                  "minimumAge": "63 Years",
                  "maximumAge": "75 Years",
                  "stdAges": [
                    "ADULT",
                    "OLDER_ADULT"
                  ]
                },
                "contactsLocationsModule": {
                  "overallOfficials": [
                    {
                      "name": "DIMITRIOS DRAGANIDIS, PhDc",
                      "affiliation": "UNIVERSITY OF THESSALY, SCHOOL OF PHYSICAL EDUCATION & SPORTS SCIENCES",
                      "role": "PRINCIPAL_INVESTIGATOR"
                    }
                  ],
                  "locations": [
                    {
                      "facility": "Exercise Biochemistry Laboratory, School of Physical Education & Sports Sciences, University of Thessaly",
                      "city": "Trikala",
                      "zip": "42100",
                      "country": "Greece",
                      "geoPoint": {
                        "lat": 39.55493,
                        "lon": 21.76837
                      }
                    }
                  ]
                }
              },
              "derivedSection": {
                "miscInfoModule": {
                  "versionHolder": "2026-02-27"
                },
                "conditionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D055948",
                      "term": "Sarcopenia"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D009133",
                      "term": "Muscular Atrophy"
                    },
                    {
                      "id": "D020879",
                      "term": "Neuromuscular Manifestations"
                    },
                    {
                      "id": "D009461",
                      "term": "Neurologic Manifestations"
                    },
                    {
                      "id": "D009422",
                      "term": "Nervous System Diseases"
                    },
                    {
                      "id": "D001284",
                      "term": "Atrophy"
                    },
                    {
                      "id": "D020763",
                      "term": "Pathological Conditions, Anatomical"
                    },
                    {
                      "id": "D013568",
                      "term": "Pathological Conditions, Signs and Symptoms"
                    },
                    {
                      "id": "D012816",
                      "term": "Signs and Symptoms"
                    }
                  ]
                }
              },
              "hasResults": false
            }
          },
          {
            "nct_id": "NCT03649698",
            "brief_title": "Exercise and Nutrition for Healthy AgeiNg",
            "official_title": "Exercise and Nutrition for Healthy AgeiNg: Anabolic Interventions for Older People With (Pre)Sarcopenia to Improve Physical Functioning, Muscle Mass and Muscle Strength and to Understand the Underlying Mechanisms of Action.",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "NA"
            ],
            "enrollment": 180,
            "primary_outcomes": [
              {
                "measure": "Change in physical functioning",
                "description": "Change in SPPB score",
                "timeFrame": "Measured at baseline, week 12 and week 24."
              },
              {
                "measure": "Percentage of participants with change in physical functioning",
                "description": "the percentage of participants with more than 1 or 1 point increase in SPPB score.",
                "timeFrame": "Measured at baseline, week 12 and week 24."
              }
            ],
            "has_results": false,
            "raw_study": {
              "protocolSection": {
                "identificationModule": {
                  "nctId": "NCT03649698",
                  "orgStudyIdInfo": {
                    "id": "S60763"
                  },
                  "organization": {
                    "fullName": "Universitaire Ziekenhuizen KU Leuven",
                    "class": "OTHER"
                  },
                  "briefTitle": "Exercise and Nutrition for Healthy AgeiNg",
                  "officialTitle": "Exercise and Nutrition for Healthy AgeiNg: Anabolic Interventions for Older People With (Pre)Sarcopenia to Improve Physical Functioning, Muscle Mass and Muscle Strength and to Understand the Underlying Mechanisms of Action.",
                  "acronym": "ENHANce"
                },
                "statusModule": {
                  "statusVerifiedDate": "2024-06",
                  "overallStatus": "RECRUITING",
                  "expandedAccessInfo": {
                    "hasExpandedAccess": false
                  },
                  "startDateStruct": {
                    "date": "2018-02-12",
                    "type": "ACTUAL"
                  },
                  "primaryCompletionDateStruct": {
                    "date": "2024-12",
                    "type": "ESTIMATED"
                  },
                  "completionDateStruct": {
                    "date": "2025-06",
                    "type": "ESTIMATED"
                  },
                  "studyFirstSubmitDate": "2018-08-07",
                  "studyFirstSubmitQcDate": "2018-08-24",
                  "studyFirstPostDateStruct": {
                    "date": "2018-08-28",
                    "type": "ACTUAL"
                  },
                  "lastUpdateSubmitDate": "2024-06-27",
                  "lastUpdatePostDateStruct": {
                    "date": "2024-06-28",
                    "type": "ACTUAL"
                  }
                },
                "sponsorCollaboratorsModule": {
                  "responsibleParty": {
                    "type": "SPONSOR"
                  },
                  "leadSponsor": {
                    "name": "Universitaire Ziekenhuizen KU Leuven",
                    "class": "OTHER"
                  },
                  "collaborators": [
                    {
                      "name": "KU Leuven",
                      "class": "OTHER"
                    },
                    {
                      "name": "VISTA-Life",
                      "class": "UNKNOWN"
                    },
                    {
                      "name": "Nestle Health Science",
                      "class": "INDUSTRY"
                    }
                  ]
                },
                "oversightModule": {
                  "oversightHasDmc": false,
                  "isFdaRegulatedDrug": false,
                  "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                  "briefSummary": "The aim of this randomized placebo-controlled 5-arm clinical trial is to evaluate the effect of combined anabolic interventions compared to single or placebo interventions on physical performance in community-dwelling (pre)sarcopenic elderly ( 65 years) and to determine the underlying mechanisms of action. Important secondary outcome measures are muscle mass, muscle strength, compliance to the interventions (exercise program, protein and omega-3 supplementation) and functional, cognitive and nutritional status.",
                  "detailedDescription": "The aim of this randomized 5-arm clinical trial is to evaluate the effect of combined anabolic interventions compared to single or placebo interventions on physical performance in community-dwelling (pre)sarcopenic elderly ( 65 years) living in Belgium. Physical performance will be evaluated using the Short Physical Performance Battery (SPPB). Muscle mass will be measured using a dual energy x-ray absorptiometry (DXA) and/or bioelectrical impedance analysis (BIA). Muscle strength will be measured by the Biodex (knee-extensor and knee-flexor) and a 1 hand-held dynamometer. The trial will also determine the underlying mechanisms of action using blood measures (such as markers of inflammation and sarcopenia) and muscle biomarkers. Important secondary outcome measures are compliance to the exercise program and to the protein and omega-3 supplementation, as well as functional, cognitive and nutritional status and the patients report on benefits and adverse events.\n\nThe study consists of four parts. Part I is the screening phase, which starts from the moment the participant has signed the informed consent until the start of the preparations of the study. During the screening, participants will be assessed for study eligibility by the study coordinator and contributors. If the participant is eligible, he or she will be randomly assigned into 1 of 5 intervention groups: Group 1: Exercise intervention; Group 2: Protein supplement; Group 3: Exercise intervention + protein supplement; Group 4: Exercise + Protein supplement + omega-3 supplement; Group 5: No intervention.\n\nPart II is the preparation phase, in which the participants starts some of the interventions before the start of the study to familiarize patients with e.g. the intake of a protein supplement. All the participants will take an oral vitamin D supplement (800 IU cholecalciferol) from 4 weeks before the start of the intervention if their vitamin D level is above 20 nmol/L. Patients with a vitamin D level \\< 20 nmol/L will receive repletion therapy. A trial diary will be completed by all participants to record PA, falls and intake of protein/omega3/placebo and vitamin D products. Participants in the exercise intervention (group 1, 3 and 4) will be invited to an information session where the Otago Exercise Program (OEP) will be explained and practiced. With respect to the protein supplementation, participants will receive an individually adapted protein supplement to achieve the recommended total daily intake of 1.5 g protein/kg. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between, before or after meals, based on the subjects' food intake assessed by a food diary. The protein powder is commercially available and consists of 4.5g protein/ 5g powder. The participants in group 2, 3 and 4 will start taking the protein supplement or matched placebo 5 days before the start of the intervention. Four weeks before the start of the intervention, the participants of group 4 will start with the intake of omega-3 (1 capsule providing in total 500 mg eicosapentanoic acid (EPA) and 450 mg docosahexaenoic acid (DHA)) or matched placebo. Placebo will be provided for the participants who are not given a protein and/or omega-3 supplement. Participants are blinded to the nutritional interventions.\n\nThe third part of the study, the intervention period, takes 12 weeks. During this period, there are 8 contact moments (at baseline, week 1, week 2, week 4, week 6, week 8, week 10 and week 12). All the participants continue with the vitamin D supplementation. Participants in the exercise intervention (group 1, 3 and 4) will perform the optimized and personally adapted OEP and will also follow a walking plan. The strength exercises of the OEP are personalised based on the individual's 1 repetition maximum. Balance exercises of the OEP are personalised based on improvements on MiniBESTest scores during the intervention period. The nutritional intervention groups (protein supplementation: group 2, 3 and 4 and omega-3 supplementation: group 4) continue with the protein and/or omega-3 supplements until the last visit of the intervention period.\n\nPart IV is the follow-up period, after the intervention. This phase takes 12 weeks and exists of 2 telephone contacts and 2 contact moments. All the participants continue the vitamin D supplementation until the last visit of the follow-up. The exercise intervention group (group 1, 3 and 4) may continue the OEP, but no personal encouragement will be given during this period. No protein and/ or omega-3 supplements will be given during the follow-up.\n\nSeveral outcomes will be measured during the contact moments of the intervention period and follow-up period (part III and part IV). This will be done by questionnaires about nutritional status, fall history and use of health care (from baseline until end of follow-up), and evaluation of functional and cognitive status. Blood, urine and muscle samples will be taken. The physical activity will be measured by wearing a movement tracker. All participants will wear a movement tracker 5 days before the intervention period and during the first two weeks of the intervention period and last two weeks of the intervention period, and during the last 2 weeks of the follow-up period. Participants who receive an exercise intervention (group 1, 3 and 4) will be encouraged to wear the movement tracker during the complete intervention period. The participants will complete a four-day food diary throughout the trial at week 1, week 6, week 12 and week 24. The participants will be asked for compliance during the preparation period and intervention period and their fall history which can be monitored by using diaries during the intervention period and the follow-up period.\n\nAddendum 27-07-2021: starting from 01-2021 a substudy was initiated in which participants of ENHANce, who agreed for participation in this substudy, collect stool samples at baseline, week 4, week 8 and week 12 of the intervention. This will allow to observe possible changes in gut microbiota composition and intestinal inflammation."
                },
                "conditionsModule": {
                  "conditions": [
                    "Sarcopenia"
                  ],
                  "keywords": [
                    "Sarcopenia",
                    "Nutrition",
                    "Protein",
                    "Vitamin D",
                    "Exercise",
                    "Older people",
                    "Frailty"
                  ]
                },
                "designModule": {
                  "studyType": "INTERVENTIONAL",
                  "phases": [
                    "NA"
                  ],
                  "designInfo": {
                    "allocation": "RANDOMIZED",
                    "interventionModel": "PARALLEL",
                    "primaryPurpose": "TREATMENT",
                    "maskingInfo": {
                      "masking": "TRIPLE",
                      "maskingDescription": "* Participant: Yes blinded for protein and omega-3\n* Investigator: Yes blinded for protein and omega-3\n* Outcomes Assessor: Yes blinded for protein and omega-3\n* No blinding for exercise intervention.\n* Statistician is blinded for protein, omega-3 and exercise intervention.",
                      "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                      ]
                    }
                  },
                  "enrollmentInfo": {
                    "count": 180,
                    "type": "ESTIMATED"
                  }
                },
                "armsInterventionsModule": {
                  "armGroups": [
                    {
                      "label": "Home-based training program",
                      "type": "EXPERIMENTAL",
                      "description": "Home-based training program + protein placebo + omega-3 placebo",
                      "interventionNames": [
                        "Behavioral: Home-based training program",
                        "Drug: Placebo protein powder",
                        "Drug: Placebo omega-3"
                      ]
                    },
                    {
                      "label": "High-quality protein supplement",
                      "type": "EXPERIMENTAL",
                      "description": "High-quality protein supplement + omega-3 placebo",
                      "interventionNames": [
                        "Dietary Supplement: High-quality protein supplement",
                        "Drug: Placebo omega-3"
                      ]
                    },
                    {
                      "label": "2 Anabolic interventions",
                      "type": "EXPERIMENTAL",
                      "description": "Home-based training program and high quality protein supplement",
                      "interventionNames": [
                        "Behavioral: Home-based training program",
                        "Dietary Supplement: High-quality protein supplement",
                        "Drug: Placebo omega-3"
                      ]
                    },
                    {
                      "label": "3 Anabolic interventions",
                      "type": "EXPERIMENTAL",
                      "description": "Home-based training program, high-quality protein supplement and omega-3 fatty acids",
                      "interventionNames": [
                        "Behavioral: Home-based training program",
                        "Dietary Supplement: High-quality protein supplement",
                        "Dietary Supplement: Omega-3 fatty acid"
                      ]
                    },
                    {
                      "label": "Placebo protein powder and omega-3",
                      "type": "PLACEBO_COMPARATOR",
                      "description": "Control group: protein placebo + omega-3 placebo",
                      "interventionNames": [
                        "Drug: Placebo protein powder",
                        "Drug: Placebo omega-3"
                      ]
                    }
                  ],
                  "interventions": [
                    {
                      "type": "BEHAVIORAL",
                      "name": "Home-based training program",
                      "description": "Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.",
                      "armGroupLabels": [
                        "2 Anabolic interventions",
                        "3 Anabolic interventions",
                        "Home-based training program"
                      ]
                    },
                    {
                      "type": "DIETARY_SUPPLEMENT",
                      "name": "High-quality protein supplement",
                      "description": "The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.",
                      "armGroupLabels": [
                        "2 Anabolic interventions",
                        "3 Anabolic interventions",
                        "High-quality protein supplement"
                      ]
                    },
                    {
                      "type": "DIETARY_SUPPLEMENT",
                      "name": "Omega-3 fatty acid",
                      "description": "Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.",
                      "armGroupLabels": [
                        "3 Anabolic interventions"
                      ]
                    },
                    {
                      "type": "DRUG",
                      "name": "Placebo protein powder",
                      "description": "Isocaloric maltodextrin powder. Amount based on food diary.",
                      "armGroupLabels": [
                        "Home-based training program",
                        "Placebo protein powder and omega-3"
                      ]
                    },
                    {
                      "type": "DRUG",
                      "name": "Placebo omega-3",
                      "description": "Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day",
                      "armGroupLabels": [
                        "2 Anabolic interventions",
                        "High-quality protein supplement",
                        "Home-based training program",
                        "Placebo protein powder and omega-3"
                      ]
                    }
                  ]
                },
                "outcomesModule": {
                  "primaryOutcomes": [
                    {
                      "measure": "Change in physical functioning",
                      "description": "Change in SPPB score",
                      "timeFrame": "Measured at baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Percentage of participants with change in physical functioning",
                      "description": "the percentage of participants with more than 1 or 1 point increase in SPPB score.",
                      "timeFrame": "Measured at baseline, week 12 and week 24."
                    }
                  ],
                  "secondaryOutcomes": [
                    {
                      "measure": "Change in muscle mass (after intervention-baseline)",
                      "description": "Appendicular lean mass will be measured with a whole-body DXA scan and by BIA.",
                      "timeFrame": "Measured at screening, week 12 and week 24 with DXA or when screening is 6 weeks prior to baseline, DXA will also be performed at baseline. At screening, baseline, week 12 and week 24 with BIA."
                    },
                    {
                      "measure": "Change in muscle strength (after intervention-baseline)",
                      "description": "Muscle strength of the knee-extensor, knee-flexor and hip abductors will be measured by Biodex and hand grip strength with dynamometer.",
                      "timeFrame": "Hand grip measured at screening, baseline, week 12 and week 24. Biodex measured at baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Compliance to the exercise intervention, subjective",
                      "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- The number of Otago sessions the participant performed divided by the number of Otago sessions the participants needed to perform. Likewise, this will be calculated for the walking program and for the integral exercise intervention.",
                      "timeFrame": "baseline until week 12"
                    },
                    {
                      "measure": "Compliance to the exercise intervention, objective",
                      "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- Monitor and diary: Length of exercise session (time). Pattern recognition of exercise groups by algorithm development",
                      "timeFrame": "baseline until week 12"
                    },
                    {
                      "measure": "Compliance to the exercise intervention, subjective, detailed",
                      "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- Diary: the reported intensity of the strength exercises",
                      "timeFrame": "baseline until week 12"
                    },
                    {
                      "measure": "Compliance to the protein supplementation, objective",
                      "description": "Compliance to protein supplementation:\n\n\\- The number of nutritional intakes the participant did divided by the number of intakes of nutritional supplement the participant was prescribed.",
                      "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                    },
                    {
                      "measure": "Compliance to the protein supplementation, subjective",
                      "description": "Compliance to protein supplementation:\n\n\\- Count and weight returned powder boxes",
                      "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                    },
                    {
                      "measure": "Compliance to the protein supplementation objective",
                      "description": "Compliance to protein supplementation:\n\n\\- N content in 8 24h urine samples by the Dumas method (28) to estimate rise in protein intake and Creatinine index to estimate the completion of the urine samples (29, 30)",
                      "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                    },
                    {
                      "measure": "Compliance to the omega-3 supplementation, subjective",
                      "description": "Compliance to omega-3 supplement\n\n\\- Count returned capsules and placebo tablets",
                      "timeFrame": "baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Compliance to the omega-3 supplementation, objective",
                      "description": "Compliance to omega-3 supplement\n\n\\- Compliance to the omega- 3 supplement is assessed by counting the number of capsules during each study visit and by analysis of red blood cell (RBC) membrane fatty acid profile",
                      "timeFrame": "baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Functional status: frailty",
                      "description": "\\- Change in physical frailty stage defined by Fried et al (frail (3-5/5), prefrail (1-2/5), robust (0/5))",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: activities of daily living",
                      "description": "Change in activity of daily living (ADL) :Barthel-index",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: balance",
                      "description": "Change in balance (Mini-BESTest)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: change in physical activity",
                      "description": "Change in PA by the MoveMonitor+ (MM+) (method under development in our research group)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: health-related quality of life",
                      "description": "\\- Change in health-related quality of life, according to Short Form Health Survey (SF-36) questionnaire",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: falls",
                      "description": "\\- Number of falls and the circumstances, identified using weekly fall calendars + Falls Efficacy Scale International (FES-I)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Cognitive status: immediate and delayed memory, attention, language and visuospatial skills",
                      "description": "\\- The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): immediate and delayed memory, attention, language and visuospatial skills;",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Cognitive status: inhibition",
                      "description": "Stroop test (inhibition)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Cognitive status",
                      "description": "\\- Maze test",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Nutritional status: malnutrition",
                      "description": "\\- Changes in numbers of participants with malnutrition, according to Mini Nutritional Assessment (MNA).",
                      "timeFrame": "at baseline (preparation for food diary), week 6, week 12 and week 24"
                    },
                    {
                      "measure": "Nutritional status: nutrient intake",
                      "description": "\\- Changes in nutrient intake, according to the four day food diary.",
                      "timeFrame": "at baseline (preparation for food diary), week 6, week 12 and week 24"
                    },
                    {
                      "measure": "Patient reported benefits and adverse effects",
                      "description": "Benefits and adverse effects are asked. Participants will describe their thoughts about the study, what they like and don't like.",
                      "timeFrame": "week 1, 4, 8, 12, 16, 20, 22, 24."
                    },
                    {
                      "measure": "Change in C reactive protein (CRP)",
                      "description": "change in hs-CRP",
                      "timeFrame": "baseline, week 1, 4, 12 and 24"
                    },
                    {
                      "measure": "Change in hemoglobin",
                      "description": "Change in hemoglobin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in creatinine",
                      "description": "Change in creatinine",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in urea",
                      "description": "Change in urea",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in serum albumin",
                      "description": "Change in serum albumin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in glucose",
                      "description": "Change in glucose",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in cholesterol (HDL, LDL, total, Triglycerides)",
                      "description": "Change in cholesterol (HDL, LDL, total, Triglycerides)",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in insulin",
                      "description": "Change in insulin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in insulin like growth factor 1 (IGF-1)",
                      "description": "Change in IGF-1",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in 25-hydroxy-vitamin D",
                      "description": "Change in 25-hydroxy-vitamin D",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in creatinine kinase",
                      "description": "Change in creatinine kinase",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in indoxyl sulfate",
                      "description": "Change in indoxyl sulfate",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in interleukin 6 (IL-6)",
                      "description": "Change in IL-6",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in IL-1b",
                      "description": "Change in IL-1b",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in tumor necrosis factor alpha (TNF-alpha)",
                      "description": "Change in TNF-alpha",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in myostatin",
                      "description": "Change in myostatin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in activin A",
                      "description": "Change in activin A",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in markers of muscle wasting",
                      "description": "Change in markers of muscle wasting (MURF1, Atrogin1, FOXO3)",
                      "timeFrame": "baseline, week 12"
                    },
                    {
                      "measure": "Change in markers of muscle regeneration",
                      "description": "Change in markers of muscle regeneration (PAX7, Myogenic factor 5 (MYF5), myoblast determination protein (MyoD), Ki67, mammalian target of rapamycin (mTOR), AMPK)",
                      "timeFrame": "baseline, week 12"
                    },
                    {
                      "measure": "Change in muscle histology",
                      "description": "Change in muscle histology",
                      "timeFrame": "baseline, week 12"
                    },
                    {
                      "measure": "Change in composition of gut microbiota",
                      "description": "Change in composition of gut microbiota",
                      "timeFrame": "baseline, week 4, week 8, week 12"
                    },
                    {
                      "measure": "Change in markers of intestinal inflammation",
                      "description": "Change in markers of intestinal inflammation (fecal calprotectin, lactoferrin, S100A12)",
                      "timeFrame": "baseline, week 4, week 8, week 12"
                    }
                  ]
                },
                "eligibilityModule": {
                  "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female persons with (pre)sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP): reduced muscle mass without (presarcopenia) or with (sarcopenia) reduced walking speed ( 0.8m/s) or muscle strength OR probable, confirmed or severe sarcopenia according to EWGSOP 2.\n2. 65 years or older;\n3. Community-dwelling elderly or assisted living;\n4. In case of one or more positive answer(s) on the health screen for exercise, subjects need approval of their general practitioner to participate in this randomized controlled trial (RCT).\n\n   * Uncontrolled or unstable health problems\n   * Uncontrolled pain or feeling unwell the day of the exercise\n   * Recently diagnosed cardiovascular events\n   * systolic blood pressure (SBP)  180 mmHg and/or diastolic blood pressure (DBP)  100 mmHg\n   * Resting tachycardia \\> 100 bpm\n   * Uncontrolled atrial or ventricular arrhythmias\n   * Unstable or acute heart failure\n   * Lasting, increased pain following a previous session\n   * Suspected acute injury\n   * Recent injurious fall without medical assessment\n   * Severe breathlessness or dizziness\n   * Uncontrolled pulmonary problems\n   * Rheumatoid arthritis flare up or acute systemic illness/infection\n   * Unexplained lethargy\n\nExclusion Criteria:\n\n1. Impairments/diseases that impose problems to participation in the study;\n2. Allergy to milk or soy or peanut;\n3. Mini-Mental State Examination (MMSE) \\< 21;\n4. Terminal illness (prognosis \\< 6 months);\n5. Persons who followed a physical training program in the last 6 months (twice or more/week);\n6. Persons with a daily intake of \\> 1.5 g protein/kg body weight (BW)/day;\n7. Diagnosis of severe kidney disease (GFR \\< 30 ml/min) or diabetes mellitus;\n8. Unable to communicate in Dutch, English or French.",
                  "healthyVolunteers": false,
                  "sex": "ALL",
                  "minimumAge": "65 Years",
                  "stdAges": [
                    "OLDER_ADULT"
                  ]
                },
                "contactsLocationsModule": {
                  "centralContacts": [
                    {
                      "name": "Laur Vercauteren, MSc",
                      "role": "CONTACT",
                      "phone": "+32 16 34 38 67",
                      "email": "laura.vercauteren@kuleuven.be"
                    },
                    {
                      "name": "Jolan Dupont, MD",
                      "role": "CONTACT",
                      "phone": "+32 16 34 32 01",
                      "email": "jolan.dupont@uzleuven.be"
                    }
                  ],
                  "overallOfficials": [
                    {
                      "name": "Evelien Gielen, Prof MD PhD",
                      "affiliation": "Gerontology and Geriatrics, Department of Public Health and primary care KU Leuven",
                      "role": "PRINCIPAL_INVESTIGATOR"
                    }
                  ],
                  "locations": [
                    {
                      "facility": "Gerontology and Geriatrics, Department of Public Health and Primary Care, KU Leuven",
                      "status": "RECRUITING",
                      "city": "Leuven",
                      "state": "Vlaams-Brabant",
                      "zip": "3000",
                      "country": "Belgium",
                      "contacts": [
                        {
                          "name": "Laura Vercauteren",
                          "role": "CONTACT",
                          "phone": "+32 16 34 38 67",
                          "email": "laura.vercauteren@kuleuven.be"
                        },
                        {
                          "name": "Jolan Dupont, PhD",
                          "role": "CONTACT",
                          "phone": "+32 16 34 32 01",
                          "email": "jolan.dupont@uzleuven.be"
                        },
                        {
                          "name": "Evelien Gielen, Prof MD PhD",
                          "role": "PRINCIPAL_INVESTIGATOR"
                        }
                      ],
                      "geoPoint": {
                        "lat": 50.87959,
                        "lon": 4.70093
                      }
                    }
                  ]
                },
                "referencesModule": {
                  "references": [
                    {
                      "pmid": "41632571",
                      "type": "DERIVED",
                      "citation": "Amini N, Dupont J, Lapauw L, Vercauteren L, Peeters L, Dedeyne L, Verschueren S, Tournoy J, Gielen E. A multicomponent intervention consisting of exercise, proteins and omega-3 supplementation to improve sarcopenia in community-dwelling older adults: Lessons learned from a 5-armed randomized controlled feasibility trial. J Frailty Aging. 2026 Feb 2;15(1):100129. doi: 10.1016/j.tjfa.2025.100129. Online ahead of print."
                    },
                    {
                      "pmid": "39787986",
                      "type": "DERIVED",
                      "citation": "Amini N, Devriendt A, Lapauw L, Dupont J, Vercauteren L, Verbeke K, Verschueren S, Tournoy J, Gielen E. Estimating protein intake in sarcopenic older adults: combining food diaries and weighed powders versus 24-hour urine collections. J Nutr Health Aging. 2025 Mar;29(3):100474. doi: 10.1016/j.jnha.2024.100474. Epub 2025 Jan 8."
                    },
                    {
                      "pmid": "37752426",
                      "type": "DERIVED",
                      "citation": "Lapauw L, Dupont J, Amini N, Vercauteren L, Verschueren S, Tournoy J, Raes J, Gielen E. Trial in Elderly with Musculoskeletal Problems due to Underlying Sarcopenia-Faeces to Unravel the Gut and Inflammation Translationally (TEMPUS-FUGIT): protocol of a cross-sequential study to explore the gut-muscle axis in the development and treatment of sarcopenia in community-dwelling older adults. BMC Geriatr. 2023 Sep 26;23(1):599. doi: 10.1186/s12877-023-04291-5."
                    },
                    {
                      "pmid": "33302879",
                      "type": "DERIVED",
                      "citation": "Dedeyne L, Dupont J, Koppo K, Verschueren S, Tournoy J, Gielen E. Exercise and Nutrition for Healthy AgeiNg (ENHANce) project - effects and mechanisms of action of combined anabolic interventions to improve physical functioning in sarcopenic older adults: study protocol of a triple blinded, randomized controlled trial. BMC Geriatr. 2020 Dec 10;20(1):532. doi: 10.1186/s12877-020-01900-5."
                    }
                  ]
                },
                "ipdSharingStatementModule": {
                  "ipdSharing": "UNDECIDED"
                }
              },
              "derivedSection": {
                "miscInfoModule": {
                  "versionHolder": "2026-02-27"
                },
                "conditionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D055948",
                      "term": "Sarcopenia"
                    },
                    {
                      "id": "D009043",
                      "term": "Motor Activity"
                    },
                    {
                      "id": "D000073496",
                      "term": "Frailty"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D009133",
                      "term": "Muscular Atrophy"
                    },
                    {
                      "id": "D020879",
                      "term": "Neuromuscular Manifestations"
                    },
                    {
                      "id": "D009461",
                      "term": "Neurologic Manifestations"
                    },
                    {
                      "id": "D009422",
                      "term": "Nervous System Diseases"
                    },
                    {
                      "id": "D001284",
                      "term": "Atrophy"
                    },
                    {
                      "id": "D020763",
                      "term": "Pathological Conditions, Anatomical"
                    },
                    {
                      "id": "D013568",
                      "term": "Pathological Conditions, Signs and Symptoms"
                    },
                    {
                      "id": "D012816",
                      "term": "Signs and Symptoms"
                    },
                    {
                      "id": "D001519",
                      "term": "Behavior"
                    },
                    {
                      "id": "D010335",
                      "term": "Pathologic Processes"
                    }
                  ]
                },
                "interventionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D015525",
                      "term": "Fatty Acids, Omega-3"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D004042",
                      "term": "Dietary Fats, Unsaturated"
                    },
                    {
                      "id": "D004041",
                      "term": "Dietary Fats"
                    },
                    {
                      "id": "D005223",
                      "term": "Fats"
                    },
                    {
                      "id": "D008055",
                      "term": "Lipids"
                    },
                    {
                      "id": "D005231",
                      "term": "Fatty Acids, Unsaturated"
                    },
                    {
                      "id": "D005227",
                      "term": "Fatty Acids"
                    },
                    {
                      "id": "D005395",
                      "term": "Fish Oils"
                    },
                    {
                      "id": "D009821",
                      "term": "Oils"
                    }
                  ]
                }
              },
              "hasResults": false
            }
          },
          {
            "nct_id": "NCT06658093",
            "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
            "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "EARLY_PHASE1"
            ],
            "enrollment": 194,
            "primary_outcomes": [
              {
                "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                "description": "The levels of the study drug will be measured in whole blood",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                "timeFrame": "Baseline to study end (approximately 12 months)"
              }
            ],
            "has_results": false,
            "raw_study": {
              "protocolSection": {
                "identificationModule": {
                  "nctId": "NCT06658093",
                  "orgStudyIdInfo": {
                    "id": "STUDY00000471"
                  },
                  "secondaryIdInfos": [
                    {
                      "id": "U01AG089242",
                      "type": "NIH",
                      "link": "https://reporter.nih.gov/quickSearch/U01AG089242"
                    }
                  ],
                  "organization": {
                    "fullName": "The University of Texas Health Science Center at San Antonio",
                    "class": "OTHER"
                  },
                  "briefTitle": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                  "officialTitle": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                  "acronym": "RESTOR"
                },
                "statusModule": {
                  "statusVerifiedDate": "2025-08",
                  "overallStatus": "RECRUITING",
                  "expandedAccessInfo": {
                    "hasExpandedAccess": false
                  },
                  "startDateStruct": {
                    "date": "2025-08-13",
                    "type": "ACTUAL"
                  },
                  "primaryCompletionDateStruct": {
                    "date": "2028-07",
                    "type": "ESTIMATED"
                  },
                  "completionDateStruct": {
                    "date": "2028-07",
                    "type": "ESTIMATED"
                  },
                  "studyFirstSubmitDate": "2024-10-22",
                  "studyFirstSubmitQcDate": "2024-10-22",
                  "studyFirstPostDateStruct": {
                    "date": "2024-10-26",
                    "type": "ACTUAL"
                  },
                  "lastUpdateSubmitDate": "2025-08-27",
                  "lastUpdatePostDateStruct": {
                    "date": "2025-09-04",
                    "type": "ACTUAL"
                  }
                },
                "sponsorCollaboratorsModule": {
                  "responsibleParty": {
                    "type": "PRINCIPAL_INVESTIGATOR",
                    "investigatorFullName": "Ellen Kraig",
                    "investigatorTitle": "Professor",
                    "investigatorAffiliation": "The University of Texas Health Science Center at San Antonio"
                  },
                  "leadSponsor": {
                    "name": "The University of Texas Health Science Center at San Antonio",
                    "class": "OTHER"
                  },
                  "collaborators": [
                    {
                      "name": "National Institute on Aging (NIA)",
                      "class": "NIH"
                    }
                  ]
                },
                "oversightModule": {
                  "oversightHasDmc": true,
                  "isFdaRegulatedDrug": true,
                  "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                  "briefSummary": "As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease. Studies in animal models have been able to identify drugs that slow the aging process, leading to a longer, healthier life. This study is focused on one such family of drugs, called mTOR inhibitors, and the investigators' goal is to test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults to find a dose and dose timing that can be used to safely inhibit mTOR to the levels seen in young healthy persons. The investigators expect that the dose that works well in women may differ from the one that is best in men, so it is important to include both sexes in this research.",
                  "detailedDescription": "The study will be done in three parts, each with different human subject groups. Participants may only enroll in one of the sub-studies.\n\nSub-study 1: Determining target mTOR activity values in YOUNG untreated subjects (ages 20-30 years): NOTE: This aim of the study is not a clinical trial, so this population will not be included in participant flow or included as an arm in the study.\n\nThis study defines \"best dose\" as the choice of drug, dose, and frequency that will come closest to restoring the \"youthful\" levels of mTOR activity in an older individual. The investigators first need to measure mTOR activity in young untreated subjects to define these target \"youthful\" mTOR activity levels.\n\nSub-study 2. Finding the most effective drug, dose, and timing for dosing for oral dosing of the mTOR inhibitor drugs in older adults (65-90 years):\n\nHealthy older persons will be recruited for a short-term (6 week treatment plus 4 week follow-up) dose-finding study. The most effective, but safe dose will then be tested in a larger number of subjects in Sub-study 3. Importantly, the best drug and dose regimen for females may differ from the one determined for males so the cohort will include both sexes.\n\nSub-study 3. Placebo controlled trial testing of DAILY (sustained) vs. INTERMITTENT mTOR inhibition in older human males and females:\n\nSub-study 3 will enroll healthy older persons (65-90 yrs) for a long-term clinical trial (6 months of treatment plus 6 months of follow-up) with 3 test groups:\n\ni) best DAILY dose/drug; ii) best INTERMITTENT dose/drug/interval, and iii) PLACEBO (a pill that looks identical to the medicine, but has no drug in it).\n\nThis study will help find out what effects, good and/or bad, Rapamycin or Everolimus have on older people who take the drug for a longer period of time. The safety of Rapamycin and Everolimus in humans has been tested in prior research studies; however, some side effects may not yet be known in healthy older persons. By completing the entire study, the Research Team hopes to learn more about how older human subjects can best be treated using these drugs (mTOR inhibitors) to help them live longer, healthier lives."
                },
                "conditionsModule": {
                  "conditions": [
                    "Aging"
                  ],
                  "keywords": [
                    "mTOR inhibitors"
                  ]
                },
                "designModule": {
                  "studyType": "INTERVENTIONAL",
                  "phases": [
                    "EARLY_PHASE1"
                  ],
                  "designInfo": {
                    "allocation": "RANDOMIZED",
                    "interventionModel": "SEQUENTIAL",
                    "interventionModelDescription": "A single site open label adaptive clinical trial (Aim 1:Sub-study 2) followed by a placebo-controlled blinded clinical trial (Aim 2) to optimize the use of mTOR inhibitors in older persons a functions of drug, dose, dosing schedule and sex. It will be carried out in 2 sub-studies:\n\nAim 1:\n\n-Sub-study 2: Comparison of 2 mTOR inhibitors in an adaptive open-label dose finding pharmacokinetic/pharmacodynamic study\n\nAim 2:\n\nSub-study 3: Assess the safety/tolerability/adverse events of optimized dose of mTOR inhibitors in daily vs intermittent dosing",
                    "primaryPurpose": "BASIC_SCIENCE",
                    "maskingInfo": {
                      "masking": "DOUBLE",
                      "maskingDescription": "Blinding will only occur in Aim 2 (Sub-study 3). Randomization will be done by the research pharmacy providing the investigational drug.",
                      "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER"
                      ]
                    }
                  },
                  "enrollmentInfo": {
                    "count": 194,
                    "type": "ESTIMATED"
                  }
                },
                "armsInterventionsModule": {
                  "armGroups": [
                    {
                      "label": "Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Rapamycin"
                      ]
                    },
                    {
                      "label": "Aim 1: Sub-study 2 Daily dosing Cohort Everolimus",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) of everolimus (EVERO) in milligrams based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Rapamycin"
                      ]
                    },
                    {
                      "label": "Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of everolimus (EVERO) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                      "type": "EXPERIMENTAL",
                      "description": "Based on the findings from Aim 1, the optimal drug (RAPA or EVERO) and dose for DAILY delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed.",
                      "interventionNames": [
                        "Drug: Rapamycin",
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor",
                      "type": "EXPERIMENTAL",
                      "description": "Based on the findings from Aim 1, the optimal drug (RAPA or EVERO), interval between doses, and dose for INTERMITTENT delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose/interval used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed. Although drug is delivered on an intermittent schedule, subjects will be given a pill each day (either drug or placebo, as scheduled) to maintain blinding.",
                      "interventionNames": [
                        "Drug: Rapamycin",
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 2: Sub-study 3 Placebo control",
                      "type": "PLACEBO_COMPARATOR",
                      "description": "Daily administration of a placebo will be given to a cohort of older human subjects. Both males and females will be enrolled as controls.",
                      "interventionNames": [
                        "Other: Placebo"
                      ]
                    }
                  ],
                  "interventions": [
                    {
                      "type": "DRUG",
                      "name": "Rapamycin",
                      "description": "mTOR inhibitor",
                      "armGroupLabels": [
                        "Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin",
                        "Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin",
                        "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                        "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor"
                      ],
                      "otherNames": [
                        "RAPA"
                      ]
                    },
                    {
                      "type": "DRUG",
                      "name": "Everolimus",
                      "description": "mTOR inhibitor",
                      "armGroupLabels": [
                        "Aim 1: Sub-study 2 Daily dosing Cohort Everolimus",
                        "Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus",
                        "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                        "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor"
                      ],
                      "otherNames": [
                        "EVERO"
                      ]
                    },
                    {
                      "type": "OTHER",
                      "name": "Placebo",
                      "description": "Inert placebo for rapamycin or everolimus",
                      "armGroupLabels": [
                        "Aim 2: Sub-study 3 Placebo control"
                      ],
                      "otherNames": [
                        "Placebo capsule"
                      ]
                    }
                  ]
                },
                "outcomesModule": {
                  "primaryOutcomes": [
                    {
                      "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                      "description": "The levels of the study drug will be measured in whole blood",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                      "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                      "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    }
                  ],
                  "secondaryOutcomes": [
                    {
                      "measure": "PK of mTOR inhibitor in fat (Aim 2 only)",
                      "description": "The levels of the study drug will be measure in fat tissue obtained by adipose biopsy",
                      "timeFrame": "Baseline and study end (approximately 12 months)"
                    },
                    {
                      "measure": "PK of mTOR inhibitor in muscle (Aim 2 only)",
                      "description": "The levels of the study drug will be measured in skeletal muscle obtained by biopsy.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in fat cells (Aim 2 only) - pS6K",
                      "description": "Proteins prepared from adipose tissue will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in muscle (Aim 2 only) - pS6K",
                      "description": "Proteins prepared from skeletal muscle tissue biopsy will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in PBMCs, S6-kinase",
                      "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in adipose cells, rpS6 (Aim 2 only)",
                      "description": "Proteins prepared from adipose biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in muscle rpS6 (Aim 2 only)",
                      "description": "Proteins prepared from muscle biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in adipose (fat) cells Akt (Aim 2 only)",
                      "description": "Proteins prepared from adipose biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in muscle Akt (Aim 2 only)",
                      "description": "Proteins prepared from muscle biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in PBMCs Akt",
                      "description": "Proteins prepared from PBMCs will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    }
                  ]
                },
                "eligibilityModule": {
                  "eligibilityCriteria": "Inclusion Criteria:\n\nOlder Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):\n\n1. Age 65 to 90 years\n2. Men and women\n3. In good health with all medical problems stable.\n4. Community-dwelling\n5. Agreement to adhere to Lifestyle Considerations throughout study duration.\n6. Ability of participant to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nOlder Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):\n\n1. Resident of nursing home or long-term care facility\n2. Subjects with diabetes or currently taking glucose lowering medications\n3. History of moderate-severe heart disease (New York Heart Classication greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one ight of stairs or less; abnormal breath sounds on auscultation); Moderate to severe valvular heart disease\n4. Active cancer or history of cancer treatment within the last 5 years\n5. Chronic inammatory condition, autoimmune disease, or infectious processes (e.g., active tuberculosis, HIV, rheumatoid arthritis, systemic lupus erythematosus, acute or chronic hepatitis B or C)\n6. History of a coagulopathy or any medical condition requiring anticoagulation (except low dose ASA)\n7. Renal insuciency with an estimated glomerular ltration rate of \\<30ml/min\n8. Uncontrolled hypercholesterolemia \\>350mg/dl or uncontrolled hypertriglyceridemia \\>500mg/dl\n9. Anemia or abnormal blood cell counts: hemoglobin level \\<9.0g.dl; white blood count \\<3500/mm3; neutrophil count \\<2000/ mm3; platelet count \\<125,000/mm3\n10. History of skin ulcers or poor wound healing\n11. Active tobacco use (within 6 months)\n12. Diagnosis of any disabling neurologic disease such as Parkinson's Disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, cerebrovascular accident with residual decits (muscle weakness or gait disorder), severe neuropathy, diagnosis of dementia or Clox1 score less than 10 at the time of screening visit, cognitive impairment due to any reason such that the patient is unable to provide informed consent\n13. Liver disease\n14. Systemic treatment with an immunosuppressant (prednisone, etc.) within the year prior to enrollment\n15. Treatment with drugs known to affect cytochrome P450 (CYP3A4), i.e., diltiazem, erythromycin.\n16. Patients with history of recent (within 6 months) myocardial infarction or active coronary disease\n17. Patients with history of recent (within 6 months) intestinal disorders\n18. History of severe head trauma, brain injury, brain surgery, inammation of the brain, or history of seizure disorder\n19. History of Long-Covid (PASC) within one year\n20. Acute Covid19 or Covid19 infection within the last 6 months\n21. Unwilling to forgo grapefruit juice consumption.\n22. Participation in mTORi study within the prior year. (Note: participants in AIM 1 will be excluded from participating in AIM 2 of the proposed trial.)\n23. Allergic to RAPA or EVERO\n24. Allergic to lidocaine\n25. Recreational drug use\n26. Donated blood over a two-month period prior to study initiation.\n27. Currently using cannabidiol (CBD) or tetrahydrocannabinol (THC) or any preparation contained these, or related, substances.\n28. Currently using hormone replacement or modulating therapies.",
                  "healthyVolunteers": true,
                  "sex": "ALL",
                  "minimumAge": "65 Years",
                  "maximumAge": "90 Years",
                  "stdAges": [
                    "OLDER_ADULT"
                  ]
                },
                "contactsLocationsModule": {
                  "centralContacts": [
                    {
                      "name": "Dean L Kellogg, Jr, MD PhD",
                      "role": "CONTACT",
                      "phone": "(210) 617 5197",
                      "email": "kelloggd@uthscsa.edu"
                    },
                    {
                      "name": "Ellen Kraig, PhD",
                      "role": "CONTACT",
                      "phone": "(210) 367-3171",
                      "email": "kraig@uthscsa.edu"
                    }
                  ],
                  "overallOfficials": [
                    {
                      "name": "Ellen Kraig, PhD",
                      "affiliation": "The University of Texas Health Science Center at San Antonio",
                      "role": "PRINCIPAL_INVESTIGATOR"
                    }
                  ],
                  "locations": [
                    {
                      "facility": "The University of Texas Health Science Center at San Antonio",
                      "status": "RECRUITING",
                      "city": "San Antonio",
                      "state": "Texas",
                      "zip": "78229",
                      "country": "United States",
                      "contacts": [
                        {
                          "name": "Dean L Kellogg Jr.,, MD PhD",
                          "role": "CONTACT",
                          "phone": "210-617-5197",
                          "email": "kelloggd@uthscsa.edu"
                        },
                        {
                          "name": "Dean L Kellogg Jr., MD PhD",
                          "role": "PRINCIPAL_INVESTIGATOR"
                        }
                      ],
                      "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                      }
                    }
                  ]
                },
                "referencesModule": {
                  "references": [
                    {
                      "pmid": "29408453",
                      "type": "BACKGROUND",
                      "citation": "Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, Benavides AD, Curiel TJ, Javors MA, Musi N, Chiodo L, Koek W, Gelfond JAL, Kellogg DL Jr. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp Gerontol. 2018 May;105:53-69. doi: 10.1016/j.exger.2017.12.026. Epub 2018 Feb 3."
                    }
                  ]
                },
                "ipdSharingStatementModule": {
                  "ipdSharing": "YES",
                  "description": "De-identified Individual participant data (IPD) that underlie results in a publication.",
                  "infoTypes": [
                    "STUDY_PROTOCOL",
                    "SAP"
                  ],
                  "timeFrame": "At the time of publication in a peer review journal"
                }
              },
              "derivedSection": {
                "miscInfoModule": {
                  "versionHolder": "2026-02-27"
                },
                "interventionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D020123",
                      "term": "Sirolimus"
                    },
                    {
                      "id": "D000068338",
                      "term": "Everolimus"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D018942",
                      "term": "Macrolides"
                    },
                    {
                      "id": "D007783",
                      "term": "Lactones"
                    },
                    {
                      "id": "D009930",
                      "term": "Organic Chemicals"
                    }
                  ]
                }
              },
              "hasResults": false
            }
          }
        ]
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "status",
          "summary": "Evaluated whether trial-publication audit should run.",
          "data": {
            "should_run": true
          },
          "ids": [],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "internal",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:36.789994Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-014"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "trial_publication_linker"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 4.4,
      "endpoint": "internal",
      "enabled": true
    },
    {
      "tool": "trial_publication_linker",
      "payload": {
        "ids": [
          "NCT03308747",
          "NCT03649698",
          "NCT06658093"
        ],
        "trials": [
          {
            "nct_id": "NCT03308747",
            "brief_title": "Inflammaging and Muscle Protein Metabolism",
            "official_title": "Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle.",
            "overall_status": "COMPLETED",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "NA"
            ],
            "enrollment": 44,
            "primary_outcomes": [
              {
                "measure": "Systemic inflammation",
                "description": "Levels of systemic inflammation will be assessed by measuring serum levels of hs-CRP, IL-6 and TNF-.",
                "timeFrame": "At baseline."
              },
              {
                "measure": "Change in muscle protein synthesis (MPS)",
                "description": "Using deuterium oxide (D2O) 70% atom administration. Individuals will consume a single bolus of 150ml D20 the day before the clinical trial and muscle biopsy samples, collected before and after the exercise bout and protein ingestion, will be analyzed for isotopic measurement using GC-P-IRMS.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              },
              {
                "measure": "Change in intracellular signaling proteins in muscle",
                "description": "Phosphorylation levels of Akt, mammalian target of rapamycin (mTOR), p70S6K and ribosomal protein S6 (rpS6) will be measure using western blotting.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              },
              {
                "measure": "Change in proteasome activities in muscle",
                "description": "Chymotrypsin-like (CT-L), caspase-like (C-L) and trypsin-like (T-L) proteasome activities will be assayed with hydrolysis of the fluorogenic peptide LLVY-AMC, LLE-AMC and LSTR-AMC, respectively.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              },
              {
                "measure": "Change in protein expression level of proteasome subunits",
                "description": "Immunoblot analysis will be used to detect protein expression levels of proteasome (5, 2 and 1) and immunoproteasome (5i, 2i and 1i) subunits.",
                "timeFrame": "At baseline and 180 min following protein ingestion."
              }
            ],
            "has_results": false,
            "raw_study": {
              "protocolSection": {
                "identificationModule": {
                  "nctId": "NCT03308747",
                  "orgStudyIdInfo": {
                    "id": "INFLAMMAGING-UTH"
                  },
                  "organization": {
                    "fullName": "University of Thessaly",
                    "class": "OTHER"
                  },
                  "briefTitle": "Inflammaging and Muscle Protein Metabolism",
                  "officialTitle": "Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle."
                },
                "statusModule": {
                  "statusVerifiedDate": "2017-10",
                  "overallStatus": "COMPLETED",
                  "expandedAccessInfo": {
                    "hasExpandedAccess": false
                  },
                  "startDateStruct": {
                    "date": "2017-09-01",
                    "type": "ACTUAL"
                  },
                  "primaryCompletionDateStruct": {
                    "date": "2018-02-15",
                    "type": "ACTUAL"
                  },
                  "completionDateStruct": {
                    "date": "2018-05-30",
                    "type": "ACTUAL"
                  },
                  "studyFirstSubmitDate": "2017-10-02",
                  "studyFirstSubmitQcDate": "2017-10-08",
                  "studyFirstPostDateStruct": {
                    "date": "2017-10-13",
                    "type": "ACTUAL"
                  },
                  "lastUpdateSubmitDate": "2018-07-18",
                  "lastUpdatePostDateStruct": {
                    "date": "2018-07-19",
                    "type": "ACTUAL"
                  }
                },
                "sponsorCollaboratorsModule": {
                  "responsibleParty": {
                    "type": "PRINCIPAL_INVESTIGATOR",
                    "investigatorFullName": "Ioannis G. Fatouros",
                    "investigatorTitle": "Associate Professor",
                    "investigatorAffiliation": "University of Thessaly"
                  },
                  "leadSponsor": {
                    "name": "University of Thessaly",
                    "class": "OTHER"
                  }
                },
                "oversightModule": {
                  "oversightHasDmc": false,
                  "isFdaRegulatedDrug": false,
                  "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                  "briefSummary": "The development of a low-grade, chronic, systemic inflammation observed in the elderly (inflammaing) has been associated with increased risk for skeletal muscle wasting, strength loss and functional impairments. According to studies performed in animals and cell cultures increased concentrations of pro-inflammatory cytokines such as IL-6 and TNF- as well as increased levels of hs-CRP lead to elevated protein degradation through proteasome activation and reduced muscle protein synthesis (MPS) via downregulation of the Akt-mTOR signaling pathway. However, evidence regarding the effects of inflammaging on skeletal muscle mass in humans is lacking. Thus, the present study will compare proteasome activation and the protein synthetic response in the fasted and postprandial period between older adults with increased systemic inflammation and their healthy control counterparts.",
                  "detailedDescription": "A total number of \\> 60 male, older adults aged 63-73 years will be initially screened for systemic levels of hs-CRP and IL-6. Of these, 24 individuals that will comply with the study criteria will be allocated to either a High (IL6:  1.7 pg/ml; hs-CRP: \\> 1.0 mg/L) (n=12) or a Low (IL6: \\< 1.7 pg/ml; hs-CRP: \\< 1.0 mg/L) (n=12) systemic inflammation group. Approximately 2 weeks before the experimental trial, anthropometry, resting metabolic rate (RMR), body composition (with DXA), sarcopenia status, functional capacity and the knee-extension one repetition maximum (1RM) will be assessed in individuals from both groups. In addition, levels of habitual physical activity will be assessed using accelerometry (over a 7-day period) and daily dietary intake will be monitored through 7-day diet recalls in all participants. 1 week before the experimental day an oral glucose tolerance test (OGTT) will be also performed over a 2-hour period, with blood sampling every 15min during the first hour and every 30min during the second hour. The day before the experimental trial, participants will consume 150ml of D2O 70% atom as a bolus. In the experimental day, participants will arrive at the laboratory after an overnight fast and a baseline blood sample and a muscle biopsy from vastus lateralis muscle will be collected. Immediately after, participants will perform 8 sets with 10 repetitions at 80% of 1RM and 2 min rest between each set, on a knee-extension machine. After exercise, they will ingest 0.4 g whey protein isolate/kg body weight as single bolus and then they will remain in a sitting position over a 3-hour period. Blood samples will be collected every 30min during the 3-hour postprandial period while a second muscle biopsy will be obtained at 3h."
                },
                "conditionsModule": {
                  "conditions": [
                    "Inflammaging",
                    "Sarcopenia"
                  ],
                  "keywords": [
                    "Low-grade systemic inflammation",
                    "Muscle protein synthesis",
                    "Proteasome activation",
                    "Anabolic signaling",
                    "Aging",
                    "Sarcopenia"
                  ]
                },
                "designModule": {
                  "studyType": "INTERVENTIONAL",
                  "phases": [
                    "NA"
                  ],
                  "designInfo": {
                    "allocation": "NON_RANDOMIZED",
                    "interventionModel": "PARALLEL",
                    "primaryPurpose": "BASIC_SCIENCE",
                    "maskingInfo": {
                      "masking": "DOUBLE",
                      "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                      ]
                    }
                  },
                  "enrollmentInfo": {
                    "count": 44,
                    "type": "ACTUAL"
                  }
                },
                "armsInterventionsModule": {
                  "armGroups": [
                    {
                      "label": "High systemic inflammation",
                      "type": "EXPERIMENTAL",
                      "description": "Individuals assigned in the high systemic inflammation group will be characterized by IL6:  1.7 pg/ml and hs-CRP: \\> 2.0 mg/L.",
                      "interventionNames": [
                        "Dietary Supplement: Instantized Whey Protein Isolate"
                      ]
                    },
                    {
                      "label": "Low systemic inflammation",
                      "type": "ACTIVE_COMPARATOR",
                      "description": "Individuals assigned in the high systemic inflammation group will be characterized by IL6: \\< 1.7 pg/ml and hs-CRP: \\< 1.0 mg/L.",
                      "interventionNames": [
                        "Dietary Supplement: Instantized Whey Protein Isolate"
                      ]
                    }
                  ],
                  "interventions": [
                    {
                      "type": "DIETARY_SUPPLEMENT",
                      "name": "Instantized Whey Protein Isolate",
                      "description": "0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.",
                      "armGroupLabels": [
                        "High systemic inflammation",
                        "Low systemic inflammation"
                      ]
                    }
                  ]
                },
                "outcomesModule": {
                  "primaryOutcomes": [
                    {
                      "measure": "Systemic inflammation",
                      "description": "Levels of systemic inflammation will be assessed by measuring serum levels of hs-CRP, IL-6 and TNF-.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Change in muscle protein synthesis (MPS)",
                      "description": "Using deuterium oxide (D2O) 70% atom administration. Individuals will consume a single bolus of 150ml D20 the day before the clinical trial and muscle biopsy samples, collected before and after the exercise bout and protein ingestion, will be analyzed for isotopic measurement using GC-P-IRMS.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Change in intracellular signaling proteins in muscle",
                      "description": "Phosphorylation levels of Akt, mammalian target of rapamycin (mTOR), p70S6K and ribosomal protein S6 (rpS6) will be measure using western blotting.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Change in proteasome activities in muscle",
                      "description": "Chymotrypsin-like (CT-L), caspase-like (C-L) and trypsin-like (T-L) proteasome activities will be assayed with hydrolysis of the fluorogenic peptide LLVY-AMC, LLE-AMC and LSTR-AMC, respectively.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Change in protein expression level of proteasome subunits",
                      "description": "Immunoblot analysis will be used to detect protein expression levels of proteasome (5, 2 and 1) and immunoproteasome (5i, 2i and 1i) subunits.",
                      "timeFrame": "At baseline and 180 min following protein ingestion."
                    }
                  ],
                  "secondaryOutcomes": [
                    {
                      "measure": "Resting metabolic rate (RMR)",
                      "description": "RMR will be assessed after an overnight fast with participants in a supine position following a 15-min stabilization period by taking 30 consecutive 1-min VO2/CO2 measurements using a portable open-circuit indirect calorimeter with a ventilated hood system following a standard calibration protocol.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Physical activity",
                      "description": "Level of habitual physical activity will be assessed using accelerometry (ActiGraph GT3X-BT accelerometer).",
                      "timeFrame": "Over a 7-day period at baseline."
                    },
                    {
                      "measure": "Dietary intake",
                      "description": "Daily dietary intake will be assessed using 7-day diet recalls.",
                      "timeFrame": "Over a 7-day period at baseline."
                    },
                    {
                      "measure": "Reduced glutathione in blood",
                      "description": "Concentration of reduced glutathione will be measured in red blood cells",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Oxidized glutathione in blood",
                      "description": "Concentration of oxidized glutathione will be measured in red blood cells",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Protein carbonyls in serum",
                      "description": "Concentration of protein carbonyls will be measured in serum.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Total antioxidant capacity",
                      "description": "Total antioxidant capacity will be measured in serum",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Malondialdehyde in serum",
                      "description": "Concentration of malondialdehyde will be measured in serum.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "White blood cell count in blood",
                      "description": "White blood cell count will be measured in blood.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Insulin sensitivity",
                      "description": "Insulin sensitivity will be assessed through an oral glucose tolerance test (OGTT) which involve ingesting glucose solution (75 g) with 5ml arterialized venous blood samples drawn at baseline and every 15 min during the first hour and every 30 min during the second hour over a 2-hour period.",
                      "timeFrame": "At baseline."
                    },
                    {
                      "measure": "Glucose concentration in blood",
                      "description": "Glucose concentration will be measured in plasma during the clinical trial.",
                      "timeFrame": "At baseline and at 30 min, 60 min, 90 min, 120 min, 150 min and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Insulin concentration in blood",
                      "description": "Insulin concentration will be measured in plasma during the clinical trial.",
                      "timeFrame": "At baseline and at 30 min, 60 min, 90 min, 120 min, 150 min and 180 min following protein ingestion."
                    },
                    {
                      "measure": "Body composition",
                      "description": "Body composition will be measured using a dual-energy x-ray absorptiometry scanner (DEXA).",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Body Mass Index (BMI)",
                      "description": "Calculated as body mass (kg) divided by the height (m) squared.",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Skeletal muscle index",
                      "description": "Calculated as an appendicular lean mass (kg) divided by height (m) squared.",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Grip strength",
                      "description": "Using handgrip dynamometry (left and right arm) in a sitting position.",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Functional performance",
                      "description": "Functional performance will be assessed using the Short Physical Performance Battery (SPPB).",
                      "timeFrame": "At baseline"
                    },
                    {
                      "measure": "Lower limb muscle strength",
                      "description": "Will be assessed by defining the 1 repetition maximum (1RM) on a knee-extension machine.",
                      "timeFrame": "At baseline"
                    }
                  ]
                },
                "eligibilityModule": {
                  "eligibilityCriteria": "Inclusion Criteria:\n\n* Non-smokers.\n* BMI 18.5 \\& BMI  35 kg/m2.\n* Moderately active but with no regular participation in heavy resistance exercise within the last 6 months.\n* Absence of chronic disease (i.e. cancer, metabolic, cardiac, or neurological diseases).\n* Free and independently living.\n\nExclusion Criteria:\n\n* Organ failure (unstable, renal, respiratory, liver).\n* Chronic use of corticosteroid medication.\n* Recent use of antibiotics.\n* Presence of frailty.\n* Body weight variation over the past 6mo \\> 10% or weight loss of more than 3kg in the last 3 months.\n* Use of anti-inflammatory or lipid-lowering medication (i.e., statins).\n* Use of medication interacting with muscle metabolism.",
                  "healthyVolunteers": true,
                  "sex": "MALE",
                  "minimumAge": "63 Years",
                  "maximumAge": "75 Years",
                  "stdAges": [
                    "ADULT",
                    "OLDER_ADULT"
                  ]
                },
                "contactsLocationsModule": {
                  "overallOfficials": [
                    {
                      "name": "DIMITRIOS DRAGANIDIS, PhDc",
                      "affiliation": "UNIVERSITY OF THESSALY, SCHOOL OF PHYSICAL EDUCATION & SPORTS SCIENCES",
                      "role": "PRINCIPAL_INVESTIGATOR"
                    }
                  ],
                  "locations": [
                    {
                      "facility": "Exercise Biochemistry Laboratory, School of Physical Education & Sports Sciences, University of Thessaly",
                      "city": "Trikala",
                      "zip": "42100",
                      "country": "Greece",
                      "geoPoint": {
                        "lat": 39.55493,
                        "lon": 21.76837
                      }
                    }
                  ]
                }
              },
              "derivedSection": {
                "miscInfoModule": {
                  "versionHolder": "2026-02-27"
                },
                "conditionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D055948",
                      "term": "Sarcopenia"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D009133",
                      "term": "Muscular Atrophy"
                    },
                    {
                      "id": "D020879",
                      "term": "Neuromuscular Manifestations"
                    },
                    {
                      "id": "D009461",
                      "term": "Neurologic Manifestations"
                    },
                    {
                      "id": "D009422",
                      "term": "Nervous System Diseases"
                    },
                    {
                      "id": "D001284",
                      "term": "Atrophy"
                    },
                    {
                      "id": "D020763",
                      "term": "Pathological Conditions, Anatomical"
                    },
                    {
                      "id": "D013568",
                      "term": "Pathological Conditions, Signs and Symptoms"
                    },
                    {
                      "id": "D012816",
                      "term": "Signs and Symptoms"
                    }
                  ]
                }
              },
              "hasResults": false
            }
          },
          {
            "nct_id": "NCT03649698",
            "brief_title": "Exercise and Nutrition for Healthy AgeiNg",
            "official_title": "Exercise and Nutrition for Healthy AgeiNg: Anabolic Interventions for Older People With (Pre)Sarcopenia to Improve Physical Functioning, Muscle Mass and Muscle Strength and to Understand the Underlying Mechanisms of Action.",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "NA"
            ],
            "enrollment": 180,
            "primary_outcomes": [
              {
                "measure": "Change in physical functioning",
                "description": "Change in SPPB score",
                "timeFrame": "Measured at baseline, week 12 and week 24."
              },
              {
                "measure": "Percentage of participants with change in physical functioning",
                "description": "the percentage of participants with more than 1 or 1 point increase in SPPB score.",
                "timeFrame": "Measured at baseline, week 12 and week 24."
              }
            ],
            "has_results": false,
            "raw_study": {
              "protocolSection": {
                "identificationModule": {
                  "nctId": "NCT03649698",
                  "orgStudyIdInfo": {
                    "id": "S60763"
                  },
                  "organization": {
                    "fullName": "Universitaire Ziekenhuizen KU Leuven",
                    "class": "OTHER"
                  },
                  "briefTitle": "Exercise and Nutrition for Healthy AgeiNg",
                  "officialTitle": "Exercise and Nutrition for Healthy AgeiNg: Anabolic Interventions for Older People With (Pre)Sarcopenia to Improve Physical Functioning, Muscle Mass and Muscle Strength and to Understand the Underlying Mechanisms of Action.",
                  "acronym": "ENHANce"
                },
                "statusModule": {
                  "statusVerifiedDate": "2024-06",
                  "overallStatus": "RECRUITING",
                  "expandedAccessInfo": {
                    "hasExpandedAccess": false
                  },
                  "startDateStruct": {
                    "date": "2018-02-12",
                    "type": "ACTUAL"
                  },
                  "primaryCompletionDateStruct": {
                    "date": "2024-12",
                    "type": "ESTIMATED"
                  },
                  "completionDateStruct": {
                    "date": "2025-06",
                    "type": "ESTIMATED"
                  },
                  "studyFirstSubmitDate": "2018-08-07",
                  "studyFirstSubmitQcDate": "2018-08-24",
                  "studyFirstPostDateStruct": {
                    "date": "2018-08-28",
                    "type": "ACTUAL"
                  },
                  "lastUpdateSubmitDate": "2024-06-27",
                  "lastUpdatePostDateStruct": {
                    "date": "2024-06-28",
                    "type": "ACTUAL"
                  }
                },
                "sponsorCollaboratorsModule": {
                  "responsibleParty": {
                    "type": "SPONSOR"
                  },
                  "leadSponsor": {
                    "name": "Universitaire Ziekenhuizen KU Leuven",
                    "class": "OTHER"
                  },
                  "collaborators": [
                    {
                      "name": "KU Leuven",
                      "class": "OTHER"
                    },
                    {
                      "name": "VISTA-Life",
                      "class": "UNKNOWN"
                    },
                    {
                      "name": "Nestle Health Science",
                      "class": "INDUSTRY"
                    }
                  ]
                },
                "oversightModule": {
                  "oversightHasDmc": false,
                  "isFdaRegulatedDrug": false,
                  "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                  "briefSummary": "The aim of this randomized placebo-controlled 5-arm clinical trial is to evaluate the effect of combined anabolic interventions compared to single or placebo interventions on physical performance in community-dwelling (pre)sarcopenic elderly ( 65 years) and to determine the underlying mechanisms of action. Important secondary outcome measures are muscle mass, muscle strength, compliance to the interventions (exercise program, protein and omega-3 supplementation) and functional, cognitive and nutritional status.",
                  "detailedDescription": "The aim of this randomized 5-arm clinical trial is to evaluate the effect of combined anabolic interventions compared to single or placebo interventions on physical performance in community-dwelling (pre)sarcopenic elderly ( 65 years) living in Belgium. Physical performance will be evaluated using the Short Physical Performance Battery (SPPB). Muscle mass will be measured using a dual energy x-ray absorptiometry (DXA) and/or bioelectrical impedance analysis (BIA). Muscle strength will be measured by the Biodex (knee-extensor and knee-flexor) and a 1 hand-held dynamometer. The trial will also determine the underlying mechanisms of action using blood measures (such as markers of inflammation and sarcopenia) and muscle biomarkers. Important secondary outcome measures are compliance to the exercise program and to the protein and omega-3 supplementation, as well as functional, cognitive and nutritional status and the patients report on benefits and adverse events.\n\nThe study consists of four parts. Part I is the screening phase, which starts from the moment the participant has signed the informed consent until the start of the preparations of the study. During the screening, participants will be assessed for study eligibility by the study coordinator and contributors. If the participant is eligible, he or she will be randomly assigned into 1 of 5 intervention groups: Group 1: Exercise intervention; Group 2: Protein supplement; Group 3: Exercise intervention + protein supplement; Group 4: Exercise + Protein supplement + omega-3 supplement; Group 5: No intervention.\n\nPart II is the preparation phase, in which the participants starts some of the interventions before the start of the study to familiarize patients with e.g. the intake of a protein supplement. All the participants will take an oral vitamin D supplement (800 IU cholecalciferol) from 4 weeks before the start of the intervention if their vitamin D level is above 20 nmol/L. Patients with a vitamin D level \\< 20 nmol/L will receive repletion therapy. A trial diary will be completed by all participants to record PA, falls and intake of protein/omega3/placebo and vitamin D products. Participants in the exercise intervention (group 1, 3 and 4) will be invited to an information session where the Otago Exercise Program (OEP) will be explained and practiced. With respect to the protein supplementation, participants will receive an individually adapted protein supplement to achieve the recommended total daily intake of 1.5 g protein/kg. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between, before or after meals, based on the subjects' food intake assessed by a food diary. The protein powder is commercially available and consists of 4.5g protein/ 5g powder. The participants in group 2, 3 and 4 will start taking the protein supplement or matched placebo 5 days before the start of the intervention. Four weeks before the start of the intervention, the participants of group 4 will start with the intake of omega-3 (1 capsule providing in total 500 mg eicosapentanoic acid (EPA) and 450 mg docosahexaenoic acid (DHA)) or matched placebo. Placebo will be provided for the participants who are not given a protein and/or omega-3 supplement. Participants are blinded to the nutritional interventions.\n\nThe third part of the study, the intervention period, takes 12 weeks. During this period, there are 8 contact moments (at baseline, week 1, week 2, week 4, week 6, week 8, week 10 and week 12). All the participants continue with the vitamin D supplementation. Participants in the exercise intervention (group 1, 3 and 4) will perform the optimized and personally adapted OEP and will also follow a walking plan. The strength exercises of the OEP are personalised based on the individual's 1 repetition maximum. Balance exercises of the OEP are personalised based on improvements on MiniBESTest scores during the intervention period. The nutritional intervention groups (protein supplementation: group 2, 3 and 4 and omega-3 supplementation: group 4) continue with the protein and/or omega-3 supplements until the last visit of the intervention period.\n\nPart IV is the follow-up period, after the intervention. This phase takes 12 weeks and exists of 2 telephone contacts and 2 contact moments. All the participants continue the vitamin D supplementation until the last visit of the follow-up. The exercise intervention group (group 1, 3 and 4) may continue the OEP, but no personal encouragement will be given during this period. No protein and/ or omega-3 supplements will be given during the follow-up.\n\nSeveral outcomes will be measured during the contact moments of the intervention period and follow-up period (part III and part IV). This will be done by questionnaires about nutritional status, fall history and use of health care (from baseline until end of follow-up), and evaluation of functional and cognitive status. Blood, urine and muscle samples will be taken. The physical activity will be measured by wearing a movement tracker. All participants will wear a movement tracker 5 days before the intervention period and during the first two weeks of the intervention period and last two weeks of the intervention period, and during the last 2 weeks of the follow-up period. Participants who receive an exercise intervention (group 1, 3 and 4) will be encouraged to wear the movement tracker during the complete intervention period. The participants will complete a four-day food diary throughout the trial at week 1, week 6, week 12 and week 24. The participants will be asked for compliance during the preparation period and intervention period and their fall history which can be monitored by using diaries during the intervention period and the follow-up period.\n\nAddendum 27-07-2021: starting from 01-2021 a substudy was initiated in which participants of ENHANce, who agreed for participation in this substudy, collect stool samples at baseline, week 4, week 8 and week 12 of the intervention. This will allow to observe possible changes in gut microbiota composition and intestinal inflammation."
                },
                "conditionsModule": {
                  "conditions": [
                    "Sarcopenia"
                  ],
                  "keywords": [
                    "Sarcopenia",
                    "Nutrition",
                    "Protein",
                    "Vitamin D",
                    "Exercise",
                    "Older people",
                    "Frailty"
                  ]
                },
                "designModule": {
                  "studyType": "INTERVENTIONAL",
                  "phases": [
                    "NA"
                  ],
                  "designInfo": {
                    "allocation": "RANDOMIZED",
                    "interventionModel": "PARALLEL",
                    "primaryPurpose": "TREATMENT",
                    "maskingInfo": {
                      "masking": "TRIPLE",
                      "maskingDescription": "* Participant: Yes blinded for protein and omega-3\n* Investigator: Yes blinded for protein and omega-3\n* Outcomes Assessor: Yes blinded for protein and omega-3\n* No blinding for exercise intervention.\n* Statistician is blinded for protein, omega-3 and exercise intervention.",
                      "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                      ]
                    }
                  },
                  "enrollmentInfo": {
                    "count": 180,
                    "type": "ESTIMATED"
                  }
                },
                "armsInterventionsModule": {
                  "armGroups": [
                    {
                      "label": "Home-based training program",
                      "type": "EXPERIMENTAL",
                      "description": "Home-based training program + protein placebo + omega-3 placebo",
                      "interventionNames": [
                        "Behavioral: Home-based training program",
                        "Drug: Placebo protein powder",
                        "Drug: Placebo omega-3"
                      ]
                    },
                    {
                      "label": "High-quality protein supplement",
                      "type": "EXPERIMENTAL",
                      "description": "High-quality protein supplement + omega-3 placebo",
                      "interventionNames": [
                        "Dietary Supplement: High-quality protein supplement",
                        "Drug: Placebo omega-3"
                      ]
                    },
                    {
                      "label": "2 Anabolic interventions",
                      "type": "EXPERIMENTAL",
                      "description": "Home-based training program and high quality protein supplement",
                      "interventionNames": [
                        "Behavioral: Home-based training program",
                        "Dietary Supplement: High-quality protein supplement",
                        "Drug: Placebo omega-3"
                      ]
                    },
                    {
                      "label": "3 Anabolic interventions",
                      "type": "EXPERIMENTAL",
                      "description": "Home-based training program, high-quality protein supplement and omega-3 fatty acids",
                      "interventionNames": [
                        "Behavioral: Home-based training program",
                        "Dietary Supplement: High-quality protein supplement",
                        "Dietary Supplement: Omega-3 fatty acid"
                      ]
                    },
                    {
                      "label": "Placebo protein powder and omega-3",
                      "type": "PLACEBO_COMPARATOR",
                      "description": "Control group: protein placebo + omega-3 placebo",
                      "interventionNames": [
                        "Drug: Placebo protein powder",
                        "Drug: Placebo omega-3"
                      ]
                    }
                  ],
                  "interventions": [
                    {
                      "type": "BEHAVIORAL",
                      "name": "Home-based training program",
                      "description": "Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.",
                      "armGroupLabels": [
                        "2 Anabolic interventions",
                        "3 Anabolic interventions",
                        "Home-based training program"
                      ]
                    },
                    {
                      "type": "DIETARY_SUPPLEMENT",
                      "name": "High-quality protein supplement",
                      "description": "The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.",
                      "armGroupLabels": [
                        "2 Anabolic interventions",
                        "3 Anabolic interventions",
                        "High-quality protein supplement"
                      ]
                    },
                    {
                      "type": "DIETARY_SUPPLEMENT",
                      "name": "Omega-3 fatty acid",
                      "description": "Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.",
                      "armGroupLabels": [
                        "3 Anabolic interventions"
                      ]
                    },
                    {
                      "type": "DRUG",
                      "name": "Placebo protein powder",
                      "description": "Isocaloric maltodextrin powder. Amount based on food diary.",
                      "armGroupLabels": [
                        "Home-based training program",
                        "Placebo protein powder and omega-3"
                      ]
                    },
                    {
                      "type": "DRUG",
                      "name": "Placebo omega-3",
                      "description": "Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day",
                      "armGroupLabels": [
                        "2 Anabolic interventions",
                        "High-quality protein supplement",
                        "Home-based training program",
                        "Placebo protein powder and omega-3"
                      ]
                    }
                  ]
                },
                "outcomesModule": {
                  "primaryOutcomes": [
                    {
                      "measure": "Change in physical functioning",
                      "description": "Change in SPPB score",
                      "timeFrame": "Measured at baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Percentage of participants with change in physical functioning",
                      "description": "the percentage of participants with more than 1 or 1 point increase in SPPB score.",
                      "timeFrame": "Measured at baseline, week 12 and week 24."
                    }
                  ],
                  "secondaryOutcomes": [
                    {
                      "measure": "Change in muscle mass (after intervention-baseline)",
                      "description": "Appendicular lean mass will be measured with a whole-body DXA scan and by BIA.",
                      "timeFrame": "Measured at screening, week 12 and week 24 with DXA or when screening is 6 weeks prior to baseline, DXA will also be performed at baseline. At screening, baseline, week 12 and week 24 with BIA."
                    },
                    {
                      "measure": "Change in muscle strength (after intervention-baseline)",
                      "description": "Muscle strength of the knee-extensor, knee-flexor and hip abductors will be measured by Biodex and hand grip strength with dynamometer.",
                      "timeFrame": "Hand grip measured at screening, baseline, week 12 and week 24. Biodex measured at baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Compliance to the exercise intervention, subjective",
                      "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- The number of Otago sessions the participant performed divided by the number of Otago sessions the participants needed to perform. Likewise, this will be calculated for the walking program and for the integral exercise intervention.",
                      "timeFrame": "baseline until week 12"
                    },
                    {
                      "measure": "Compliance to the exercise intervention, objective",
                      "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- Monitor and diary: Length of exercise session (time). Pattern recognition of exercise groups by algorithm development",
                      "timeFrame": "baseline until week 12"
                    },
                    {
                      "measure": "Compliance to the exercise intervention, subjective, detailed",
                      "description": "Compliance to the Otago program will be assessed by measure of:\n\n\\- Diary: the reported intensity of the strength exercises",
                      "timeFrame": "baseline until week 12"
                    },
                    {
                      "measure": "Compliance to the protein supplementation, objective",
                      "description": "Compliance to protein supplementation:\n\n\\- The number of nutritional intakes the participant did divided by the number of intakes of nutritional supplement the participant was prescribed.",
                      "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                    },
                    {
                      "measure": "Compliance to the protein supplementation, subjective",
                      "description": "Compliance to protein supplementation:\n\n\\- Count and weight returned powder boxes",
                      "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                    },
                    {
                      "measure": "Compliance to the protein supplementation objective",
                      "description": "Compliance to protein supplementation:\n\n\\- N content in 8 24h urine samples by the Dumas method (28) to estimate rise in protein intake and Creatinine index to estimate the completion of the urine samples (29, 30)",
                      "timeFrame": "Urine samples at baseline, week 1, 2, 4, 6, 8, 10, 12, 24."
                    },
                    {
                      "measure": "Compliance to the omega-3 supplementation, subjective",
                      "description": "Compliance to omega-3 supplement\n\n\\- Count returned capsules and placebo tablets",
                      "timeFrame": "baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Compliance to the omega-3 supplementation, objective",
                      "description": "Compliance to omega-3 supplement\n\n\\- Compliance to the omega- 3 supplement is assessed by counting the number of capsules during each study visit and by analysis of red blood cell (RBC) membrane fatty acid profile",
                      "timeFrame": "baseline, week 12 and week 24."
                    },
                    {
                      "measure": "Functional status: frailty",
                      "description": "\\- Change in physical frailty stage defined by Fried et al (frail (3-5/5), prefrail (1-2/5), robust (0/5))",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: activities of daily living",
                      "description": "Change in activity of daily living (ADL) :Barthel-index",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: balance",
                      "description": "Change in balance (Mini-BESTest)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: change in physical activity",
                      "description": "Change in PA by the MoveMonitor+ (MM+) (method under development in our research group)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: health-related quality of life",
                      "description": "\\- Change in health-related quality of life, according to Short Form Health Survey (SF-36) questionnaire",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Functional status: falls",
                      "description": "\\- Number of falls and the circumstances, identified using weekly fall calendars + Falls Efficacy Scale International (FES-I)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Cognitive status: immediate and delayed memory, attention, language and visuospatial skills",
                      "description": "\\- The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): immediate and delayed memory, attention, language and visuospatial skills;",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Cognitive status: inhibition",
                      "description": "Stroop test (inhibition)",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Cognitive status",
                      "description": "\\- Maze test",
                      "timeFrame": "baseline, week 12 and 24"
                    },
                    {
                      "measure": "Nutritional status: malnutrition",
                      "description": "\\- Changes in numbers of participants with malnutrition, according to Mini Nutritional Assessment (MNA).",
                      "timeFrame": "at baseline (preparation for food diary), week 6, week 12 and week 24"
                    },
                    {
                      "measure": "Nutritional status: nutrient intake",
                      "description": "\\- Changes in nutrient intake, according to the four day food diary.",
                      "timeFrame": "at baseline (preparation for food diary), week 6, week 12 and week 24"
                    },
                    {
                      "measure": "Patient reported benefits and adverse effects",
                      "description": "Benefits and adverse effects are asked. Participants will describe their thoughts about the study, what they like and don't like.",
                      "timeFrame": "week 1, 4, 8, 12, 16, 20, 22, 24."
                    },
                    {
                      "measure": "Change in C reactive protein (CRP)",
                      "description": "change in hs-CRP",
                      "timeFrame": "baseline, week 1, 4, 12 and 24"
                    },
                    {
                      "measure": "Change in hemoglobin",
                      "description": "Change in hemoglobin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in creatinine",
                      "description": "Change in creatinine",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in urea",
                      "description": "Change in urea",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in serum albumin",
                      "description": "Change in serum albumin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in glucose",
                      "description": "Change in glucose",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in cholesterol (HDL, LDL, total, Triglycerides)",
                      "description": "Change in cholesterol (HDL, LDL, total, Triglycerides)",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in insulin",
                      "description": "Change in insulin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in insulin like growth factor 1 (IGF-1)",
                      "description": "Change in IGF-1",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in 25-hydroxy-vitamin D",
                      "description": "Change in 25-hydroxy-vitamin D",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in creatinine kinase",
                      "description": "Change in creatinine kinase",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in indoxyl sulfate",
                      "description": "Change in indoxyl sulfate",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in interleukin 6 (IL-6)",
                      "description": "Change in IL-6",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in IL-1b",
                      "description": "Change in IL-1b",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in tumor necrosis factor alpha (TNF-alpha)",
                      "description": "Change in TNF-alpha",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in myostatin",
                      "description": "Change in myostatin",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in activin A",
                      "description": "Change in activin A",
                      "timeFrame": "baseline, week 12 and week 24"
                    },
                    {
                      "measure": "Change in markers of muscle wasting",
                      "description": "Change in markers of muscle wasting (MURF1, Atrogin1, FOXO3)",
                      "timeFrame": "baseline, week 12"
                    },
                    {
                      "measure": "Change in markers of muscle regeneration",
                      "description": "Change in markers of muscle regeneration (PAX7, Myogenic factor 5 (MYF5), myoblast determination protein (MyoD), Ki67, mammalian target of rapamycin (mTOR), AMPK)",
                      "timeFrame": "baseline, week 12"
                    },
                    {
                      "measure": "Change in muscle histology",
                      "description": "Change in muscle histology",
                      "timeFrame": "baseline, week 12"
                    },
                    {
                      "measure": "Change in composition of gut microbiota",
                      "description": "Change in composition of gut microbiota",
                      "timeFrame": "baseline, week 4, week 8, week 12"
                    },
                    {
                      "measure": "Change in markers of intestinal inflammation",
                      "description": "Change in markers of intestinal inflammation (fecal calprotectin, lactoferrin, S100A12)",
                      "timeFrame": "baseline, week 4, week 8, week 12"
                    }
                  ]
                },
                "eligibilityModule": {
                  "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female persons with (pre)sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP): reduced muscle mass without (presarcopenia) or with (sarcopenia) reduced walking speed ( 0.8m/s) or muscle strength OR probable, confirmed or severe sarcopenia according to EWGSOP 2.\n2. 65 years or older;\n3. Community-dwelling elderly or assisted living;\n4. In case of one or more positive answer(s) on the health screen for exercise, subjects need approval of their general practitioner to participate in this randomized controlled trial (RCT).\n\n   * Uncontrolled or unstable health problems\n   * Uncontrolled pain or feeling unwell the day of the exercise\n   * Recently diagnosed cardiovascular events\n   * systolic blood pressure (SBP)  180 mmHg and/or diastolic blood pressure (DBP)  100 mmHg\n   * Resting tachycardia \\> 100 bpm\n   * Uncontrolled atrial or ventricular arrhythmias\n   * Unstable or acute heart failure\n   * Lasting, increased pain following a previous session\n   * Suspected acute injury\n   * Recent injurious fall without medical assessment\n   * Severe breathlessness or dizziness\n   * Uncontrolled pulmonary problems\n   * Rheumatoid arthritis flare up or acute systemic illness/infection\n   * Unexplained lethargy\n\nExclusion Criteria:\n\n1. Impairments/diseases that impose problems to participation in the study;\n2. Allergy to milk or soy or peanut;\n3. Mini-Mental State Examination (MMSE) \\< 21;\n4. Terminal illness (prognosis \\< 6 months);\n5. Persons who followed a physical training program in the last 6 months (twice or more/week);\n6. Persons with a daily intake of \\> 1.5 g protein/kg body weight (BW)/day;\n7. Diagnosis of severe kidney disease (GFR \\< 30 ml/min) or diabetes mellitus;\n8. Unable to communicate in Dutch, English or French.",
                  "healthyVolunteers": false,
                  "sex": "ALL",
                  "minimumAge": "65 Years",
                  "stdAges": [
                    "OLDER_ADULT"
                  ]
                },
                "contactsLocationsModule": {
                  "centralContacts": [
                    {
                      "name": "Laur Vercauteren, MSc",
                      "role": "CONTACT",
                      "phone": "+32 16 34 38 67",
                      "email": "laura.vercauteren@kuleuven.be"
                    },
                    {
                      "name": "Jolan Dupont, MD",
                      "role": "CONTACT",
                      "phone": "+32 16 34 32 01",
                      "email": "jolan.dupont@uzleuven.be"
                    }
                  ],
                  "overallOfficials": [
                    {
                      "name": "Evelien Gielen, Prof MD PhD",
                      "affiliation": "Gerontology and Geriatrics, Department of Public Health and primary care KU Leuven",
                      "role": "PRINCIPAL_INVESTIGATOR"
                    }
                  ],
                  "locations": [
                    {
                      "facility": "Gerontology and Geriatrics, Department of Public Health and Primary Care, KU Leuven",
                      "status": "RECRUITING",
                      "city": "Leuven",
                      "state": "Vlaams-Brabant",
                      "zip": "3000",
                      "country": "Belgium",
                      "contacts": [
                        {
                          "name": "Laura Vercauteren",
                          "role": "CONTACT",
                          "phone": "+32 16 34 38 67",
                          "email": "laura.vercauteren@kuleuven.be"
                        },
                        {
                          "name": "Jolan Dupont, PhD",
                          "role": "CONTACT",
                          "phone": "+32 16 34 32 01",
                          "email": "jolan.dupont@uzleuven.be"
                        },
                        {
                          "name": "Evelien Gielen, Prof MD PhD",
                          "role": "PRINCIPAL_INVESTIGATOR"
                        }
                      ],
                      "geoPoint": {
                        "lat": 50.87959,
                        "lon": 4.70093
                      }
                    }
                  ]
                },
                "referencesModule": {
                  "references": [
                    {
                      "pmid": "41632571",
                      "type": "DERIVED",
                      "citation": "Amini N, Dupont J, Lapauw L, Vercauteren L, Peeters L, Dedeyne L, Verschueren S, Tournoy J, Gielen E. A multicomponent intervention consisting of exercise, proteins and omega-3 supplementation to improve sarcopenia in community-dwelling older adults: Lessons learned from a 5-armed randomized controlled feasibility trial. J Frailty Aging. 2026 Feb 2;15(1):100129. doi: 10.1016/j.tjfa.2025.100129. Online ahead of print."
                    },
                    {
                      "pmid": "39787986",
                      "type": "DERIVED",
                      "citation": "Amini N, Devriendt A, Lapauw L, Dupont J, Vercauteren L, Verbeke K, Verschueren S, Tournoy J, Gielen E. Estimating protein intake in sarcopenic older adults: combining food diaries and weighed powders versus 24-hour urine collections. J Nutr Health Aging. 2025 Mar;29(3):100474. doi: 10.1016/j.jnha.2024.100474. Epub 2025 Jan 8."
                    },
                    {
                      "pmid": "37752426",
                      "type": "DERIVED",
                      "citation": "Lapauw L, Dupont J, Amini N, Vercauteren L, Verschueren S, Tournoy J, Raes J, Gielen E. Trial in Elderly with Musculoskeletal Problems due to Underlying Sarcopenia-Faeces to Unravel the Gut and Inflammation Translationally (TEMPUS-FUGIT): protocol of a cross-sequential study to explore the gut-muscle axis in the development and treatment of sarcopenia in community-dwelling older adults. BMC Geriatr. 2023 Sep 26;23(1):599. doi: 10.1186/s12877-023-04291-5."
                    },
                    {
                      "pmid": "33302879",
                      "type": "DERIVED",
                      "citation": "Dedeyne L, Dupont J, Koppo K, Verschueren S, Tournoy J, Gielen E. Exercise and Nutrition for Healthy AgeiNg (ENHANce) project - effects and mechanisms of action of combined anabolic interventions to improve physical functioning in sarcopenic older adults: study protocol of a triple blinded, randomized controlled trial. BMC Geriatr. 2020 Dec 10;20(1):532. doi: 10.1186/s12877-020-01900-5."
                    }
                  ]
                },
                "ipdSharingStatementModule": {
                  "ipdSharing": "UNDECIDED"
                }
              },
              "derivedSection": {
                "miscInfoModule": {
                  "versionHolder": "2026-02-27"
                },
                "conditionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D055948",
                      "term": "Sarcopenia"
                    },
                    {
                      "id": "D009043",
                      "term": "Motor Activity"
                    },
                    {
                      "id": "D000073496",
                      "term": "Frailty"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D009133",
                      "term": "Muscular Atrophy"
                    },
                    {
                      "id": "D020879",
                      "term": "Neuromuscular Manifestations"
                    },
                    {
                      "id": "D009461",
                      "term": "Neurologic Manifestations"
                    },
                    {
                      "id": "D009422",
                      "term": "Nervous System Diseases"
                    },
                    {
                      "id": "D001284",
                      "term": "Atrophy"
                    },
                    {
                      "id": "D020763",
                      "term": "Pathological Conditions, Anatomical"
                    },
                    {
                      "id": "D013568",
                      "term": "Pathological Conditions, Signs and Symptoms"
                    },
                    {
                      "id": "D012816",
                      "term": "Signs and Symptoms"
                    },
                    {
                      "id": "D001519",
                      "term": "Behavior"
                    },
                    {
                      "id": "D010335",
                      "term": "Pathologic Processes"
                    }
                  ]
                },
                "interventionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D015525",
                      "term": "Fatty Acids, Omega-3"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D004042",
                      "term": "Dietary Fats, Unsaturated"
                    },
                    {
                      "id": "D004041",
                      "term": "Dietary Fats"
                    },
                    {
                      "id": "D005223",
                      "term": "Fats"
                    },
                    {
                      "id": "D008055",
                      "term": "Lipids"
                    },
                    {
                      "id": "D005231",
                      "term": "Fatty Acids, Unsaturated"
                    },
                    {
                      "id": "D005227",
                      "term": "Fatty Acids"
                    },
                    {
                      "id": "D005395",
                      "term": "Fish Oils"
                    },
                    {
                      "id": "D009821",
                      "term": "Oils"
                    }
                  ]
                }
              },
              "hasResults": false
            }
          },
          {
            "nct_id": "NCT06658093",
            "brief_title": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
            "official_title": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
            "overall_status": "RECRUITING",
            "study_type": "INTERVENTIONAL",
            "phases": [
              "EARLY_PHASE1"
            ],
            "enrollment": 194,
            "primary_outcomes": [
              {
                "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                "description": "The levels of the study drug will be measured in whole blood",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
              },
              {
                "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                "timeFrame": "Baseline to study end (approximately 12 months)"
              }
            ],
            "has_results": false,
            "raw_study": {
              "protocolSection": {
                "identificationModule": {
                  "nctId": "NCT06658093",
                  "orgStudyIdInfo": {
                    "id": "STUDY00000471"
                  },
                  "secondaryIdInfos": [
                    {
                      "id": "U01AG089242",
                      "type": "NIH",
                      "link": "https://reporter.nih.gov/quickSearch/U01AG089242"
                    }
                  ],
                  "organization": {
                    "fullName": "The University of Texas Health Science Center at San Antonio",
                    "class": "OTHER"
                  },
                  "briefTitle": "RESTOR: PK/PD mTORi Inhibition in Older Adults",
                  "officialTitle": "RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An Exploratory PK/PD Study of mTOR Inhibition in Older Human Subjects",
                  "acronym": "RESTOR"
                },
                "statusModule": {
                  "statusVerifiedDate": "2025-08",
                  "overallStatus": "RECRUITING",
                  "expandedAccessInfo": {
                    "hasExpandedAccess": false
                  },
                  "startDateStruct": {
                    "date": "2025-08-13",
                    "type": "ACTUAL"
                  },
                  "primaryCompletionDateStruct": {
                    "date": "2028-07",
                    "type": "ESTIMATED"
                  },
                  "completionDateStruct": {
                    "date": "2028-07",
                    "type": "ESTIMATED"
                  },
                  "studyFirstSubmitDate": "2024-10-22",
                  "studyFirstSubmitQcDate": "2024-10-22",
                  "studyFirstPostDateStruct": {
                    "date": "2024-10-26",
                    "type": "ACTUAL"
                  },
                  "lastUpdateSubmitDate": "2025-08-27",
                  "lastUpdatePostDateStruct": {
                    "date": "2025-09-04",
                    "type": "ACTUAL"
                  }
                },
                "sponsorCollaboratorsModule": {
                  "responsibleParty": {
                    "type": "PRINCIPAL_INVESTIGATOR",
                    "investigatorFullName": "Ellen Kraig",
                    "investigatorTitle": "Professor",
                    "investigatorAffiliation": "The University of Texas Health Science Center at San Antonio"
                  },
                  "leadSponsor": {
                    "name": "The University of Texas Health Science Center at San Antonio",
                    "class": "OTHER"
                  },
                  "collaborators": [
                    {
                      "name": "National Institute on Aging (NIA)",
                      "class": "NIH"
                    }
                  ]
                },
                "oversightModule": {
                  "oversightHasDmc": true,
                  "isFdaRegulatedDrug": true,
                  "isFdaRegulatedDevice": false
                },
                "descriptionModule": {
                  "briefSummary": "As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease. Studies in animal models have been able to identify drugs that slow the aging process, leading to a longer, healthier life. This study is focused on one such family of drugs, called mTOR inhibitors, and the investigators' goal is to test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults to find a dose and dose timing that can be used to safely inhibit mTOR to the levels seen in young healthy persons. The investigators expect that the dose that works well in women may differ from the one that is best in men, so it is important to include both sexes in this research.",
                  "detailedDescription": "The study will be done in three parts, each with different human subject groups. Participants may only enroll in one of the sub-studies.\n\nSub-study 1: Determining target mTOR activity values in YOUNG untreated subjects (ages 20-30 years): NOTE: This aim of the study is not a clinical trial, so this population will not be included in participant flow or included as an arm in the study.\n\nThis study defines \"best dose\" as the choice of drug, dose, and frequency that will come closest to restoring the \"youthful\" levels of mTOR activity in an older individual. The investigators first need to measure mTOR activity in young untreated subjects to define these target \"youthful\" mTOR activity levels.\n\nSub-study 2. Finding the most effective drug, dose, and timing for dosing for oral dosing of the mTOR inhibitor drugs in older adults (65-90 years):\n\nHealthy older persons will be recruited for a short-term (6 week treatment plus 4 week follow-up) dose-finding study. The most effective, but safe dose will then be tested in a larger number of subjects in Sub-study 3. Importantly, the best drug and dose regimen for females may differ from the one determined for males so the cohort will include both sexes.\n\nSub-study 3. Placebo controlled trial testing of DAILY (sustained) vs. INTERMITTENT mTOR inhibition in older human males and females:\n\nSub-study 3 will enroll healthy older persons (65-90 yrs) for a long-term clinical trial (6 months of treatment plus 6 months of follow-up) with 3 test groups:\n\ni) best DAILY dose/drug; ii) best INTERMITTENT dose/drug/interval, and iii) PLACEBO (a pill that looks identical to the medicine, but has no drug in it).\n\nThis study will help find out what effects, good and/or bad, Rapamycin or Everolimus have on older people who take the drug for a longer period of time. The safety of Rapamycin and Everolimus in humans has been tested in prior research studies; however, some side effects may not yet be known in healthy older persons. By completing the entire study, the Research Team hopes to learn more about how older human subjects can best be treated using these drugs (mTOR inhibitors) to help them live longer, healthier lives."
                },
                "conditionsModule": {
                  "conditions": [
                    "Aging"
                  ],
                  "keywords": [
                    "mTOR inhibitors"
                  ]
                },
                "designModule": {
                  "studyType": "INTERVENTIONAL",
                  "phases": [
                    "EARLY_PHASE1"
                  ],
                  "designInfo": {
                    "allocation": "RANDOMIZED",
                    "interventionModel": "SEQUENTIAL",
                    "interventionModelDescription": "A single site open label adaptive clinical trial (Aim 1:Sub-study 2) followed by a placebo-controlled blinded clinical trial (Aim 2) to optimize the use of mTOR inhibitors in older persons a functions of drug, dose, dosing schedule and sex. It will be carried out in 2 sub-studies:\n\nAim 1:\n\n-Sub-study 2: Comparison of 2 mTOR inhibitors in an adaptive open-label dose finding pharmacokinetic/pharmacodynamic study\n\nAim 2:\n\nSub-study 3: Assess the safety/tolerability/adverse events of optimized dose of mTOR inhibitors in daily vs intermittent dosing",
                    "primaryPurpose": "BASIC_SCIENCE",
                    "maskingInfo": {
                      "masking": "DOUBLE",
                      "maskingDescription": "Blinding will only occur in Aim 2 (Sub-study 3). Randomization will be done by the research pharmacy providing the investigational drug.",
                      "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER"
                      ]
                    }
                  },
                  "enrollmentInfo": {
                    "count": 194,
                    "type": "ESTIMATED"
                  }
                },
                "armsInterventionsModule": {
                  "armGroups": [
                    {
                      "label": "Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Rapamycin"
                      ]
                    },
                    {
                      "label": "Aim 1: Sub-study 2 Daily dosing Cohort Everolimus",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) of everolimus (EVERO) in milligrams based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of rapamycin (RAPA) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Rapamycin"
                      ]
                    },
                    {
                      "label": "Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus",
                      "type": "EXPERIMENTAL",
                      "description": "Aim 1 is an open label, adaptive, dose finding PK/PD trial in older women and men.\n\nIn sub-study 2 (part of Aim 1), an older cohort will be studied to determine the optimal dose (OD) in milligrams and the optimal interval for intermittent delivery of everolimus (EVERO) based on changes in PD parameters 'downstream' from mTOR. Based on the data acquired, additional older cohorts will be tested at higher/lower doses in an adaptive, step-wise trial design.",
                      "interventionNames": [
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                      "type": "EXPERIMENTAL",
                      "description": "Based on the findings from Aim 1, the optimal drug (RAPA or EVERO) and dose for DAILY delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed.",
                      "interventionNames": [
                        "Drug: Rapamycin",
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor",
                      "type": "EXPERIMENTAL",
                      "description": "Based on the findings from Aim 1, the optimal drug (RAPA or EVERO), interval between doses, and dose for INTERMITTENT delivery will be tested in a blinded placebo-controlled trial in older human subjects. The drug/dose/interval used in males may differ from the one used in females as the OD will be determined independently for the two sexes. PD parameters 'downstream' from mTOR will be followed. Although drug is delivered on an intermittent schedule, subjects will be given a pill each day (either drug or placebo, as scheduled) to maintain blinding.",
                      "interventionNames": [
                        "Drug: Rapamycin",
                        "Drug: Everolimus"
                      ]
                    },
                    {
                      "label": "Aim 2: Sub-study 3 Placebo control",
                      "type": "PLACEBO_COMPARATOR",
                      "description": "Daily administration of a placebo will be given to a cohort of older human subjects. Both males and females will be enrolled as controls.",
                      "interventionNames": [
                        "Other: Placebo"
                      ]
                    }
                  ],
                  "interventions": [
                    {
                      "type": "DRUG",
                      "name": "Rapamycin",
                      "description": "mTOR inhibitor",
                      "armGroupLabels": [
                        "Aim 1:Sub-study 2 Daily dosing Cohort Rapamycin",
                        "Aim 1:Sub-study 2 Intermittent dosing Cohort Rapamycin",
                        "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                        "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor"
                      ],
                      "otherNames": [
                        "RAPA"
                      ]
                    },
                    {
                      "type": "DRUG",
                      "name": "Everolimus",
                      "description": "mTOR inhibitor",
                      "armGroupLabels": [
                        "Aim 1: Sub-study 2 Daily dosing Cohort Everolimus",
                        "Aim 1: Sub-study 2 Intermittent dosing Cohort Everolimus",
                        "Aim 2: Sub-study 3 Optimized DAILY Dose of an mTOR inhibitor",
                        "Aim 2: Sub-study 3 Optimized INTERMITTENT Dosing of an mTOR inhibitor"
                      ],
                      "otherNames": [
                        "EVERO"
                      ]
                    },
                    {
                      "type": "OTHER",
                      "name": "Placebo",
                      "description": "Inert placebo for rapamycin or everolimus",
                      "armGroupLabels": [
                        "Aim 2: Sub-study 3 Placebo control"
                      ],
                      "otherNames": [
                        "Placebo capsule"
                      ]
                    }
                  ]
                },
                "outcomesModule": {
                  "primaryOutcomes": [
                    {
                      "measure": "Pharmacokinetics (PK) of mTOR inhibitor in blood",
                      "description": "The levels of the study drug will be measured in whole blood",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in blood cells - p-rpS6",
                      "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)"
                    },
                    {
                      "measure": "Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)",
                      "description": "The level of soluble (s)ICAM-1 will be measured in serum.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    }
                  ],
                  "secondaryOutcomes": [
                    {
                      "measure": "PK of mTOR inhibitor in fat (Aim 2 only)",
                      "description": "The levels of the study drug will be measure in fat tissue obtained by adipose biopsy",
                      "timeFrame": "Baseline and study end (approximately 12 months)"
                    },
                    {
                      "measure": "PK of mTOR inhibitor in muscle (Aim 2 only)",
                      "description": "The levels of the study drug will be measured in skeletal muscle obtained by biopsy.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in fat cells (Aim 2 only) - pS6K",
                      "description": "Proteins prepared from adipose tissue will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in muscle (Aim 2 only) - pS6K",
                      "description": "Proteins prepared from skeletal muscle tissue biopsy will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in PBMCs, S6-kinase",
                      "description": "Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of S6kinase, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in adipose cells, rpS6 (Aim 2 only)",
                      "description": "Proteins prepared from adipose biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in muscle rpS6 (Aim 2 only)",
                      "description": "Proteins prepared from muscle biopsies will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in adipose (fat) cells Akt (Aim 2 only)",
                      "description": "Proteins prepared from adipose biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in muscle Akt (Aim 2 only)",
                      "description": "Proteins prepared from muscle biopsies will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    },
                    {
                      "measure": "PD measure of inhibition of mTOR activity in PBMCs Akt",
                      "description": "Proteins prepared from PBMCs will be analyzed for phosphorylation of Akt, downstream of mTORC2.",
                      "timeFrame": "Baseline to study end (approximately 12 months)"
                    }
                  ]
                },
                "eligibilityModule": {
                  "eligibilityCriteria": "Inclusion Criteria:\n\nOlder Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):\n\n1. Age 65 to 90 years\n2. Men and women\n3. In good health with all medical problems stable.\n4. Community-dwelling\n5. Agreement to adhere to Lifestyle Considerations throughout study duration.\n6. Ability of participant to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\nOlder Cohort Sub-study 2 (AIM 1) and Sub-study 3 (AIM 2):\n\n1. Resident of nursing home or long-term care facility\n2. Subjects with diabetes or currently taking glucose lowering medications\n3. History of moderate-severe heart disease (New York Heart Classication greater than grade II) or pulmonary disease (dyspnea on exertion upon climbing one ight of stairs or less; abnormal breath sounds on auscultation); Moderate to severe valvular heart disease\n4. Active cancer or history of cancer treatment within the last 5 years\n5. Chronic inammatory condition, autoimmune disease, or infectious processes (e.g., active tuberculosis, HIV, rheumatoid arthritis, systemic lupus erythematosus, acute or chronic hepatitis B or C)\n6. History of a coagulopathy or any medical condition requiring anticoagulation (except low dose ASA)\n7. Renal insuciency with an estimated glomerular ltration rate of \\<30ml/min\n8. Uncontrolled hypercholesterolemia \\>350mg/dl or uncontrolled hypertriglyceridemia \\>500mg/dl\n9. Anemia or abnormal blood cell counts: hemoglobin level \\<9.0g.dl; white blood count \\<3500/mm3; neutrophil count \\<2000/ mm3; platelet count \\<125,000/mm3\n10. History of skin ulcers or poor wound healing\n11. Active tobacco use (within 6 months)\n12. Diagnosis of any disabling neurologic disease such as Parkinson's Disease, Amyotrophic Lateral Sclerosis, multiple sclerosis, cerebrovascular accident with residual decits (muscle weakness or gait disorder), severe neuropathy, diagnosis of dementia or Clox1 score less than 10 at the time of screening visit, cognitive impairment due to any reason such that the patient is unable to provide informed consent\n13. Liver disease\n14. Systemic treatment with an immunosuppressant (prednisone, etc.) within the year prior to enrollment\n15. Treatment with drugs known to affect cytochrome P450 (CYP3A4), i.e., diltiazem, erythromycin.\n16. Patients with history of recent (within 6 months) myocardial infarction or active coronary disease\n17. Patients with history of recent (within 6 months) intestinal disorders\n18. History of severe head trauma, brain injury, brain surgery, inammation of the brain, or history of seizure disorder\n19. History of Long-Covid (PASC) within one year\n20. Acute Covid19 or Covid19 infection within the last 6 months\n21. Unwilling to forgo grapefruit juice consumption.\n22. Participation in mTORi study within the prior year. (Note: participants in AIM 1 will be excluded from participating in AIM 2 of the proposed trial.)\n23. Allergic to RAPA or EVERO\n24. Allergic to lidocaine\n25. Recreational drug use\n26. Donated blood over a two-month period prior to study initiation.\n27. Currently using cannabidiol (CBD) or tetrahydrocannabinol (THC) or any preparation contained these, or related, substances.\n28. Currently using hormone replacement or modulating therapies.",
                  "healthyVolunteers": true,
                  "sex": "ALL",
                  "minimumAge": "65 Years",
                  "maximumAge": "90 Years",
                  "stdAges": [
                    "OLDER_ADULT"
                  ]
                },
                "contactsLocationsModule": {
                  "centralContacts": [
                    {
                      "name": "Dean L Kellogg, Jr, MD PhD",
                      "role": "CONTACT",
                      "phone": "(210) 617 5197",
                      "email": "kelloggd@uthscsa.edu"
                    },
                    {
                      "name": "Ellen Kraig, PhD",
                      "role": "CONTACT",
                      "phone": "(210) 367-3171",
                      "email": "kraig@uthscsa.edu"
                    }
                  ],
                  "overallOfficials": [
                    {
                      "name": "Ellen Kraig, PhD",
                      "affiliation": "The University of Texas Health Science Center at San Antonio",
                      "role": "PRINCIPAL_INVESTIGATOR"
                    }
                  ],
                  "locations": [
                    {
                      "facility": "The University of Texas Health Science Center at San Antonio",
                      "status": "RECRUITING",
                      "city": "San Antonio",
                      "state": "Texas",
                      "zip": "78229",
                      "country": "United States",
                      "contacts": [
                        {
                          "name": "Dean L Kellogg Jr.,, MD PhD",
                          "role": "CONTACT",
                          "phone": "210-617-5197",
                          "email": "kelloggd@uthscsa.edu"
                        },
                        {
                          "name": "Dean L Kellogg Jr., MD PhD",
                          "role": "PRINCIPAL_INVESTIGATOR"
                        }
                      ],
                      "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                      }
                    }
                  ]
                },
                "referencesModule": {
                  "references": [
                    {
                      "pmid": "29408453",
                      "type": "BACKGROUND",
                      "citation": "Kraig E, Linehan LA, Liang H, Romo TQ, Liu Q, Wu Y, Benavides AD, Curiel TJ, Javors MA, Musi N, Chiodo L, Koek W, Gelfond JAL, Kellogg DL Jr. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp Gerontol. 2018 May;105:53-69. doi: 10.1016/j.exger.2017.12.026. Epub 2018 Feb 3."
                    }
                  ]
                },
                "ipdSharingStatementModule": {
                  "ipdSharing": "YES",
                  "description": "De-identified Individual participant data (IPD) that underlie results in a publication.",
                  "infoTypes": [
                    "STUDY_PROTOCOL",
                    "SAP"
                  ],
                  "timeFrame": "At the time of publication in a peer review journal"
                }
              },
              "derivedSection": {
                "miscInfoModule": {
                  "versionHolder": "2026-02-27"
                },
                "interventionBrowseModule": {
                  "meshes": [
                    {
                      "id": "D020123",
                      "term": "Sirolimus"
                    },
                    {
                      "id": "D000068338",
                      "term": "Everolimus"
                    }
                  ],
                  "ancestors": [
                    {
                      "id": "D018942",
                      "term": "Macrolides"
                    },
                    {
                      "id": "D007783",
                      "term": "Lactones"
                    },
                    {
                      "id": "D009930",
                      "term": "Organic Chemicals"
                    }
                  ]
                }
              },
              "hasResults": false
            }
          }
        ],
        "mode": "balanced"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Linked 3 trial(s) to publication evidence.",
          "data": {
            "mode": "balanced",
            "links": [
              {
                "nct_id": "NCT03308747",
                "status": "COMPLETED",
                "has_results": false,
                "pmids": [],
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": "completed_but_unpublished_possible"
              },
              {
                "nct_id": "NCT03649698",
                "status": "RECRUITING",
                "has_results": false,
                "pmids": [
                  "41632571",
                  "41548852",
                  "39787986",
                  "37752426",
                  "34434950",
                  "33302879"
                ],
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 6,
                  "openalex_count": 0
                },
                "flag": null
              },
              {
                "nct_id": "NCT06658093",
                "status": "RECRUITING",
                "has_results": false,
                "pmids": [],
                "openalex_ids": [],
                "counts": {
                  "pmid_count": 0,
                  "openalex_count": 0
                },
                "flag": null
              }
            ]
          },
          "ids": [
            "NCT03308747",
            "NCT03649698",
            "NCT06658093"
          ],
          "citations": [],
          "warnings": [
            "OpenAlex key missing; linker used PubMed only.",
            "OpenAlex key missing; linker used PubMed only.",
            "OpenAlex key missing; linker used PubMed only."
          ],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "trial_publication_linker",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:38.580561Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-015"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "pubmed_fetch"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 1791.8,
      "endpoint": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi",
      "enabled": true
    },
    {
      "tool": "dailymed_search",
      "payload": {
        "query": "sirolimus",
        "mode": "precision",
        "limit": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 5 DailyMed SPL label(s) for 'sirolimus'.",
          "data": {
            "query": "sirolimus",
            "mode": "precision",
            "records": [
              {
                "setid": "0f9bb784-53e2-46f9-a65d-1c6c2a230eaf",
                "title": "FYARRO (SIROLIMUS) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [AADI BIOSCIENCE, INC.]",
                "published_date": "Feb 09, 2026"
              },
              {
                "setid": "57fb4d90-3ccb-4a69-af1e-53be83f7a504",
                "title": "SIROLIMUS TABLET, FILM COATED [GLENMARK PHARMACEUTICALS INC., USA]",
                "published_date": "Jan 29, 2026"
              },
              {
                "setid": "19880f51-badb-4846-a02a-592a210690ab",
                "title": "SIROLIMUS SOLUTION [VISTAPHARM, LLC]",
                "published_date": "Jan 14, 2026"
              },
              {
                "setid": "6a85ad01-8144-4d9c-e053-2991aa0a4f85",
                "title": "SIROLIMUS TABLET [AVPAK]",
                "published_date": "Jan 12, 2026"
              },
              {
                "setid": "fb495630-5105-4f76-a4ce-6966149f02fa",
                "title": "FELYCIN-CA1 0.4 (SIROLIMUS) TABLET FELYCIN-CA1 1.2 (SIROLIMUS) TABLET FELYCIN-CA1 2.4 (SIROLIMUS) TABLET [PEGASUS LABORATORIES, INC.]",
                "published_date": "Dec 31, 2025"
              }
            ]
          },
          "ids": [
            "0f9bb784-53e2-46f9-a65d-1c6c2a230eaf",
            "57fb4d90-3ccb-4a69-af1e-53be83f7a504",
            "19880f51-badb-4846-a02a-592a210690ab",
            "6a85ad01-8144-4d9c-e053-2991aa0a4f85",
            "fb495630-5105-4f76-a4ce-6966149f02fa"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "dailymed_search_sirolimus_1.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/dailymed_search/manual-016/raw/dailymed_search_sirolimus_1.json",
              "sha256": "97970abf469536ab8a48f8df8a8d1cc6523695b03916f34fac9c47e11ba07699",
              "size_bytes": 1617
            }
          ],
          "pagination": {
            "next_page_token": "2",
            "has_more": true
          },
          "source_meta": {
            "source": "dailymed",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:39.472392Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-016"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "dailymed_fetch_sections"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 891.32,
      "endpoint": "https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json",
      "enabled": true
    },
    {
      "tool": "dailymed_fetch_sections",
      "payload": {
        "ids": [
          "0f9bb784-53e2-46f9-a65d-1c6c2a230eaf"
        ],
        "mode": "balanced"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched DailyMed sections for 1 SPL label(s).",
          "data": {
            "mode": "balanced",
            "records": [
              {
                "setid": "0f9bb784-53e2-46f9-a65d-1c6c2a230eaf",
                "sections": [
                  "These highlights do not include all the information needed to use FYARRO safely and effectively. See full prescribing information for FYARRO.",
                  "1 INDICATIONS AND USAGE",
                  "2 DOSAGE AND ADMINISTRATION",
                  "2.1 Recommended Dosage",
                  "2.2 Dosage Modifications for Adverse Reactions",
                  "2.3 Dosage Modifications for Concomitant Use with CYP3A4 and/or P-gp Inhibitors and Inducers",
                  "2.4 Patients with Hepatic Impairment",
                  "2.5 Preparation and Administration",
                  "2.6 Stability",
                  "3 DOSAGE FORMS AND STRENGTHS",
                  "4 CONTRAINDICATIONS",
                  "5 WARNINGS AND PRECAUTIONS",
                  "5.1 Stomatitis",
                  "5.2 Myelosuppression",
                  "5.3 Infections",
                  "5.4 Hypokalemia",
                  "5.5 Hyperglycemia",
                  "5.6 Interstitial Lung Disease / Non-Infectious Pneumonitis",
                  "5.7 Hemorrhage",
                  "5.8 Hypersensitivity Reactions",
                  "5.9 Embryo-Fetal Toxicity",
                  "5.10 Male Infertility",
                  "5.11 Immunizations and Risks Associated with Live Vaccines",
                  "5.12 Risk of Transmission of Infectious Agents with Human Albumin",
                  "6 ADVERSE REACTIONS",
                  "6.1 Clinical Trials Experience",
                  "7 DRUG INTERACTIONS",
                  "7.1 Effects of Other Drugs on FYARRO",
                  "8 USE IN SPECIFIC POPULATIONS",
                  "8.1 Pregnancy",
                  "8.2 Lactation",
                  "8.3 Females and Males of Reproductive Potential",
                  "8.4 Pediatric Use",
                  "8.5 Geriatric Use",
                  "8.6 Hepatic Impairment",
                  "11 DESCRIPTION",
                  "12 CLINICAL PHARMACOLOGY",
                  "12.1 Mechanism of Action",
                  "12.2 Pharmacodynamics",
                  "12.3 Pharmacokinetics",
                  "13 NONCLINICAL TOXICOLOGY",
                  "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility",
                  "14 CLINICAL STUDIES",
                  "14.1 Perivascular Epithelioid Cell Tumor (PEComa)",
                  "15 REFERENCES",
                  "16 HOW SUPPLIED/STORAGE AND HANDLING",
                  "17 PATIENT COUNSELING INFORMATION"
                ]
              }
            ]
          },
          "ids": [
            "0f9bb784-53e2-46f9-a65d-1c6c2a230eaf"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "file",
              "name": "dailymed_0f9bb784-53e2-46f9-a65d-1c6c2a230eaf.xml",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/dailymed_fetch_sections/manual-017/raw/dailymed_0f9bb784-53e2-46f9-a65d-1c6c2a230eaf.xml",
              "sha256": "0788aeea8a47b84c72b9b7ea0f926ff9f058c4060b7f1a99ff2b8afae0c5d823",
              "size_bytes": 137302
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "dailymed",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:40.460248Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-017"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "openfda_faers_aggregate"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 987.85,
      "endpoint": "https://dailymed.nlm.nih.gov/dailymed/services/v2/spls/{setid}.xml",
      "enabled": true
    },
    {
      "tool": "openfda_faers_aggregate",
      "payload": {
        "query": "patient.drug.medicinalproduct:SIROLIMUS",
        "mode": "precision",
        "limit": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "aggregate",
          "summary": "Aggregated 5 FAERS bucket(s) from openFDA.",
          "data": {
            "query": "patient.drug.medicinalproduct:SIROLIMUS",
            "mode": "precision",
            "count_field": "patient.reaction.reactionmeddrapt.exact",
            "rows": [
              {
                "term": "OFF LABEL USE",
                "count": 1927
              },
              {
                "term": "DRUG INEFFECTIVE",
                "count": 1056
              },
              {
                "term": "PRODUCT USE IN UNAPPROVED INDICATION",
                "count": 757
              },
              {
                "term": "DIARRHOEA",
                "count": 536
              },
              {
                "term": "PYREXIA",
                "count": 533
              }
            ],
            "note": "Spontaneous reports are signal-only and do not establish incidence or causality."
          },
          "ids": [
            "OFF LABEL USE",
            "DRUG INEFFECTIVE",
            "PRODUCT USE IN UNAPPROVED INDICATION",
            "DIARRHOEA",
            "PYREXIA"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "raw_json",
              "name": "openfda_faers_aggregate.json",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/openfda_faers_aggregate/manual-018/raw/openfda_faers_aggregate.json",
              "sha256": "226991ff14d66c5ba82dad2922c9b3658e1670bb574e3c46e0eb576b67420579",
              "size_bytes": 782
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "openfda",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:41.483071Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-018"
            }
          },
          "guidance": {
            "next_recommended_tools": []
          }
        }
      },
      "note": null,
      "latency_ms": 1023.1,
      "endpoint": "https://api.fda.gov/drug/event.json",
      "enabled": true
    },
    {
      "tool": "longevity_drugage_refresh",
      "payload": {
        "mode": "balanced"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "status",
          "summary": "Refreshed DrugAge cache with 3423 row(s).",
          "data": {
            "mode": "balanced",
            "local_path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/cache/sources/hagr_drugage/drugage_20260227T232942Z.zip",
            "rows": 3423,
            "stale_cache": false,
            "source_url": "https://genomics.senescence.info/drugs/dataset.zip"
          },
          "ids": [
            "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/cache/sources/hagr_drugage/drugage_20260227T232942Z.zip"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "file",
              "name": "drugage_20260227T232942Z.zip",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/longevity_drugage_refresh/manual-019/files/drugage_20260227T232942Z.zip",
              "sha256": "d12f59717de60a207748f53bdbcdb484ed07e30d8608eb8e4a101e2a08d7fa80",
              "size_bytes": 45365
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "hagr_drugage",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:42.165384Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-019"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "longevity_drugage_query"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 682.23,
      "endpoint": "https://genomics.senescence.info/drugs/dataset.zip",
      "enabled": true
    },
    {
      "tool": "longevity_drugage_query",
      "payload": {
        "query": "rapamycin",
        "mode": "balanced",
        "limit": 10
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 10 DrugAge row(s) matching 'rapamycin'.",
          "data": {
            "query": "rapamycin",
            "mode": "balanced",
            "species_filter": null,
            "entries": [
              {
                "compound": "Rapamycin",
                "species": "Mus musculus",
                "strain": "UM-HET3",
                "sex": "Female",
                "dose": "14 ppm food (2.24 ppm/day bodyweight)",
                "avg_median_lifespan_change_pct": "13",
                "max_lifespan_change_pct": "14",
                "reference": "19587680",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Mus musculus",
                  "strain": "UM-HET3",
                  "dosage": "14 ppm food (2.24 ppm/day bodyweight)",
                  "age_at_initiation": "20 months",
                  "treatment_duration": "until death",
                  "avg_lifespan_change_percent": "13",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "14",
                  "max_lifespan_significance": "S",
                  "gender": "Female",
                  "weight_change_percent": "",
                  "weight_change_significance": "NA",
                  "itp": "Yes",
                  "pubmed_id": "19587680"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Mus musculus",
                "strain": "UM-HET3",
                "sex": "Male",
                "dose": "14 ppm food (2.24 ppm/day bodyweight)",
                "avg_median_lifespan_change_pct": "9",
                "max_lifespan_change_pct": "9",
                "reference": "19587680",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Mus musculus",
                  "strain": "UM-HET3",
                  "dosage": "14 ppm food (2.24 ppm/day bodyweight)",
                  "age_at_initiation": "20 months",
                  "treatment_duration": "until death",
                  "avg_lifespan_change_percent": "9",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "9",
                  "max_lifespan_significance": "S",
                  "gender": "Male",
                  "weight_change_percent": "",
                  "weight_change_significance": "NA",
                  "itp": "Yes",
                  "pubmed_id": "19587680"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Drosophila melanogaster",
                "strain": "white Dahomey",
                "sex": "Female",
                "dose": "200 M",
                "avg_median_lifespan_change_pct": "13",
                "max_lifespan_change_pct": null,
                "reference": "20074526",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Drosophila melanogaster",
                  "strain": "white Dahomey",
                  "dosage": "200 M",
                  "age_at_initiation": "",
                  "treatment_duration": "",
                  "avg_lifespan_change_percent": "13",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "",
                  "max_lifespan_significance": "NA",
                  "gender": "Female",
                  "weight_change_percent": "",
                  "weight_change_significance": "NA",
                  "itp": "No",
                  "pubmed_id": "20074526"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Mus musculus",
                "strain": "UM-HET3",
                "sex": "Female",
                "dose": "14 ppm food (2.24 ppm/day bodyweight)",
                "avg_median_lifespan_change_pct": "18",
                "max_lifespan_change_pct": "13",
                "reference": "20974732",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Mus musculus",
                  "strain": "UM-HET3",
                  "dosage": "14 ppm food (2.24 ppm/day bodyweight)",
                  "age_at_initiation": "9 months",
                  "treatment_duration": "until death",
                  "avg_lifespan_change_percent": "18",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "13",
                  "max_lifespan_significance": "S",
                  "gender": "Female",
                  "weight_change_percent": "-6",
                  "weight_change_significance": "S",
                  "itp": "Yes",
                  "pubmed_id": "20974732"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Mus musculus",
                "strain": "UM-HET3",
                "sex": "Male",
                "dose": "14 ppm food (2.24 ppm/day bodyweight)",
                "avg_median_lifespan_change_pct": "10",
                "max_lifespan_change_pct": "16",
                "reference": "20974732",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Mus musculus",
                  "strain": "UM-HET3",
                  "dosage": "14 ppm food (2.24 ppm/day bodyweight)",
                  "age_at_initiation": "9 months",
                  "treatment_duration": "until death",
                  "avg_lifespan_change_percent": "10",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "16",
                  "max_lifespan_significance": "S",
                  "gender": "Male",
                  "weight_change_percent": "-10",
                  "weight_change_significance": "S",
                  "itp": "Yes",
                  "pubmed_id": "20974732"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Mus musculus",
                "strain": "129/Sv",
                "sex": "Female",
                "dose": "1.5 ppm bodyweight subcutaneous injection 3 times a week for 2 weeks followed by a 2-week break",
                "avg_median_lifespan_change_pct": "10",
                "max_lifespan_change_pct": "8",
                "reference": "22107964",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Mus musculus",
                  "strain": "129/Sv",
                  "dosage": "1.5 ppm bodyweight subcutaneous injection 3 times a week for 2 weeks followed by a 2-week break",
                  "age_at_initiation": "2 months",
                  "treatment_duration": "until death",
                  "avg_lifespan_change_percent": "10",
                  "avg_lifespan_significance": "NS",
                  "max_lifespan_change_percent": "8",
                  "max_lifespan_significance": "S",
                  "gender": "Female",
                  "weight_change_percent": "-8",
                  "weight_change_significance": "S",
                  "itp": "No",
                  "pubmed_id": "22107964"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Caenorhabditis elegans",
                "strain": "N2",
                "sex": "Unknown",
                "dose": "100 M",
                "avg_median_lifespan_change_pct": "19",
                "max_lifespan_change_pct": null,
                "reference": "22560223",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Caenorhabditis elegans",
                  "strain": "N2",
                  "dosage": "100 M",
                  "age_at_initiation": "",
                  "treatment_duration": "",
                  "avg_lifespan_change_percent": "19",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "",
                  "max_lifespan_significance": "NA",
                  "gender": "Unknown",
                  "weight_change_percent": "",
                  "weight_change_significance": "NA",
                  "itp": "No",
                  "pubmed_id": "22560223"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Caenorhabditis elegans",
                "strain": "N2",
                "sex": "Unknown",
                "dose": "1 nM",
                "avg_median_lifespan_change_pct": "16.2",
                "max_lifespan_change_pct": null,
                "reference": "23698443",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Caenorhabditis elegans",
                  "strain": "N2",
                  "dosage": "1 nM",
                  "age_at_initiation": "",
                  "treatment_duration": "",
                  "avg_lifespan_change_percent": "16.2",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "",
                  "max_lifespan_significance": "NA",
                  "gender": "Unknown",
                  "weight_change_percent": "",
                  "weight_change_significance": "NA",
                  "itp": "No",
                  "pubmed_id": "23698443"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Caenorhabditis elegans",
                "strain": "N2",
                "sex": "Unknown",
                "dose": "1 nM",
                "avg_median_lifespan_change_pct": "20.6",
                "max_lifespan_change_pct": null,
                "reference": "23698443",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Caenorhabditis elegans",
                  "strain": "N2",
                  "dosage": "1 nM",
                  "age_at_initiation": "",
                  "treatment_duration": "",
                  "avg_lifespan_change_percent": "20.6",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "",
                  "max_lifespan_significance": "NA",
                  "gender": "Unknown",
                  "weight_change_percent": "",
                  "weight_change_significance": "NA",
                  "itp": "No",
                  "pubmed_id": "23698443"
                }
              },
              {
                "compound": "Rapamycin",
                "species": "Caenorhabditis elegans",
                "strain": "N2",
                "sex": "Unknown",
                "dose": "100 M",
                "avg_median_lifespan_change_pct": "26",
                "max_lifespan_change_pct": "34.84",
                "reference": "24332851",
                "raw": {
                  "compound_name": "Rapamycin",
                  "species": "Caenorhabditis elegans",
                  "strain": "N2",
                  "dosage": "100 M",
                  "age_at_initiation": "",
                  "treatment_duration": "",
                  "avg_lifespan_change_percent": "26",
                  "avg_lifespan_significance": "S",
                  "max_lifespan_change_percent": "34.84",
                  "max_lifespan_significance": "NA",
                  "gender": "Unknown",
                  "weight_change_percent": "",
                  "weight_change_significance": "NA",
                  "itp": "No",
                  "pubmed_id": "24332851"
                }
              }
            ],
            "cache_path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/cache/sources/hagr_drugage/drugage_20260227T232942Z.zip"
          },
          "ids": [
            "19587680",
            "19587680",
            "20074526",
            "20974732",
            "20974732",
            "22107964",
            "22560223",
            "23698443",
            "23698443",
            "24332851"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "hagr_drugage",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:42.187373Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-020"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "pubmed_fetch"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 21.27,
      "endpoint": "local_cache:hagr_drugage",
      "enabled": true
    },
    {
      "tool": "longevity_itp_fetch_summary",
      "payload": {
        "ids": [
          "https://phenome.jax.org/itp/surv/MetRapa/C2011"
        ],
        "mode": "precision"
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Fetched 1 ITP survival summary page(s).",
          "data": {
            "mode": "precision",
            "records": [
              {
                "requested_url": "https://phenome.jax.org/itp/surv/MetRapa/C2011",
                "url": "https://phenome.jax.org/itp/surv/MetRapa/C2011",
                "source_host": "phenome.jax.org",
                "blocked_by_waf": false,
                "fallback_used": false,
                "fallback_url": null,
                "text_preview": "MPD: ITP survival analysis: &nbsp; metformin and rapamycin Cookie Policy Welcome! Our website uses cookies exclusively for usage analytics and reporting metrics to our stakeholders and funding agencies about site usage. These cookies also help us understand how visitors interact with our site, enabling us to improve your browsing experience and the content we offer. We respect your privacy and ensure that all data collected is anonymized and used solely to guide our enhancements. Additionally, we do not use this data for marketing purposes nor do we share any user information with third parties. By clicking \"Accept,\" you consent to our use of cookies for these purposes. For more detailed information on the cookies we use and how we handle your data, please review our Privacy Policy . Accept Decline Toggle navigation &nbsp;&nbsp; Home Menu Phenotypes Genotypes Strains Panels, Populations QTL Archive Protocols Contributors Phenotyping procedures Behavior tests Drug and diet studies Pathogen and challenge studies Ontologies Aging studies Molecular studies Replicability analysis Multi-measure study designs What's new Submit data Downloads MPD data API Data changelog Tools demo About MyMPD &nbsp;&nbsp;My Collection &nbsp;&nbsp;Sign In / Register Search &nbsp; Examples ITP survival analysis: &nbsp; metformin and rapamycin Intervention: &nbsp; metformin and rapamycin &nbsp; &nbsp; Trial code: MetRapa Dose: Met:1000 ppm and Rapa:14 ppm initiated at age: 9 mo Sex: both Cohort: C2011 This compound had a significant effect on survival: &nbsp; both sexes p Results are based on the use of pooled factor(s) that is/are stratified within the survival analysis model. All test sites combined &ndash; female Download plot Download data Survival analysis details -- Female Statistical definitions MetRapa effect on survival, females, test site = All Log-rank test chisq = 82.5421 p &lt; 0.0001 Wang-Allison test odds ratio = 13.6982 p &lt; 0.0001 Quantiles MetRapa Control % difference 25% died before day: 918 771 +19 % Median lifespan (days) 1079 873 +24 % 75% died before day: 1197 985 +22 % 90% died before day: 1272 1089 +17 % Max lifespan observed (days) 1413 1456 Number of mice at start 142 281 Animal censor events are denoted by + marks in the plot All test sites combined &ndash; male Download plot Download data Survival analysis details -- Male Statistical definitions MetRapa effect on survival, males, test site = All Log-rank test chisq = 43.7855 p &lt; 0.0001 Wang-Allison t",
                "p_values": [
                  "0.0006",
                  "0.0363",
                  "0.002",
                  "0.0027",
                  "0.1481"
                ]
              }
            ]
          },
          "ids": [
            "https://phenome.jax.org/itp/surv/MetRapa/C2011"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [
            {
              "kind": "file",
              "name": "itp_20260227T232943Z.html",
              "path": "/Users/amt42/projects/hackathon-agent-core/backend/artifacts/threads/tool-validate-thread-20260227T232927Z/lineages/tool-validate-run-20260227T232927Z/tools/longevity_itp_fetch_summary/manual-021/raw/itp_20260227T232943Z.html",
              "sha256": "a1988670cb7c7f25fcc09edfaaccdf6a3335677ebd3476d9539652f1d8f89eb8",
              "size_bytes": 233899
            }
          ],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "itp",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:43.493565Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-021"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "pubmed_search"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 1306.12,
      "endpoint": "https://phenome.jax.org/itp/surv/MetRapa/C2011",
      "enabled": true
    },
    {
      "tool": "chembl_search",
      "payload": {
        "query": "sirolimus",
        "mode": "balanced",
        "limit": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 5 ChEMBL molecule candidate(s).",
          "data": {
            "query": "sirolimus",
            "mode": "balanced",
            "records": [
              {
                "chembl_id": "CHEMBL263427",
                "pref_name": null,
                "molecule_type": "Small molecule",
                "max_phase": null
              },
              {
                "chembl_id": "CHEMBL264340",
                "pref_name": null,
                "molecule_type": "Small molecule",
                "max_phase": null
              },
              {
                "chembl_id": "CHEMBL3544670",
                "pref_name": null,
                "molecule_type": "Small molecule",
                "max_phase": null
              },
              {
                "chembl_id": "CHEMBL3544763",
                "pref_name": null,
                "molecule_type": "Small molecule",
                "max_phase": null
              },
              {
                "chembl_id": "CHEMBL269721",
                "pref_name": null,
                "molecule_type": "Small molecule",
                "max_phase": null
              }
            ]
          },
          "ids": [
            "CHEMBL263427",
            "CHEMBL264340",
            "CHEMBL3544670",
            "CHEMBL3544763",
            "CHEMBL269721"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": null,
            "has_more": false
          },
          "source_meta": {
            "source": "chembl",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:43.824395Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-022"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "chembl_fetch"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 332.11,
      "endpoint": "https://www.ebi.ac.uk/chembl/api/data/molecule/search.json",
      "enabled": true
    },
    {
      "tool": "chebi_search",
      "payload": {
        "query": "nicotinamide mononucleotide",
        "mode": "balanced",
        "limit": 5
      },
      "result": {
        "status": "success",
        "output": {
          "contract_version": "2.0",
          "result_kind": "record_list",
          "summary": "Found 5 ChEBI candidate(s).",
          "data": {
            "query": "nicotinamide mononucleotide",
            "mode": "balanced",
            "page": 1,
            "records": [
              {
                "chebi_id": "CHEBI:13193",
                "name": "hydrogen acceptor",
                "stars": 3,
                "mass": 0.0,
                "formula": "A",
                "inchikey": null
              },
              {
                "chebi_id": "CHEBI:100282",
                "name": "1-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(4-phenoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-3-propan-2-ylurea",
                "stars": 2,
                "mass": 491.61,
                "formula": "C24H33N3O6S",
                "inchikey": "URVFCIGKBRHLNA-AKIFATBCSA-N"
              },
              {
                "chebi_id": "CHEBI:100283",
                "name": "LSM-11658",
                "stars": 2,
                "mass": 485.493,
                "formula": "C23H20FN3O6S",
                "inchikey": "OZRBNBICDFVIFO-NXXWWENFSA-N"
              },
              {
                "chebi_id": "CHEBI:100284",
                "name": "2-[(2S,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide",
                "stars": 2,
                "mass": 453.495,
                "formula": "C24H27N3O6",
                "inchikey": "UDMIDSQAUXVXMN-SXTKRDDTSA-N"
              },
              {
                "chebi_id": "CHEBI:100285",
                "name": "4-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(phenylmethyl)sulfonylamino]ethyl]-3-oxanyl]benzenesulfonamide",
                "stars": 2,
                "mass": 486.587,
                "formula": "C21H27FN2O6S2",
                "inchikey": "ZTKNNPSVJPUDLJ-GIVPXCGWSA-N"
              }
            ]
          },
          "ids": [
            "CHEBI:13193",
            "CHEBI:100282",
            "CHEBI:100283",
            "CHEBI:100284",
            "CHEBI:100285"
          ],
          "citations": [],
          "warnings": [],
          "artifacts": [],
          "pagination": {
            "next_page_token": "2",
            "has_more": true
          },
          "source_meta": {
            "source": "chebi",
            "request_id": null,
            "retrieved_at": "2026-02-27T23:29:44.176804Z",
            "auth": {
              "required": false,
              "configured": true
            },
            "lineage": {
              "thread_id": "tool-validate-thread-20260227T232927Z",
              "run_id": "tool-validate-run-20260227T232927Z",
              "tool_use_id": "manual-023"
            }
          },
          "guidance": {
            "next_recommended_tools": [
              "chebi_fetch"
            ]
          }
        }
      },
      "note": null,
      "latency_ms": 352.15,
      "endpoint": "https://www.ebi.ac.uk/chebi/backend/api/public/es_search/",
      "enabled": true
    },
    {
      "tool": "semanticscholar_search",
      "payload": {
        "query": "rapamycin aging trial",
        "mode": "balanced",
        "limit": 5
      },
      "result": {
        "status": "error",
        "error": {
          "code": "RATE_LIMIT",
          "message": "Rate limited by upstream source: https://api.semanticscholar.org/graph/v1/paper/search?query=rapamycin+aging+trial&limit=5&fields=title%2Cyear%2CpaperId%2CexternalIds%2CcitationCount",
          "retryable": true,
          "details": {}
        }
      },
      "note": null,
      "latency_ms": 3089.25,
      "endpoint": "https://api.semanticscholar.org/graph/v1/paper/search",
      "enabled": true
    }
  ]
}